https://www.osservatoriomalattierare.it/weekly0.5 https://www.osservatoriomalattierare.it/ipercolesterolemia-familiare-che-cose2017-11-15T22:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/emofilie-cosa-sono2018-12-18T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/angioedema-ereditario-che-cose2018-01-26T10:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/distrofia-di-duchenne-che-cose2019-08-06T10:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rariweekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas2016-12-02T11:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/22956-tumore-al-pancreas-necessaria-la-rete-nazionale-dei-centri-specializzati2026-04-20T17:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/22907-tumore-del-pancreas-fondazione-veronesi-e-ficog-lanciano-un-bando-per-la-ricerca2026-04-02T16:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/22831-tumore-al-pancreas-la-corsa-di-carlo-vanzini-e-la-rivoluzione-dello-studio-cassandra2026-03-10T20:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/22715-tumore-al-pancreas-tra-nuovi-farmaci-approvati-e-trattamenti-in-via-di-sviluppo2026-02-03T22:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/22536-tumore-al-pancreas-in-italia-aumenta-il-numero-di-pazienti-vivi-dopo-la-diagnosi2025-11-20T19:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/22080-tumore-al-pancreas-studio-italiano-potrebbe-cambiare-le-linee-guida-sul-trattamento-della-patologia2025-06-12T17:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/21515-tumore-al-pancreas-e-in-aumento-il-numero-dei-decessi2024-11-22T13:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/20900-tumore-al-pancreas-scoperta-l-impronta-molecolare-delle-lesioni-cistiche-pre-cancerose2024-04-22T15:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/20743-tumore-al-pancreas-metastatico-nuove-opportunita-di-trattamento-grazie-alle-nanotecnologie2024-03-12T14:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/20516-tumore-al-pancreas-ecco-perche-si-trasforma-in-metastasi2024-01-15T11:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/20307-tumore-al-pancreas-scoperto-un-meccanismo-chiave-nella-patogenesi-della-malattia2023-11-09T17:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/20032-tumore-al-pancreas-pieve-skin-chiede-di-attivare-le-pancreas-unit-anche-in-emilia-romagna2023-07-26T07:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/18727-tumore-al-pancreas-in-lombardia-nascono-le-pancreas-units2022-06-04T14:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/18015-tumore-al-pancreas-il-18-novembre-e-la-giornata-mondiale2021-11-17T22:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/17754-tumore-al-pancreas-un-approccio-rivoluzionario-riapre-la-strada-all-immunoterapia2021-09-07T15:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/17281-tumore-al-pancreas-fondazione-humanitas-lancia-una-raccolta-fondi-per-la-ricerca2021-04-11T19:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/16228-tumore-del-pancreas-al-gemelli-di-roma-un-pca-e-un-centro-chirurgico-dedicati2020-06-29T08:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/15672-tumore-al-pancreas-scoperta-una-nuova-mutazione-associata2020-02-17T19:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/15389-adenocarcinoma-al-pancreas-entro-il-2030-sara-la-seconda-causa-di-morte-tra-i-tumori2019-11-09T14:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/14837-tumore-al-pancreas-fda-accoglie-la-domanda-di-registrazione-dell-eriaspasi2019-05-21T18:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/14148-tumore-al-pancreas-in-italia-studio-clinico-su-adroterapia-piu-chemioterapia2018-11-14T12:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/14133-tumore-al-pancreas-inaugurato-il-gemelli-pancreatic-advanced-research-center2018-11-07T18:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/13243-tumore-al-pancreas-ora-i-pazienti-sardi-potranno-essere-operati-a-cagliari2018-02-18T23:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/11530-cancro-del-pancreas-pubblicate-le-nuove-linee-guida-delineano-il-corretto-iter-terapeutico2016-10-26T15:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/10238-tumore-al-pancreas-in-italia-molti-interventi-chirurgici-ma-poca-esperienza2016-03-22T15:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/10084-cancro-al-pancreas-sono-quattro-le-varianti-possibili2016-03-02T09:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/9795-tumore-al-pancreas-la-diagnosi-precoce-con-un-semplice-esame-del-sangue2016-01-22T11:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/6904-adenocarcinoma-del-pancreas-conoscere-le-mutazioni-generiche-per-diagnosticare-il-tumore-prima-che-sia-troppo-tardi2020-02-17T17:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/6663-tumore-al-pancreas-unaspirina-al-giorno-riduce-la-probabilita-di-sviluppare-questa-patologia2019-06-18T18:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/6401-tumore-al-pancreas-al-cerms-si-studia-un-vaccino-rivoluzionario2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/5145-cancro-pancreas-il-fumo-aumenta-il-rischio-del-702015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/3123-tumore-al-pancreas-dalla-medicina-cinese-un-farmaco-che-potrebbe-migliorare-la-terapia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-al-pancreas/1711-cancro-del-pancreas-positivi-i-risultati-della-sperimentazione-con-th-302-con-gemcitabina2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma2015-02-17T18:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/22595-morta-la-scrittrice-sophie-kinsella-era-affetta-da-glioblastoma2025-12-11T16:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/22339-glioblastoma-nuovo-anticorpo-sperimentale-sembra-in-grado-di-rallentare-la-progressione-del-tumore2025-09-25T14:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/20882-la-scrittrice-sophie-kinsella-annuncia-di-essere-malata-e-affetta-da-glioblastoma2024-04-18T08:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/20249-glioblastoma-via-libera-in-campania-a-un-nuovo-percorso-diagnostico-terapeutico-assistenziale2023-10-23T08:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/19806-glioblastoma-alta-tecnologia-per-una-gestione-della-malattia-sempre-piu-personalizzata2023-05-14T13:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/18995-glioblastoma-multiforme-nuova-potenziale-terapia-per-il-trattamento-delle-recidive2022-08-12T17:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/12528-glioblastoma-scoperto-un-anticorpo-potenzialmente-in-grado-di-bloccarne-la-crescita2017-07-27T14:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/12213-glioblastoma-riprodotto-in-provetta-il-tumore-per-studiare-nuove-cure-personalizzate2017-04-23T09:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/11096-glioblastoma-attenzione-all-uso-di-corticosteroidi2016-08-05T12:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/7252-glioblastoma-bevacizumab-combinato-con-lomustina-ha-dimostrato-maggiore-efficacia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/6553-glioblastoma-multiforme-nuovo-farmaco-orfano-disponibile-in-europa-e-usa2016-07-18T15:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/6440-glioblastoma-multiforme-risultati-incoraggianti-con-nuovo-vaccino-autologo-antitumorale2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/5402-glioblastoma-due-nuovi-bersagli-terapeutici2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/5299-glioblastoma-nuovo-vaccino-migliora-sopravvivenza-libera-da-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/5150-glioblastoma-possibile-un-legame-con-il-papillomavirus2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/4913-glioblastoma-al-besta-quattro-sperimentazioni-con-due-diversi-vaccini2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/4692-un-virus-contro-il-glioblastoma-primi-esperimenti-su-modello-animale2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/4596-glioblastoma-e-malattie-cerebrovascolari-una-tecnica-innovativa-per-cure-personalizzate2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/glioblastoma/4262-glioblastoma-promettenti-risultati-da-una-terapia-sperimentale-che-agisce-sul-polivirus2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/gist-tumori-stromali-gastrointestinali2024-03-13T12:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/gist-tumori-stromali-gastrointestinali/18651-tumori-gastrointestinali-un-indagine-svela-i-bisogni-prioritari-dei-pazienti2022-05-14T14:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/gist-tumori-stromali-gastrointestinali/16364-tumori-stromali-gastrointestinali-avapritinib-riceve-parere-positivo-dal-chmp2020-08-10T16:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/gist-tumori-stromali-gastrointestinali/6499-tumori-stromali-gastrointesinali-gist-approvato-in-europa-il-trattamento-con-regorafenib2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/gist-tumori-stromali-gastrointestinali/3904-gist-nuovo-anticorpo-monoclonale-si-dimostra-efficace-nei-pazienti-resistenti-allimatinib2015-05-27T08:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/gist-tumori-stromali-gastrointestinali/3215-gist-e-tumore-metastatico-del-colon-retto-nuovi-dati-positivi-per-regorafenib2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/gist-tumori-stromali-gastrointestinali/908-gist-casali-limatinib-e-in-grado-di-ridurre-la-recidiva-nei-pazienti-a-rischio2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/gist-tumori-stromali-gastrointestinali/909-gist-i-pazienti-chiedono-linclusione-nellelenco-delle-malattie-rare-la-toscana-lha-gia-fatto2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto2022-10-31T14:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/21281-tumore-del-colon-retto-lo-screening-e-fondamentale-in-italia-necessaria-ancora-piu-attenzione2024-09-16T07:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/20726-tumore-al-colon-retto-il-2-5-dei-casi-e-associato-a-sindromi-familiari-a-carattere-ereditario2024-03-06T20:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/19250-tumore-al-colon-retto-nuova-potenziale-strategia-per-prevenire-le-metastasi-al-fegato2022-11-05T15:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/17633-poliposi-adenomatosa-familiare-in-friuli-venezia-giulia-un-pdta-dedicato-alla-malattia2022-10-31T15:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/14673-oncologia-a-milano-due-giorni-dedicati-a-progressi-scientifici-e-pratica-clinica2022-10-31T14:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/14388-tumore-metastatico-del-colon-retto-confermata-la-sicurezza-ed-efficacia-della-combinazione-di-encorafenib-binimetinib-e-cetuximab2022-10-31T14:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/12837-tumore-colon-retto-maggior-sopravvivenza-con-tas-102-nei-pazienti-che-hanno-gia-ben-risposto-a-regorafenib2022-10-31T14:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/12406-tumore-colon-retto-messaggi-dalle-cellule-malate-stimolano-la-crescita-del-cancro2022-10-31T14:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/12190-tumore-al-colon-retto-acido-acetilsalicilico-per-la-prevenzione-primaria-della-malattia2022-10-31T14:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/11430-tumore-colon-retto-nintedanib-migliora-la-sopravvivenza-libera-da-progressione-ma-non-quella-globale2022-10-31T14:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/10103-tumore-colon-retto-novita-diagnostiche-il-test-non-invasivo-su-dna-e-emoglobina-fecale2022-10-31T14:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/9782-tumore-colon-retto-dalla-terapia-genica-un-nuovo-approccio-terapeutico-contro-le-metastasi-al-fegato2022-10-31T14:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/9470-tumore-colon-retto-primato-mondiale-per-programma-italiano-di-terapie-personalizzate2022-10-31T14:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/8738-tumore-del-colon-retto-da-uno-studio-emerge-che-un-terzo-dei-casi-diagnosticati-prima-dei-35-anni-ha-origine-ereditaria2022-10-31T14:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/8518-tumore-del-colon-retto-un-pannello-di-biomarcatori-puo-predire-l-esito-clinico-dei-pazienti-in-trattamento-con-cetuximab2022-10-31T14:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/6973-la-terapia-mirata-nel-tumore-del-colon-retto-il-contributo-italiano-alla-ricerca-sugli-anticorpi-monoclonali2022-10-31T14:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/6580-tumore-metastatico-colorettale-cetuximab-preferibile-a-bevacizumab-come-trattamento-di-prima-linea-associato-alla-chemioterapia2015-05-26T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/6585-cancro-metastatico-del-colon-retto-potenzialmente-resecabile-maggior-sopravvivenza-globale-con-luso-degli-anticorpi-monoclonali-anti-egfr2022-10-31T15:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/5761-test-genetici-e-terapie-su-misura-per-il-carcinoma-del-colon-retto-metastatico2015-05-26T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/5435-cancro-al-colon-retto-la-chemio-adiuvante-non-aumenta-la-sopravvivenza2015-05-26T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/4346-carcinoma-colorettale-metastatico-risultati-promettenti-da-nuovo-immunomodulatore2015-05-26T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/4344-carcinoma-colorettale-aflibercept-e-ora-disponibile-in-italia2015-05-26T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/4220-tumore-del-colon-retto-al-via-la-campagna-pronto-a-chiamare-del-policlinico-gemenelli2015-05-26T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/2442-cancro-al-colon-retto-con-regorafenib-un-mese-in-piu-per-i-pazienti-molte-le-prospettive-per-i-ricercatori2015-05-26T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/1547-cancro-colon-retto-metastatico-regorafenib-aumenta-sopravvivenza-globale-dei-pazienti2015-05-26T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumore-metastatico-colon-retto/1371-cancro-colon-retto-metastatico-positivi-gli-studi-di-fase-tre-su-regorafenib2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide2019-05-24T15:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/21870-tumore-della-tiroide-dietro-i-casi-in-aumento-c-e-un-problema-di-sovra-diagnosi2025-04-02T15:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/14020-tumore-alla-tiroide-nuove-linee-guida-per-individuare-i-soggetti-a-rischio2019-06-10T10:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/12407-tumore-della-tiroide-generalmente-curabile-raramente-piu-aggressivo2018-10-10T16:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/11785-tumore-alla-tiroide-dieci-anni-di-esperienza-con-le-terapie-mirate2017-06-19T15:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/11368-tumori-tiroidei-40-000-gli-interventi-all-anno2017-06-19T15:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/9397-tumori-tiroidei-presentata-la-nuova-classificazione-citologica-delle-lesioni2018-10-10T16:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/8579-tumore-differenziato-della-tiroide-negli-anziani-la-tiroidectomia-totale-e-l-operazione-chirurgica-di-scelta2018-10-10T16:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/7032-tumore-della-tiroide-gli-inibitori-della-chinasi-sono-efficaci-ma-hanno-unelevata-tossicita2018-10-10T16:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/5210-tumore-papillifero-della-tiroide-e-in-aumento-tra-le-cause-radiazioni-e-alimentazione2018-10-10T16:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/4169-carcinoma-differenziato-della-tiroide-aumenta-lo-sopravvivenza-con-sorafenib2015-05-26T08:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-differenziati-della-tiroide/3443-tumore-differenziato-della-tiroide-successo-per-lo-studio-di-fase-iii-su-sorafenib2018-10-10T16:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd2024-03-13T12:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/22564-sindromi-mielodisplastiche-aifa-approva-limpiego-di-luspatercept-come-terapia-di-prima-linea-per-lanemia2025-12-01T17:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/22116-sindromi-mielodisplastiche-buone-premesse-per-la-terapia-orale-per-pazienti-ad-alto-rischio2025-06-22T14:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/18764-sindromi-mielodisplastiche-studio-italiano-analizza-il-rischio-di-evoluzione-in-leucemia-acuta2022-06-13T14:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/17338-sindromi-mielodisplastiche-trattamenti-piu-personalizzati-grazie-allo-studio-del-genoma2021-04-25T21:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/15337-sindromi-mielodisplastiche-ail-e-aipasim-fanno-il-punto-della-situazione2019-10-22T15:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/14788-sindromi-mielodisplastiche-il-duro-percorso-di-sandra-per-avere-una-diagnosi2019-05-08T11:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/14316-sindromi-mielodisplastiche-presentati-i-risultati-di-fase-iii-di-luspatercept2018-12-30T21:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/13856-sindromi-mielodisplastiche-cruciale-il-ruolo-di-associazioni-e-reti-di-patologia2018-08-24T14:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/13854-sindromi-mielodisplastiche-realizzata-la-prima-mappatura-italiana2018-08-22T08:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/13619-sindromi-mielodisplastiche-e-leucemia-dai-farmaci-epigenetici-al-futuro-del-trattamento2018-06-04T12:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/13083-sindromi-mielodisplastiche-buon-controllo-dell-anemia-con-luspatercept2018-01-05T10:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/11258-sindromi-mielodisplastiche-l-analisi-del-genoma-puo-predire-la-risposta-dei-pazienti-al-trapianto-di-staminali2017-06-19T15:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/10811-sindromi-mielodisplastiche-nuovi-esiti-clinici-per-il-farmaco-sperimentale-luspatercept2017-06-19T15:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/10635-sindromi-mielodisplastiche-humanitas-cancer-center-ora-e-centro-di-eccellenza-internazionale2017-06-19T15:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/6603-malattia-infiammatoria-intestinale-la-terapia-puo-aumentare-il-rischio-di-leucemia-mieloide-acuta-e-sindromi-mielodisplastiche2019-06-18T18:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/6587-sindromi-mielodisplastiche-con-delezione-5q-il-punto-sul-ruolo-della-lenalidomide2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/6163-sindromi-mielodisplastiche-associate-a-del5q-gli-effetti-positivi-del-trattamento-con-lenalidomide2019-06-18T18:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/5352-tumori-del-sangue-li-innesca-una-mutazione-nelle-cellule-ossee2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/5308-sindromi-mielodisplastiche-trapianto-anche-per-i-piu-anziani2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/5126-sindromi-mielodisplastiche-primi-risultati-del-trattamento-con-azaticidina2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/5038-sindromi-mielodisplastiche-santini-non-discriminare-in-base-alleta2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/4908-sindromi-mielodisplastiche-la-terapia-chelante-evita-liron-overload-il-danno-da-ferro2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/4251-sindromi-mielodisplastiche-con-delezione-5q-la-commissione-europea-approva-la-terapia-orale-con-lenalidomide2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/sindromi-mielodisplastiche-smd/3862-sindromi-mielodisplastiche-identificato-gene-associato-ad-accumulo-di-ferro-per-le-trasfusioni2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide2018-01-31T22:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/14397-carcinoma-midollare-tiroideo-all-istituto-oncologico-della-svizzera-italiana-un-percorso-specifico-per-individuarlo-in-fretta2019-01-29T11:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/14396-carcinoma-midollare-della-tiroide-l-importanza-il-dosaggio-della-procalcitonina-per-la-diagnosi2019-01-29T11:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/12862-carcinoma-midollare-della-tiroide-il-test-della-calcitonina-puo-facilitarne-la-diagnosi2017-11-05T14:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/11317-un-epidemia-mondiale-di-cancro-alla-tiroide2017-11-05T14:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/8873-carcinoma-midollare-della-tiroide-a-pisa-proseguono-le-ricerche-sulla-diagnosi-precoce2017-11-05T14:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/7425-carcinoma-midollare-della-tiroide-ecografia-sospetta-e-aggressivita-del-tumore-sono-correlate2015-05-26T08:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/7173-carcinoma-midollare-della-tiroide-puo-colpire-anche-i-bambini-a-pisa-leccellenza-italiana2015-06-12T12:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/4773-carcinoma-midollare-della-tiroide-cosa-dice-la-biopsia-con-ago-aspirato2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/4769-carcinoma-midollare-della-tiroide-individuata-una-nuova-mutazione-che-causa-il-tumore2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/4627-terapia-e-prevenzione-del-carcinoma-midollare-della-tiroide2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/4617-carcinoma-midollare-della-tiroide-gaetano-convive-da-anni-con-la-malattia-grazie-al-jazz-non-ha-mai-perso-la-speranza2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/4616-tumore-midollare-della-tiroide-disponibile-anche-in-italia-il-primo-farmaco-per-la-rara-malattia-oncologica2015-05-28T12:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/4621-manifesto-del-tumore-midollare-della-tiroide-10-punti-per-conoscere-e-riconoscere-una-malattia-rara2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/4593-sindrome-di-cushing-associata-a-tumore-midollare-della-tiroide-e-efficace-il-vandetanib2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/4377-carcinoma-midollare-della-tiroide-vandetanib-piu-efficace-se-luso-e-selettivo2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/617-carcinoma-midollare-tiroideo-negli-usa-approvato-vandetanib-per-i-casi-inoperabili-e-metastatici2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-midollare-della-tiroide/318-carcinoma-midollare-della-tiroide-apertura-della-fda-a-nuovo-farmaco-oncologico2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma2015-02-17T18:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/20917-mesotelioma-il-raro-e-aggressivo-tumore-che-ha-colpito-lo-stimato-giornalista-franco-di-mare2024-05-24T07:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/20905-mesotelioma-il-tumore-dell-amianto-che-continua-a-colpire-in-italia2024-04-29T10:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/13594-mesotelioma-pubblicati-i-risultati-completi-di-ngr-htnf2018-05-26T15:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/12818-mesotelioma-studio-made-in-italy-su-nuova-immunoterapia-di-combinazione2018-05-26T17:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/12379-mesotelioma-pleurico-incoraggianti-dati-di-sopravvivenza-per-nintedanib2018-05-26T17:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/10671-mesotelioma-non-solo-amianto-possibile-una-predisposizione-genetica2018-05-26T17:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/9504-mesotelioma-pleurico-maligno-le-statistiche-sulla-gestione-clinica-della-malattia-in-francia2018-05-26T17:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/6254-mesotelioma-buoni-risultati-per-il-trattamento-con-tremelimumab2018-05-26T18:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/6125-mesotelioma-pleurico-maligno-molmed-annuncia-i-risultati-di-ngr-htnf-nello-studio-di-fase-iii2018-05-26T18:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/5313-tumore-da-amianto-si-muore-ancora-e-si-prevede-un-aumento-di-casi2018-05-26T18:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/4818-mesotelioma-attivo-lambulatorio-oncologico-online-ona2018-05-26T18:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/4657-mesotelioma-pleurico-pubblicati-i-risultati-di-una-nuova-possibile-cura2018-05-26T18:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/4416-mesotelioma-avviati-ad-alessandria-due-sperimentazioni-cliniche2018-05-26T18:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/4297-mesotelioma-presentati-i-dati-della-lung-sparing-tecnica-che-risparmia-la-parte-sana-del-polmone2018-05-26T18:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mesotelioma/1024-mesotelioma-veterani-della-marina-americana-a-rischio-da-soli-rappresentano-un-terzo-dei-casi2018-05-26T18:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo2024-03-13T12:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/22731-mieloma-multiplo-duplice-terapia-mostra-risultati-promettenti-nelle-forme-extra-midollari2026-02-10T15:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/22677-mieloma-multiplo-scoperto-un-nuovo-meccanismo-di-resistenza-alle-terapie2026-01-20T14:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/22673-giovanni-allevi-torna-in-tour-il-mieloma-multiplo-non-lo-ferma2026-01-20T17:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/22115-mieloma-multiplo-aifa-approva-la-rimborsabilita-di-elranatamab2025-06-22T14:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/21283-mieloma-multiplo-progressi-nel-trattamento-di-questo-raro-tumore2024-09-13T16:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/20862-mieloma-multiplo-oltre-25mila-euro-all-anno-spesi-per-ogni-paziente2024-04-10T16:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/20775-mieloma-multiplo-approvazione-europea-per-elranatamab2024-03-18T17:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/20720-mieloma-multiplo-un-tumore-senza-una-cura-definitiva-oppure-no2024-03-11T12:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/20607-sanremo-2024-giovanni-allevi-parla-del-mieloma-multiplo-il-tumore-che-lo-ha-colpito2024-02-08T16:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/19805-mieloma-multiplo-arriva-in-italia-il-farmaco-teclistamab2023-05-14T12:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/19298-mieloma-multiplo-oltre-10-000-euro-i-costi-annuali-per-pazienti-e-caregiver2022-11-22T08:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/18118-mieloma-multiplo-al-via-il-bando-research-to-care2021-12-20T19:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/18112-mieloma-multiplo-disponibile-in-italia-la-formulazione-sottocutanea-di-daratumumab2026-04-09T14:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/18068-mieloma-multiplo-il-farmaco-belantamab-mafodotin-approvato-anche-in-italia2021-12-05T16:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/18027-mieloma-multiplo-il-golf-come-strumento-per-promuovere-il-benessere-dei-pazienti2021-11-21T23:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/17892-mieloma-multiplo-recidivato-refrattario-isatuximab-disponibile-in-italia2021-10-16T21:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/17464-mieloma-multiplo-il-primo-studio-su-sicurezza-e-immunogenicita-del-vaccino-anti-sars-cov-22021-11-15T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/16849-mieloma-multiplo-in-italia-si-stimano-circa-6-000-nuovi-casi-all-anno2022-05-11T11:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/16761-mieloma-multiplo-dallo-sport-un-aiuto-contro-la-malattia2020-11-30T21:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/16744-mieloma-multiplo-la-battaglia-piu-ardua-e-contro-le-continue-recidive-di-malattia2020-11-29T21:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/16327-covid-19-e-mieloma-multiplo-avviato-uno-studio-osservazionale-europeo2020-07-26T15:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/16180-mieloma-multiplo-approvato-in-europa-il-farmaco-isatuximab2020-06-14T23:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/15944-mieloma-multiplo-parere-positivo-del-chmp-per-isatuximab2020-04-13T17:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/15738-mieloma-multiplo-approvazione-usa-per-isatuximab2020-03-09T13:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/15655-mieloma-multiplo-al-san-raffaele-parte-il-trial-clinico-sulla-terapia-car-t2020-02-12T18:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/14630-mieloma-multiplo-ixazomib-ora-e-disponibile-anche-in-italia2019-03-25T17:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/14241-mieloma-multiplo-in-liguria-si-fa-rete-per-garantire-percorsi-di-cura-e-assistenza2019-03-26T17:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/13710-mieloma-multiplo-in-italia-estesa-la-rimborsabilita-di-lenalidomide2018-06-29T15:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/13034-mieloma-multiplo-recidivato-o-refrattario-carfilzomib-aumenta-la-sopravvivenza-globale2017-12-16T16:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/12566-mieloma-multiplo-risultati-positivi-dalla-terapia-di-mantenimento-con-lenalidomide2017-08-03T16:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/11577-mieloma-multiplo-oggi-la-malattia-si-puo-fermare2016-11-12T15:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/11580-mieloma-multiplo-con-carfilzomib-piu-prolungata-inibizione-del-proteasoma-e-piu-elevata-attivita-antitumorale2016-11-08T22:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/11572-mieloma-multiplo-30-000-i-pazienti-in-italia-incidenza-maggiore-negli-over-652016-11-08T08:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/11180-mieloma-multiplo-carfilzomib-efficace-ma-attenzione-a-possibili-effetti-cardiotossici2016-09-01T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/10939-mieloma-multiplo-i-livelli-della-proteina-cd38-influenzano-la-risposta-al-farmaco-daratumumab2016-07-08T17:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/10011-malattie-rare-i-progressi-dell-ematologia2016-02-23T17:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/8061-mieloma-multiplo-i-consigli-per-ottimizzare-il-trattamento-dei-pazienti-con-insufficienza-renale2015-05-26T07:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/6668-mieloma-multiplo-trattamento-con-bortezomib-meglio-per-via-sottocutanea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/6665-mieloma-multiplo-limpatto-di-anomalie-cromosomiche-immunofenotipo-e-nuove-terapie-sulla-sopravvivenza2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/6691-mieloma-multiplo-la-sopravvivenza-raddoppia-se-il-trapianto-viene-eseguito-alla-diagnosi2016-02-09T12:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/6282-mieloma-multiplo-patologia-diagnosi-e-terapia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/5426-mieloma-multiplo-in-un-solo-tumore-scoperte-diverse-mutazioni2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/5362-tumori-rai-il-successo-di-celgene-che-ha-cambiato-la-prognosi-del-mieloma-multiplo2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/5149-mieloma-multiplo-nuova-strategia-contro-lesioni-ossee2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/4559-mieloma-multiplo-la-curcumina-potrebbe-rendere-efficace-la-talidomide2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/4221-mieloma-multiplo-pazienti-over-75-quale-terapia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/3895-mieloma-multiplo-aifa-raccomanda-attenzione-nel-trattamento-con-talidomide2018-08-20T16:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/3838-mieloma-multiplo-nuovo-approccio-terapeutico-proposto-da-un-team-italiano2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mieloma-multiplo/688-linfomi-e-mielomi-dal-gimo-una-consensus-italiana-che-aiutera-lautotrapianto-di-staminali2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari2015-04-08T16:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/23061-sarcoma-epitelioide-un-tumore-raro-aggressivo-e-difficile-da-diagnosticare2026-05-20T07:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/23030-uno-studio-dellistituto-regina-elena-indaga-la-sessualita-dei-giovani-adulti-affetti-da-sarcoma2026-05-11T17:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22927-glioma-un-sistema-sperimentale-in-3d-per-valutare-possibili-terapie2026-04-13T17:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22825-tumori-rari-infantili-un-progetto-per-ridurre-le-disuguaglianze-nella-cura2026-03-09T17:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22730-tumori-aifa-approva-luso-di-pembrolizumab-in-tre-nuove-indicazioni2026-02-10T15:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22706-cordoma-un-tumore-di-cui-bisogna-approfondire-il-profilo-genetico2026-02-03T08:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22665-cordoma-la-malattia-che-ha-causato-la-morte-della-figlia-di-freddy-mercury2026-05-11T17:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22637-tumore-desmoide-nuove-prospettive-di-trattamento-dagli-inibitori-della-gamma-secretasi2026-01-02T18:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22497-epatocarcinoma-aumentano-in-casi-correlati-a-disfunzione-metabolica2025-11-07T16:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22435-melanoma-uveale-le-nuove-possibilita-terapeutiche-ridisegnano-il-percorso-dei-pazienti2025-10-22T14:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22378-blood-cancer-summit-si-e-svolto-a-roma-il-primo-vertice-dedicato-ai-tumori-ematologici2025-10-08T10:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22357-glioma-di-basso-grado-idh-mutato-vorasidenib-approvato-in-europa2025-09-29T11:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22355-tumori-del-sangue-ail-accende-i-riflettori-sullimportanza-della-comunicazione-medico-paziente2025-09-28T16:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22266-melanoma-oculare-al-cnao-di-pavia-trattati-piu-di-600-pazienti-con-la-protonterapia2025-08-31T19:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22100-con-il-sopraggiungere-dell-estate-cresce-l-attenzione-verso-i-melanomi2025-06-17T15:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/22059-tumori-pediatrici-cresce-la-speranza-ma-restano-le-disuguaglianze-territoriali2025-06-06T15:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21993-idea4rc-un-alleanza-europea-per-rivoluzionare-la-ricerca-sui-tumori-rari2025-05-16T17:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21955-tumore-alla-gola-la-prevenzione-primaria-puo-abbattere-il-numero-di-casi2025-05-08T15:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21958-leiomiosarcoma-al-san-camillo-effettuato-con-successo-un-intervento-chirurgico-all-avanguardia2025-05-07T14:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21787-sarcomi-la-diagnosi-e-tardiva-per-un-paziente-su-due2025-03-07T15:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21617-epatocarcinoma-linee-guida-aggiornate-su-prevenzione-diagnosi-e-trattamento2025-01-08T11:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21550-tumore-ovarico-approvazione-della-commissione-europea-per-mirvetuximab-soravtansine2024-12-05T19:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21258-adenocarcinoma-del-piccolo-intestino-l-associazione-con-celiachia-e-morbo-di-crohn2024-09-04T18:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21247-tumori-ematologici-pediatrici-fiagop-e-admo-siglano-protocollo-d-intesa2024-09-02T08:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21126-successo-dell-immunoterapia-contro-i-tumori-delle-vie-biliari2024-06-29T11:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21111-sarcomi-presentato-il-primo-libro-bianco2024-06-25T11:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21068-tumori-pediatrici-in-italia-quali-sono-e-dove-curarli2024-06-11T07:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21064-tumori-pediatrici-e-rete-nazionale-tumori-rari-ecco-dove-curarsi2024-06-10T13:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21063-tumori-in-adolescenza-una-fascia-d-eta-critica-per-la-quale-e-necessaria-maggiore-attenzione2024-06-10T13:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21066-tumori-pediatrici-in-italia-quasi-2500-diagnosi-ogni-anno2024-06-10T13:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21062-tumori-pediatrici-circa-il-50-dei-bambini-viene-curato-fuori-dalla-propria-regione2024-06-11T07:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/21009-oncologia-di-precisione-il-futuro-della-lotta-ai-tumori2024-05-24T15:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20995-sarcomi-del-retroperitoneo-la-chirurgia-e-la-scelta-terapeutica-principale2024-05-23T12:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20903-leucemia-promielocitica-acuta-la-terapia-orale-per-migliorare-la-qualita-di-vita-dei-pazienti2024-04-24T16:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20812-pseudomixoma-peritonei-un-tumore-che-cresce-all-interno-dell-addome2024-03-28T11:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20807-quando-il-sesso-fa-la-differenza-il-carcinoma-alla-mammella-maschile2024-03-29T18:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20806-sarcomi-al-policlinico-gemelli-nasce-un-centro-dedicato2024-03-26T15:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20707-sarcoma-la-cantante-cat-janice-si-e-spenta-per-un-tumore-raro2024-05-29T10:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20658-adenomi-ipofisari-serve-un-sistema-di-classificazione-aggiornato2024-02-26T13:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20646-test-genomici-per-il-cancro-quando-ha-senso-farli2024-03-29T18:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20647-salvo-testa-dalla-diagnosi-di-mutazione-brca1-alla-fondazione-mutagens2024-02-16T16:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20628-colangiocarcinoma-oggi-la-giornata-mondiale-la-notizia-messo-a-punto-in-italia-un-modello-tridimensionale-del-tumore2024-02-14T12:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20493-tumori-del-fegato-irccs-de-bellis-e-fujifilm-insieme-per-la-diagnosi-precoce2024-02-08T11:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20433-tumori-ginecologici-prevenzione-e-farmaci-mirati-possono-sconfiggerli2023-12-12T15:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20326-sarcoma-epitelioide-pubblicato-uno-studio-sulle-prospettive-di-cura-future2023-11-12T21:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20264-sam-neill-protagonista-di-jurassic-park-e-affetto-da-un-linfoma-a-cellule-t2023-10-27T18:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20184-tumori-testa-collo-al-gemelli-si-e-svolto-il-9-congresso-nazionale-aiocc2023-10-02T17:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20101-linfomi-i-gruppi-pazienti-ail-per-la-tutela-dell-informazione-e-dei-diritti-del-malato2023-09-15T08:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20102-linfomi-sapere-cosa-sono-per-affrontarli-nel-migliore-dei-modi2023-09-09T07:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/20030-sarcoma-al-via-indagine-nazionale-rivolta-ai-pazienti2023-07-24T10:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19809-leucemia-mieloide-acuta-e-colangiocarcinoma-idh1-mutati-approvazione-europea-per-ivosidenib2023-05-18T16:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19703-leucemia-mielomonocitica-cronica-la-malattia-che-sembra-aver-colpito-silvio-berlusconi2023-04-07T18:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19670-leucemia-mieloide-acuta-identificate-cellule-tumorali-responsabili-delle-ricadute-di-malattia2023-03-28T16:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19654-l-eredita-di-sofia-sacchitelli-un-contributo-allo-studio-dell-angiosarcoma2023-03-21T15:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19620-leucemia-mieloide-acuta-e-colangiocarcinoma-parere-positivo-del-chmp-per-ivosidenib2023-03-12T10:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19542-tumore-alle-tube-nuove-opportunita-terapeutiche-grazie-alla-ricerca2023-02-17T16:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19485-leucemia-mieloide-acuta-nasce-la-rete-nazionale-palm2023-01-27T22:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19377-colangiocarcinoma-al-gemelli-un-percorso-clinico-assistenziale-dedicato2022-12-10T19:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19278-glioma-terapia-sperimentale-aumenta-l-aspettativa-di-vita-dei-piccoli-pazienti2022-11-15T18:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/19057-linfomi-la-maggior-parte-degli-italiani-conosce-solo-superficialmente-questi-tumori2024-10-16T15:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18906-leucemia-a-grandi-linfociti-granulati-t-individuati-nuovi-marcatori-di-progressione-della-patologia2022-07-09T21:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18751-epatocarcinoma-a-napoli-la-prima-tappa-del-roadshow-di-roche2022-06-11T10:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18711-tumori-rari-dentro-all-acceleratore-di-particelle-sviluppato-per-combatterli2025-08-31T19:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18652-colangiocarcinoma-una-patologia-in-progressiva-crescita2022-05-14T15:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18615-gliomi-diffusi-della-linea-mediana-tumori-cerebrali-tanto-rari-quanto-pericolosi2022-11-15T18:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18596-leucemia-mieloide-acuta-pubblicati-i-dati-dell-indagine-un-viaggio-da-fare-insieme2022-05-01T17:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18573-tumori-rari-al-cnao-di-pavia-corsi-di-arte-musica-e-yoga-per-pazienti-e-caregiver2022-04-24T17:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18572-leucemia-mieloide-acuta-rapida-nel-decorso-e-ad-alto-rischio-di-recidiva2022-04-24T17:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18555-carcinoma-epatocellulare-nuovo-studio-chiarisce-il-meccanismo-d-azione-del-farmaco-5-azacitidina2022-04-15T21:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18417-tumori-rari-il-centro-nazionale-di-adroterapia-oncologica-entra-nella-rete-europea-euracan2022-03-13T20:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18227-tumori-rari-l-istituzionalizzazione-della-rete-nazionale-e-ancora-un-miraggio2022-01-28T10:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18190-tumori-ematologici-e-online-il-nuovo-portale-gimema-alliance2022-01-19T10:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18156-sinovialsarcoma-all-istituto-regina-elena-effettuato-un-raro-e-delicato-intervento2022-01-05T14:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/18089-carcinoma-ovarico-avanzato-via-libera-in-italia-a-niraparib2021-12-12T16:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17874-linfoma-anaplastico-e-di-hodgkin-nuove-indicazioni-rimborsate-in-italia-per-brentuximab-vedotin2021-10-09T19:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17873-adenoma-ipofisario-ne-era-affetta-anche-la-venere-di-botticelli2026-04-24T11:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17721-armare-il-sistema-immunitario-per-combattere-le-leucemie2021-08-21T11:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17716-leucemia-mieloide-acuta-per-lo-sviluppo-di-nuove-terapie-e-utile-studiare-il-microambiente-tumorale2021-08-16T11:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17702-medulloblastoma-scoperto-il-meccanismo-che-ne-scatena-la-forma-piu-aggressiva2021-08-01T15:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17686-adroterapia-un-approccio-innovativo-per-il-trattamento-dei-tumori-rari2021-07-25T18:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17677-tumori-cerebrali-e-spinali-attivato-un-nuovo-pdta-al-san-giovanni-addolorata-di-roma2021-07-25T15:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17614-lanciata-la-campagna-facciamo-rete-contro-i-sarcomi2021-07-03T15:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17554-leucemia-mieloide-acuta-approvazione-europea-per-venetoclax-in-combinazione-con-un-agente-ipometilante2021-06-20T13:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17516-tumori-in-stadio-avanzato-cemiplimab-ottiene-doppio-parere-positivo-dal-chmp2021-06-06T21:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17442-melanoma-scoperta-la-proteina-che-controlla-la-formazione-di-metastasi2021-05-16T16:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17334-colangiocarcinoma-dall-oncologia-di-precisione-una-concreta-speranza-per-i-pazienti2021-04-27T18:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17313-carcinoma-epatocellulare-si-e-concluso-con-successo-l-hackathon-hack-for-hcc2021-04-18T15:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17253-colangiocarcinoma-approvazione-europea-per-pemigatinib2021-04-03T14:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17071-tumori-rari-discusso-ieri-un-ordine-del-giorno-presentato-dall-on-pagano2021-02-24T11:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/17016-tumori-oculari-rari-e-ad-alta-incidenza-di-metastasi2021-02-14T18:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16916-colangiocarcinoma-dalla-genetica-indizi-per-lo-studio-di-nuove-possibilita-terapeutiche2021-01-23T22:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16809-leucemia-mieloide-acuta-elevati-tassi-di-risposta-con-magrolimab-piu-azacitidina2020-12-15T11:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16793-tumori-rari-occorre-definire-la-rete-nazionale-e-investire-in-telemedicina-e-precision-medicine2020-12-11T10:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16729-premio-brusamolino-2020-premiati-progetti-innovativi-nella-cura-dei-linfomi2020-11-23T13:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16359-piu-forti-del-sarcoma-grande-successo-per-la-campagna-di-sensibilizzazione2020-08-03T22:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16330-tumore-fibroso-solitario-risultati-incoraggianti-dall-impiego-di-pazopanib2020-07-26T17:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16335-al-via-bersaglio-melanoma-pazienti-e-specialisti-alleati-per-la-prevenzione-e-la-diagnosi-precoce2020-07-28T08:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16301-sarcoma-cinque-storie-di-ragazzi-per-raccontare-la-malattia2020-07-20T16:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16278-carcinoma-epatocellulare-il-trapianto-di-fegato-si-conferma-la-miglior-terapia2020-07-12T15:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/16050-carcinoma-basocellulare-avanzato-risposte-significative-e-durature-con-cemiplimab2020-05-11T00:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15925-linfoma-anaplastico-sistemico-parere-favorevole-del-chmp-per-brentuximab-vedotin2020-04-08T16:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15911-leucemia-mieloide-acuta-gilteritinib-disponibile-in-italia2020-04-06T15:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15671-leucemie-e-linfomi-in-humanitas-una-car-t-unit-per-la-nuova-terapia-cellulare2020-02-17T19:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15649-colangiocarcinoma-oggi-e-la-giornata-mondiale2020-02-11T19:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15635-tumori-testa-collo-il-gene-p53-influenza-la-risposta-al-farmaco-alpelisib2020-02-05T20:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15575-colangiocarcinoma-convalidata-la-domanda-di-approvazione-di-pemigatinib-in-europa2020-02-26T22:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15510-colangiocarcinoma-un-tumore-raro-a-cui-la-ricerca-sta-dedicando-piu-attenzione2020-01-09T18:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15488-colangiocarcinoma-un-nuovo-farmaco-in-sperimentazione2019-12-08T20:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15472-colangiocarcinoma-le-mutazioni-genetiche-sono-la-chiave-di-volta-per-le-future-terapie2019-12-02T13:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15144-osteosarcoma-non-ce-l-ha-fatta-la-figlia-dell-allenatore-luis-enrique2019-08-30T13:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/15079-tumori-studiato-un-nuovo-farmaco-in-grado-di-addormentare-le-cellule-neoplastiche2019-07-30T14:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/14968-tumore-desmoide-fin-da-bambina-enrica-lotta-contro-questa-aggressiva-neoplasia2019-07-01T21:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/14922-linfoma-follicolare-messa-a-punto-una-nuova-strategia-immunoterapica2019-06-15T17:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/14847-linfoma-primitivo-del-sistema-nervoso-centrale-farmaco-sperimentale-testato-al-san-raffaele2019-05-26T08:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/14644-leucemia-mieloide-acuta-scoperto-perche-la-malattia-puo-tornare-dopo-il-trapianto-di-midollo2019-03-26T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/14624-linfoma-follicolare-obinutuzumab-e-rimborsabile-in-italia2019-03-22T18:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/14330-linfoma-indolente-presentati-i-dati-su-lenalidomide-in-combinazione-con-rituximab2019-01-06T18:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/14235-colangiocarcinoma-dall-istituto-nazionale-dei-tumori-una-nuova-prospettiva-farmacologica2018-12-04T21:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/14136-neurinoma-del-nervo-acustico-nuovi-benefici-dalla-radiochirurgia2018-11-08T19:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/13739-cordoma-in-avvio-uno-studio-clinico-su-una-potenziale-terapia-farmacologica2018-07-07T16:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/13672-linfoma-cerebrale-nuovi-dati-sul-potenziale-terapeutico-di-ngr-htnf2018-06-16T14:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/13639-rabdomiosarcoma-nuova-strategia-terapeutica-aumenta-le-probabilita-di-cura2018-06-07T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/13566-leucemia-mieloide-acuta-il-paziente-anziano-subisce-il-peso-della-chemioterapia2018-05-19T14:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/13104-cordoma-sviluppata-nuova-linea-cellulare-per-lo-studio-di-questo-tumore2018-01-14T21:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/13061-tumori-testa-collo-nel-2030-un-malato-su-2-sara-over-652017-12-23T10:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/13050-cordoma-del-sacro-in-italia-primo-studio-al-mondo-su-chirurgia-e-adroterapia2017-12-19T11:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/12524-in-italia-900mila-persone-vivono-con-un-tumore-raro-ma-manca-ancora-una-rete2017-07-21T10:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/12402-leucemia-mieloide-acuta-recidivante-o-refrattaria-buone-risposte-da-enasidenib2017-06-17T13:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/11752-leucemia-promielocitica-acuta-in-europa-la-malattia-potra-essere-affrontata-senza-la-chemioterapia2016-12-28T18:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/11226-glioma-a-basso-grado-la-sopravvivenza-globale-aumenta-con-la-chemioterapia-in-aggiunta-alla-radioterapia2016-09-14T10:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/11210-leucemia-mieloide-acuta-recidiva-il-sorafenib-potrebbe-rappresentare-un-valido-trattamento2019-05-21T15:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/11177-linfoma-di-burkitt-l-aggiunta-di-rituximab-alla-chemioterapia-migliora-la-sopravvivenza-libera-da-eventi2016-09-01T16:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/10699-carcinoma-papillare-della-tiroide-l-analisi-molecolare-serve-ad-orientare-la-terapia2016-07-06T14:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/10560-carcinoma-delle-paratirotidi2019-05-24T16:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/10459-tumori-del-cavo-orale-le-sei-regole-per-l-autodiagnosi2016-04-26T15:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/10183-tumori-testa-e-collo-tra-i-fattori-di-rischio-fumo-alcol-e-virus-comuni2016-03-16T08:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/10182-tumori-testa-e-collo-l-approccio-multidisciplinare-e-essenziale2016-03-11T14:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/10119-leucemia-a-cellule-capellute-un-percorso-verso-la-remissione-completa-senza-la-chemioterapia2016-03-04T14:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/9607-tumore-della-mammella-triplo-negativo-lo-studio-frida-apre-la-strada-ad-una-possibile-terapia2015-12-11T13:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/8763-carcinoma-a-cellule-basali-fda-approva-il-farmaco-sonidegib2015-08-06T18:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/8541-sarcomi-dei-tessuti-molli-al-gemelli-esperti-a-confronto2015-06-30T13:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/7553-leucemia-positiva-al-cromosoma-philadelphia-un-nuovo-farmaco-supera-la-resistenza-al-trattamento2015-05-26T08:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/7473-tumore-al-timo-colpiti-piu-di-un-paziente-per-milione2015-05-26T08:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/7406-linfoma-anaplastico-a-grandi-cellule-nuovi-dati-di-efficacia-per-il-farmaco-adcetris2015-05-26T08:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/7146-carcinoma-papillare-della-tiroide-la-terapia-con-iodio-radioattivo-aumenta-la-sopravvivenza2025-11-20T08:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/6389-linfoma-di-hodgkin-e-da-linfoma-anaplastico-a-grandi-cellule-sistemico-ora-il-farmaco-adcetris-e-rimborsabile-in-classe-h2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/6334-osteosarcoma-limportanza-della-formazione-e-dellaggiornamento-nella-terapia-medica-e-chirurgica-di-questa-patologia2023-01-17T22:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/5852-malattia-di-waldenstrom-definizione-della-patologia-e-nuove-prospettive-di-cura2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/5702-carcinoma-epatico-fibrolamellare-la-formazione-di-una-chimera-accomuna-i-pazienti2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/5688-cancro-tiroideo-nei-giovani-prognosi-peggiore-se-e-secondario2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/5598-linfoma-non-hodgkin-anche-il-nice-approva-pixantrone2024-10-16T15:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/5490-rimuovere-lastrocitoma-con-successo-possibile-se-ce-una-mutazione-genetica-specifica2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/5355-craniofaringioma-una-scoperta-scientifica-apre-la-strada-a-nuova-terapia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/5032-carcinoma-pancreatico-primo-si-dellema-al-nabpaclitaxel-in-combinazione-con-gemcitabina2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/4996-sostanze-naturali-in-oncologia-terapie-integrate-non-alternative2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/4982-cancro-papillare-della-tiroide-il-ruolo-incerto-del-gene-braf2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/4951-carcinoma-renale-papillare-metastatico-risultati-promettenti-per-everolimus2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/4765-tumore-renale-metastatico-sancita-la-pari-efficacia-per-sunitinib-e-pazopani2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/4403-tumori-gastrointestinali-in-piemonte-la-nuova-tecnica-di-rimozione-endoscopica-in-grado-di-preservare-gli-organi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/4388-leucemia-neutrofila-cronica-cnl-usato-per-la-prima-volta-il-ruxolitinib-in-un-paziente-con-mutazione-nel-gene-csf3r2019-06-19T08:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/4380-tumore-del-timo-essenziale-rivolgersi-a-centri-specializzati2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/4101-sarcoma-alveolare-asps-risultati-positivi-con-cediranib2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/3945-rabdomiosarcoma-e-leucemia-mieloide-acuta-dallema-una-guida-per-migliorare-i-trial2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/3857-melanoma-a-siena-si-sperimenta-una-terapia-combinata-contro-le-metastasi-cerebrali2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/3766-premio-omar-il-premio-speciale-celgene-assegnato-a-lidia-scognamiglio2024-03-28T11:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/2363-leucemia-mieloide-acuta-lassociazione-di-tre-farmaci-sembra-dare-ottimi-risultati2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/1919-tumori-rari-tcr-gene-editing-e-una-nuova-tecnologia-per-la-cura-delle-leucemie2018-02-09T10:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/1880-aspirina-tre-studi-confermano-il-potenziale-ruolo-preventivo-su-cancro-e-metastasi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/1877-sarcoma-dei-tessuti-molli-respinto-il-farmaco-sperimentale-di-merckaco-accettato-quello-di-glaxo2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/1712-melanoma-metastatico-il-trattamento-con-vemurafenib-puo-aumentare-la-sopravvivenza2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/1530-carcinoma-a-piccole-cellule-della-vescica-il-punto-su-diagnosi-e-terapie2021-11-02T15:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/1429-tumori-neuroendrocrini-everolimus-sembra-rallentare-la-progressione2018-12-16T10:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/1072-tumori-della-testa-e-del-collo-la-conoscenza-in-europa-e-troppo-bassa2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/972-epatocarcinoma-al-gemelli-la-radioembolizzazione-tratto-con-successo-il-primo-paziente2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/954-tumori-novita-sul-legame-tra-virus-e-malattie-e-su-possibile-terapie-innovative2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/797-leucemia-mieloide-cronica-il-desanitib-si-avvicina-sempre-piu-ad-essere-trattamento-di-prima-linea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/686-retinoblastoma-grazie-allattore-peppe-quintale-alle-scotte-di-siena-nuovo-laser-per-la-cura2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/576-leucemia-mieloide-acuta-sono-tre-i-gruppi-di-geni-che-collaborano-alla-sviluppo-del-cancro2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/536-linfoma-anaplasico-a-grandi-cellule-due-pazienti-italiani-con-recidiva-trattati-con-crizonitib2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/521-carcinoma-tiroideo-avanzato-pacini-raccomandare-la-target-therapy-ai-pazienti-e-un-dovere2015-06-08T10:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/503-tumori-rari-del-polmone-nasce-un-sito-dedicato-coordinato-da-modena2021-11-02T17:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/316-leucemia-mieloide-acuta-ricerca-americana-scopre-meccanismo-di-avvelenamento-generato-da-una-mutazione-genetica2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/290-retinoblastoma-nuova-tecnica-messa-a-punto-a-le-scotte-di-siena-ha-guarito-il-60-per-cento-dei-pazienti2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/252-tumori-rari-allistituto-scientifico-romagnolo-per-la-cura-dei-tumori-nuove-ricerche-sul-carcinoma-della-mammella-maschile2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/altri-tumori-rari/186-macroglobulinemia-di-waldenstrom-mw-il-niguarda-e-centro-di-riferimento-europeo-tre-due-sui-ricercatori-riceveranno-il-young-investigator-award2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net2025-03-25T19:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/22834-neuroblastoma-la-sfida-di-chieti-e-londra-bloccare-il-gene-che-alimenta-il-tumore2026-03-11T19:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/22546-neuroblastoma-al-gemelli-un-nuovo-approccio-per-il-monitoraggio-delle-masse-surrenaliche-neonatali2025-11-25T09:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/22249-tumori-neuroendocrini-la-terapia-radiorecettoriale-con-lutezio-177-si-puo-fare-in-day-hospital2025-08-18T21:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/22165-tumori-neuroendocrini-semaforo-verde-da-parte-dell-ema-per-cabozantinib2025-07-07T15:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/21911-neuroblastoma-al-san-camillo-operata-con-successo-una-neonata-di-soli-5-mesi2025-04-15T12:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/21299-neuroblastoma-libera-da-malattia-dopo-3-anni-grazie-a-un-farmaco-innovativo2024-09-18T13:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/20861-neuroblastoma-come-la-genetica-sta-migliorando-le-possibilita-di-trattamento2024-04-10T16:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/20729-preme-un-progetto-per-colpire-in-maniera-mirata-il-neuroblastoma2024-03-08T18:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/20472-tumori-neuroendocrini-la-chirurgia-e-un-opzione-importante-ma-va-attentamente-pianificata2023-12-21T16:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/20466-tumori-neuroendocrini-le-prospettive-future-della-terapia-con-radiofarmaci2023-12-19T18:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/20435-tumori-neuroendocrini-l-obiettivo-e-estendere-la-terapia-con-radioligandi-a-un-maggior-numero-di-pazienti2023-12-12T19:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/20420-tumori-neuroendocrini-il-ruolo-delle-associazioni-ascoltare-le-necessita-dei-pazienti-e-riportarle-ai-medici2023-12-06T15:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/20387-tumori-neuroendocrini-conclusa-con-successo-la-x-edizione-del-congresso-itanet2023-11-27T15:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/20305-tumori-neuroendocrini-oggi-la-giornata-mondiale-tra-consolidamenti-diagnostici-e-novita-terapeutiche2023-11-06T23:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/19514-tumore-neuroendocrino-polmonare-si-esplorano-potenzialita-della-medicina-nucleare2023-02-08T19:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/19331-tumori-neuroendocrini-trattamenti-sempre-piu-efficaci-e-con-minor-tossicita2022-11-27T11:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/19303-neuroblastoma-parte-la-campagna-di-natale-dono-ricerca-ridono-la-vita2022-11-25T16:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/19259-tumori-neuroendocrini-i-pazienti-vanno-supportati-e-orientati-nel-loro-percorso-di-cura2022-11-09T15:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/19261-tumori-neuroendocrini-il-10-novembre-e-la-giornata-mondiale2022-11-09T15:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/18598-tumori-neuroendocrini-una-web-radio-per-dare-voce-ai-pazienti2022-05-01T17:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/18441-neuroblastoma-sviluppato-modello-predittivo-che-evita-la-biopsia-ai-piccoli-pazienti2022-03-21T16:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/18149-il-musicista-chad-gilbert-operato-d-urgenza-dopo-una-diagnosi-di-feocromocitoma2021-12-31T12:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/18049-tumori-neuroendocrini-un-libro-per-raccontare-le-storie-dei-pazienti2021-11-27T23:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/16918-neuroblastoma-individuati-due-marcatori-che-predicono-le-possibilita-di-sopravvivenza2021-01-23T23:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/16230-tumori-neuroendocrini-per-la-diagnosi-e-importante-saper-riconoscere-la-sindrome-da-carcinoide2020-06-29T09:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/16064-tumori-neuroendocrini-la-terapia-radiorecettoriale-ritarda-la-progressione-di-malattia2020-05-12T20:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/16028-tumori-neuroendocrini-il-cinema-indiano-piange-irrfan-khan2020-05-05T15:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/15874-tumori-neuroendocrini-come-comportarsi-nell-emergenza-covid-192020-03-30T17:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/15720-neuroblastoma-ospedale-meyer-ed-enea-onlus-lanciano-un-progetto-di-ricerca2020-03-04T16:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/15594-tumori-neuroendocrini-il-san-gerardo-di-monza-in-prima-linea-nella-ricerca2020-06-26T09:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/15463-neoplasia-endocrina-multipla-un-calendario-per-far-conoscere-la-malattia2026-02-19T09:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14787-tumori-neuroendocrini-gep-net-fondamentale-l-approccio-multidisciplinare2019-05-08T11:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14780-tumori-neuroendocrini-cosa-sono-e-come-possono-essere-trattati2019-05-08T11:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14745-tumori-neuroendocrini-cos-e-la-teragnostica-e-come-sta-cambiando-la-medicina-nucleare2022-11-25T17:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14722-tumori-neuroendocrini-da-oggi-disponibile-una-terapia-innovativa2019-04-15T14:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14721-tumori-neuroendocrini-matteo-benedetta-e-federico-storie-diverse-per-la-stessa-diagnosi2019-04-13T18:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14713-tumori-neuroendocrini-aifa-autorizza-l-immissione-in-commercio-di-lutathera2019-04-13T11:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14631-tumori-neuroendrocini-in-italia-si-attende-a-breve-l-arrivo-del-lutezio-177lu-oxodotreotide2019-03-28T15:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14465-neoplasie-endocrine-multiple-cruciale-che-il-paziente-giunga-presto-dallo-specialista2019-05-24T10:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14445-tumori-neuroendocrini-dello-stomaco-forme-rare-da-non-sottovalutare2019-02-10T21:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14434-neoplasia-endocrina-multipla-di-tipo-1-piu-attenzione-alle-forme-familiari2019-05-24T10:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14345-tumori-neuroendocrini-il-net-cancer-day-come-occasione-per-riunire-esperti-e-pazienti2019-01-09T19:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/14064-feocromocitomi-e-paragangliomi-metastatici-comprenderli-per-trovare-nuove-cure2018-10-21T18:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/13644-neuroblastoma-l-immunoterapia-e-una-delle-strategie-di-trattamento-piu-promettenti2019-05-24T09:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/13329-von-hippel-lindau-la-sindrome-che-predispone-a-un-numero-incredibile-di-tumori2019-05-24T14:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/13315-tumori-neuroendocrini-alla-conferenza-enets-la-star-e-la-terapia-radiorecettoriale2018-03-09T14:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/13227-feocromocitoma-un-tumore-raro-che-mima-comuni-attacchi-d-ansia2018-02-12T23:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/13207-feocromocitoma-il-tumore-solido-con-la-piu-estesa-base-genetica2018-03-12T03:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/13070-neuroblastoma-la-genetica-e-fondamentale-per-lo-studio-di-nuovi-trattamenti2019-05-24T09:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/12952-tumori-neuroendocrini-con-le-radiazioni-e-possibile-coniugare-diagnosi-e-terapia2017-11-28T20:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/12893-tumori-neuroendocrini-un-ptda-impedisce-che-i-pazienti-si-disperdano-in-cerca-di-diagnosi2019-03-26T17:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/12856-tumori-neuroendocrini-la-terapia-radiorecettoriale-efficace-nella-malattia-in-fase-avanzata2017-11-02T16:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/12857-tumori-neuroendocrini-approda-in-europa-nuovo-radiofarmaco-mirato2017-11-02T16:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/12119-tumori-neuroendocrini-studiale-le-mutazioni-genetiche-correlate-puo-aiutare-a-scegliere-la-terapia2017-07-16T17:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/11735-tumori-neuroendocrini-net-con-anticorpi-monoclonali-come-everolimus-e-sunitinib-sempre-piu-pazienti-hanno-una-chance-terapeutica-valida2017-06-19T15:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/11150-tumori-neuroendocrini-net-grazie-a-diagnostica-e-terapia-oggi-sono-patologie-gestibili2023-02-01T12:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/10541-tumori-neuroendocrini-gli-analoghi-della-somatostatina-sono-il-cardine-del-trattamento2016-05-06T10:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/10397-tumori-neuroendocrini-gli-analoghi-della-somatostatina-hanno-un-effetto-antineoplastico2016-04-19T08:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/10369-tumori-neuroendocrini-in-italia-sei-centri-d-eccellenza2016-04-13T09:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/10368-approvata-la-nuova-indicazione-per-lanreotide-come-farmaco-ad-attivita-antiproliferativa-nel-trattamento-di-tumori-neuroendocrini-gastroenteropancreatici2016-04-14T08:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/5666-tumori-neuroendocrini-del-tratto-gastro-entero-pancreatico-gallio-68-dotatate-ottiene-la-denominazione-di-farmaco-orfano2015-11-03T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/5420-dallospedale-psichiatrico-alla-diagnosi-di-malattia-rara-i-medici-credevano-fosse-depressione2019-05-24T16:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/4882-tumori-neuroendocrini-il-dialogo-come-cura-domani-al-gemelli-lincontro-tra-medici-pazienti-e-familiari2015-11-03T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/4819-tumori-neuroendocrini-100-mila-casi-in-europa-negli-ultimi-cinque-anni2023-11-23T17:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/4811-tumori-neuroendocrini-dellintestino-tenue-raggiunta-quota-100-pazienti-nella-fase-iii-di-sperimentazione-clinica-del-radiofarmaco-italiano-lutathera2015-11-03T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/3868-tumore-neuroendocrino-ileale-a-perugia-effettuato-con-successo-intervento-di-chirurgia-radioguidata2019-05-24T08:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/701-tumori-neuroendocrini-domani-alle-scotte-di-siena-il-summit-nazionale2026-04-04T13:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/580-neuroblastoma-al-gemelli-nuova-strategia-contro-il-tumore-radio-e-chemio-fin-dal-principio2019-05-24T09:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/523-tumori-neuroendocrini-il-gruppo-oncologico-multidisciplinare-dellumbria-nominato-centro-di-eccellenza2015-11-03T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/443-tumori-neuroendocrini-pancreatici-leverolimus-puo-ridurre-fino-al-65-per-cento-la-progressione2018-12-16T10:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/339-neuroblastoma-studio-italiano-scopre-la-mutazione-genetica-collegata-al-tumore2019-05-24T09:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/325-tumori-neuroendocrini-lassociazione-umbra-vivere-la-speranza-ha-assegnato-due-borse-di-studio2015-11-03T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/226-sindromi-men-lassociazione-vivere-la-speranza-premia-il-dottor-diego-ferone-di-genova2019-05-24T10:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/220-sindromi-men-la-combinazione-di-farmaci-target-e-terapia-biologica-possono-aprire-la-strada-per-la-regressione2019-05-24T11:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/157-neoplasia-endocrina-multipla-clara-ha-atteso-la-diagnosi-per-dieci-anni2019-05-24T10:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/tumori-neuroendocrini-net/139-neoplasie-endocrine-multiple-troppo-tempo-per-arrivare-alla-diagnosi2019-05-24T10:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel2025-04-07T15:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/22468-carcinoma-a-cellule-di-merkel-approvato-in-italia-un-nuovo-farmaco2025-11-04T23:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/15454-carcinoma-a-cellule-di-merkel-la-radioterapia-adiuvante-e-utile2019-11-26T17:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/14988-carcinoma-a-cellule-di-merkel-a-padova-gli-specialisti-a-confronto2019-07-06T14:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/14765-carcinoma-a-cellule-di-merkel-la-terapia-con-gli-inibitori-dei-checkpoint-immunitari2026-04-02T15:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/14063-carcinoma-a-cellule-di-merkel-avelumab-disponibile-in-italia2018-10-21T18:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/13338-carcinoma-a-cellule-di-merkel-tra-le-cause-l-infezione-da-poliomavirus2018-03-14T12:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/12927-carcinoma-a-cellule-di-merkel-a-differenza-del-melanoma-se-ne-parla-ancora-troppo-poco2017-11-21T10:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/12574-carcinoma-a-cellule-di-merkel-con-la-chemioterapia-breve-la-risposta-e-scarsa-la-sopravvivenza2017-08-09T15:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/12252-carcinoma-a-cellule-di-merkel-approvazione-usa-per-avelumab2019-01-17T17:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/12060-carcinoma-a-cellule-di-merkel-due-nuovi-farmaci-ne-rallentano-la-progressione2017-06-19T15:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/11967-le-cellule-di-merkel-aumentano-notevolmente-con-le-lesioni-della-rasatura2017-06-19T15:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/11955-carcinoma-a-cellule-di-merkel-un-tumore-della-pelle-raro-e-aggressivo2017-02-20T10:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/carcinoma-a-cellule-di-merkel/10494-carcinoma-a-cellule-di-merkel-un-caso-italiano-di-regressione-spontanea2016-12-07T16:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera2024-03-13T12:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/21076-al-via-la-campagna-la-policitemia-e-vera-io-non-aspetto2024-06-13T15:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/20567-policitemia-vera-le-prospettive-terapeutiche-aggiornate-al-20242024-03-12T14:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/20518-policitemia-vera-al-congresso-ash-nuovi-dati-su-ropeginterferone-alfa-2b2024-01-15T12:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/19667-policitemia-vera-continuita-terapeutica-a-rischio-per-i-pazienti-arruolati-in-uno-studio-clinico2023-03-27T18:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/18971-policitemia-vera-positivi-i-dati-finali-su-ropeginterferone-alfa-2b2022-07-29T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/18761-policitemia-vera-ropeginterferone-alfa-2-b-rimborsabile-in-italia2022-06-12T12:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/17389-policitemia-vera-necessario-incrementare-la-formazione-di-specialisti-e-medici-di-base2021-05-04T13:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/13735-policitemia-vera-ruxolitinib-associato-a-un-minor-rischio-di-trombosi-e-morte2018-07-07T09:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/13427-policitemia-vera-quale-terapia-per-la-rara-neoplasia-mieloproliferativa2018-04-17T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/13428-policitemia-vera-come-si-arriva-alla-diagnosi-i-sintomi-gli-accertamenti-e-i-criteri-diagnostici2021-05-03T18:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/13362-policitemia-vera-la-risposta-a-ruxolitinib-persiste-a-distanza-di-anni2018-04-17T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/13158-neoplasie-mieloproliferative-in-alcuni-pazienti-la-malattia-evolve-in-un-altra2018-04-17T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/13035-policitemia-vera-presentati-i-dati-clinici-di-fase-i-e-ii-su-givinostat2018-04-17T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/12978-policitemia-vera-la-scoperta-della-causa-genetica-ha-rivoluzionato-diagnosi-e-terapia2018-04-17T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/10695-policitemia-vera-e-beta-talassemia-test-preclinici-promettenti-su-un-nuovo-tipo-di-peptide-sintetico2018-04-17T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/9651-mielofibrosi-e-policitemia-vera-presentati-i-dati-di-successo-del-farmaco-jakavi-ruxolitinib2018-04-19T18:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/8193-policitemia-vera-buoni-risultati-col-trattamento-con-ruxolitinib-ora-approvato-anche-da-ema2018-04-17T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/6344-policitemia-vera-risultati-positivi-per-ruxolitinib-dallo-studio-response2018-04-19T18:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/policitemia-vera/487-policitemia-vera-trovato-il-gene-sano-coinvolto-nellinsorgere-della-malattia2018-04-17T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi2026-02-10T18:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/22709-mielofibrosi-momelotinib-migliora-lanemia-e-riduce-il-bisogno-di-trasfusioni2026-02-03T08:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/22362-presentato-a-roma-il-progetto-uniti-per-la-mielofibrosi2025-09-29T14:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/21245-mielofibrosi-il-racconto-di-marinella-la-mia-milza-era-cresciuta-tanto-da-comprimere-gli-altri-organi2024-08-30T09:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/21208-mielofibrosi-a-volte-la-diagnosi-puo-arrivare-come-un-fulmine-a-ciel-sereno2024-08-05T07:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/21171-mielofibrosi-nuove-possibilita-terapeutiche-grazie-agli-anticorpi-farmaco-coniugati2024-07-12T14:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/21158-mielofibrosi-la-storia-di-nazzareno-da-30-anni-alle-prese-con-la-malattia2024-07-09T11:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/21140-mielofibrosi-il-trattamento-va-definito-sulla-condizione-del-singolo-paziente2024-07-03T12:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/21115-mielofibrosi-occorre-saper-riconoscere-la-malattia-per-giungere-a-una-diagnosi-tempestiva2024-07-01T10:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/20578-mielofibrosi-via-libera-della-commissione-europea-a-momelotinib2024-01-30T13:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/19993-tumori-ematologici-una-guida-per-migliorare-l-interazione-dei-pazienti-con-medici-e-familiari2023-07-10T10:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/13795-mielofibrosi-risultati-positivi-in-termini-di-efficacia-e-tollerabilita-per-terapia-con-ruxolinitb2018-07-30T17:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/13527-mielofibrosi-ritardo-diagnostico-e-rischio-di-depressione-ma-con-la-giusta-terapia-una-vita-di-qualita2018-05-05T14:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/13450-mielofibrosi-quali-possibilita-terapeutiche-per-questa-neoplasia2018-04-16T16:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/13449-mielofibrosi-fondamentale-la-diagnosi-precoce-la-parola-all-esperto2018-05-22T06:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/13142-neoplasie-mieloproliferative-il-peso-della-malattia-puo-spingere-i-pazienti-ad-isolarsi2018-01-24T16:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/13036-mielofibrosi-ruxolitinib-e-una-possibile-alternativa-al-trapianto-di-staminali2018-01-04T11:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/13017-mielofibrosi-una-sola-malattia-ma-contraddistinta-da-diversi-gradi-di-rischio2017-12-11T16:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/10785-mielofibrosi-il-farmaco-ruxolitinib-evidenzia-benefici-nella-sopravvivenza-dei-pazienti2018-04-24T10:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/7362-malattie-mieloproliferative-ph-negative-luso-degli-interferoni-e-limportanza-dei-fattori-genetici2018-04-24T10:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/7361-patologie-mieloproliferative-croniche-le-novita-terapeutiche-dallaash-di-s-francisco2018-04-24T10:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/4609-terapia-con-ruxolitinib-aumenta-la-sopravvivenza-dei-pazienti-con-mielofibrosi2017-10-08T18:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/3962-mileofibrosi-terapie-sintomatiche-in-attesa-di-scoprirne-i-meccanismi-molecolari2017-10-08T23:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/2265-terapia-con-ruxolitinib-per-la-mielofibrosi-efficacia-confermata-da-due-nuovi-studi-clinici2017-10-08T23:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/2072-mielofibrosi-comitato-ue-approva-ruxolitinib-per-i-pazienti-in-pericolo-di-vita2017-10-08T23:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/1764-mielofibrosi-ruxolitinib-in-grado-di-contrastare-i-sintomi-della-malattia2017-10-08T23:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/mielofibrosi/634-malattie-mieloproliferative-i-farmaci-a-disposizione-non-sono-la-cura-ma-migliorano-la-vita2017-10-08T23:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla2024-03-13T12:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/23085-sangue-bianco-al-festival-di-cannes-un-cortometraggio-sulla-leucemia-linfoblastica-acuta2026-05-26T11:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/22708-nuove-prospettive-per-la-leucemia-linfoblastica-acuta-a-cellule-t2026-02-03T22:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/21336-leucemia-linfoblastica-acuta-neonatale-dimostrata-l-origine-prenatale-e-non-ereditaria-di-una-nuova-alterazione-genetica2024-09-30T15:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/21232-leucemia-linfoblastica-acuta-agire-sul-microambiente-tumorale-per-combattere-la-malattia2024-08-13T15:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/20137-leucemia-linfoblastica-acuta-scoperte-alterazioni-genetiche-che-ne-influenzano-l-esito-nei-bimbi-con-sindrome-di-down2023-09-18T15:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/19356-leucemia-linfoblastica-acuta-nuovo-marcatore-orienta-la-terapia-nei-bambini2024-08-13T10:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/18876-tumori-ematologici-nei-bambini-due-varianti-di-un-gene-potrebbero-aumentarne-il-rischio2022-07-03T20:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/18151-leucemia-linfoblastica-acuta-di-tipo-t-decifrato-il-linguaggio-delle-cellule-tumorali2022-01-02T14:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/17557-leucemia-linfoblastica-acuta-dimostrata-l-efficacia-della-terapia-senza-chemioleucemia-linfoblastica-acuta-dimostrata-l-efficacia-della-terapia-senza-chemio2021-06-23T08:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/17514-leucemia-linfoblastica-acuta-di-tipo-t-un-anticorpo-sentinella-e-in-grado-di-riconoscere-le-cellule-tumorali2021-06-06T20:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/16955-leucemia-linfoblastica-acuta-ph-in-sperimentazione-una-nuova-terapia-di-combinazione2021-01-31T00:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/16868-leucemia-linfoblastica-acuta-due-geni-aiutano-a-prevederne-la-gravita-nei-neonati2021-01-07T19:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/16658-leucemia-linfoblastica-acuta-verso-una-terapia-chemio-free2020-11-09T10:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/16529-leucemia-linfoblastica-acuta-aifa-approva-l-estensione-d-uso-di-blinatumomab2020-10-04T18:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/15114-leucemia-lla-e-linfoma-dlbcl-la-terapia-car-t-arriva-in-italia2019-08-12T17:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/14292-leucemia-linfoblastica-acuta-ph-da-un-nuovo-studio-clinico-una-speranza-di-guarigione2018-12-17T18:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/14032-leucemia-linfoblastica-acuta-inotuzumab-ozogamicin-disponibile-in-italia2018-10-14T17:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/13868-leucemia-linfoblastica-acuta-la-terapia-car-t-arriva-anche-in-europa2019-01-17T15:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/13190-leucemia-linfoblastica-acuta-piccolo-paziente-curato-al-bambino-gesu-con-terapia-car-t2018-02-04T23:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/6925-leucemia-linfoblastica-acuta-remissione-completa-con-la-terapia-ctl0192015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/5856-leucemia-linfoblastica-acuta-negli-adulti-il-tasso-di-sopravvivenza-negli-ultimi-anni-e-aumentato2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/3639-leucemia-linfoblastica-acuta-scoperto-il-punto-debole-del-tumore2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/552-leucemia-linfoblastica-acuta-status-orfano-per-un-farmaco-che-rompe-le-cellule-tumorali2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/419-leucemia-linfoblastica-acuta-nuove-conferme-per-limatinib2019-02-13T19:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/200-leucemia-linfoblastica-il-meyer-al-centro-di-uno-studio-internazionale-porte-aperte-per-i-trial-sui-farmaci-intelligenti2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfoblastica-acuta-lla/199-leucemia-linfoblastica-acuta-ricerca-internazionale-guidata-dal-meyer-fa-il-punto-sulla-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica2024-03-13T12:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/22571-leucemia-mieloide-cronica-asciminib-approvato-in-europa-anche-per-i-pazienti-di-nuova-diagnosi2025-12-01T17:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/21899-leucemia-mieloide-cronica-da-due-nuove-indagini-emerge-il-racconto-di-una-malattia-non-ancora-risolta2025-04-13T11:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/21588-leucemia-mieloide-cronica-nuovi-dati-a-lungo-termine-avvalorano-l-efficacia-di-asciminib2024-12-18T09:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/19109-leucemia-mieloide-cronica-un-cortometraggio-per-conoscerla-e-non-temerla2022-09-24T19:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/16785-leucemia-mieloide-cronica-cml-percorso-di-vita-e-claude-vincono-il-cml-innovation-hub2020-12-08T22:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/11687-leucemia-mieloide-cronica-studi-sulla-proteina-gab2-aprono-a-nuove-alternative-terapeutiche2024-08-13T15:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/7459-leucemia-mieloide-cronica-e-leucemia-linfoblastica-acuta-ottenuta-approvazione-ema-per-il-farmaco-ponatinib2024-08-13T10:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/3881-leucemia-mieloide-cronica-la-commissione-europea-approva-il-trattamento-con-bosutinib2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/267-leucemia-mieloide-cronica-scoperta-la-mutazione-che-fa-fallire-la-chemioterapia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-mieloide-cronica/246-leucemia-mieloide-cronica-il-farmaco-intelligente-imatinib-potrebbe-proteggere-dalle-ricadute-anche-dopo-due-anni-e-prendersi-una-vacanza-dal-farmaco-non-genera-resistenza2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica2024-03-13T12:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/20809-leucemia-linfatica-cronica-la-dieta-mima-digiuno-abbinata-ai-farmaci-puo-contribuire-alla-regressione-tumorale2024-03-27T16:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/20408-leucemia-linfatica-cronica-e-linfoma-della-zona-marginale-aifa-approva-zanubrutinib2023-12-04T11:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/20225-long-covid-nei-pazienti-affetti-da-leucemia-linfatica-cronica-le-nuove-evidenze-scientifiche2023-10-14T11:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/20179-leucemia-linfatica-cronica-al-via-faccia-a-faccia-con-la-llc2023-10-02T11:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/18574-leucemia-linfatica-cronica-individuati-i-marcatori-associati-al-rischio-di-sviluppo-di-sindrome-di-richter2022-04-24T18:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/18131-malattie-oncoematologiche-da-fondazione-quattropani-un-servizio-di-medical-coaching-per-i-pazienti2021-12-24T12:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/17423-leucemia-linfatica-cronica-con-venetoclax-piu-rituximab-miglioramenti-nella-qualita-di-vita2021-05-11T15:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/16354-leucemia-linfatica-cronica-chmp-dice-si-all-estensione-d-indicazione-per-ibrutinib-piu-rituximab2020-08-02T15:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/16201-leucemia-linfatica-cronica-confermati-i-benefici-della-terapia-con-venetoclax-piu-rituximab2020-06-21T19:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/15555-leucemia-linfatica-cronica-aifa-concede-rimborsabilita-a-venetoclax-in-combinazione-con-rituximab2020-01-07T16:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/11497-leucemia-linfatica-cronica-chmp-raccomanda-venetoclax-per-pazienti-difficili-da-trattare2016-10-20T12:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/7556-leucemia-linfatica-cronica-scoperta-la-causa-delle-recidive-dopo-il-trattamento2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/3288-leucemia-maggiore-rischio-per-i-lavoratori-che-hanno-ripulito-chernobyl2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/2030-leucemia-linfatica-cronica-il-citomegalovirus-potrebbe-esserne-la-causa2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/1274-leucemia-linfatica-cronica-arriva-ofatumumab-nuova-arma-contro-i-casi-resistenti2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/leucemia-linfatica-cronica-che-cos-e2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/leucemia-linfatica-cronica/486-leucemia-linfocitica-cronica-llc-lunga-sopravvivenza-grazie-a-rituximab-e-fludarabine2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t2026-02-02T10:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/23053-linfoma-cutaneo-a-cellule-t-dallo-studio-proclipi-segnali-positivi-per-mogamulizumab2026-05-15T13:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/22752-linfoma-cutaneo-a-cellule-t-il-valore-della-radioterapia-per-ridurre-le-lesioni-della-cute2026-02-17T08:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/21665-linfoma-cutaneo-a-cellule-t-un-tumore-multiforme-che-rende-complessa-la-diagnosi2025-01-28T17:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/20977-linfoma-cutaneo-a-cellule-t-arrivera-anche-la-terapia-con-car-t2024-05-15T15:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/20888-linfoma-cutaneo-a-cellule-t-presentati-i-primi-risultati-dello-studio-prosper-su-mogalizumab2024-04-19T14:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/20593-linfoma-cutaneo-a-cellule-t-il-rischio-di-sepsi-sembra-essere-piu-alto-nei-pazienti-afroamericani2024-02-06T08:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/20294-linfoma-cutaneo-a-cellule-t-il-ruolo-chiave-dell-anatomo-patologo-nella-diagnosi-di-malattia2023-11-06T20:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/19503-linfoma-cutaneo-a-cellule-t-un-video-spiega-cosa-significhi-affrontare-una-diagnosi-di-tumore-raro2023-02-03T18:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/19352-linfoma-cutaneo-a-cellule-t-il-prurito-alla-pelle-puo-essere-un-indicatore-della-qualita-di-vita2022-12-02T17:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/17783-linfoma-cutaneo-a-cellule-t-fino-a-7-anni-per-una-diagnosi-corretta2021-09-16T10:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/17611-linfoma-cutaneo-a-cellule-t-con-mogamulizumab-migliore-qualita-di-vita-nei-pazienti-con-coinvolgimento-del-sangue2021-07-03T14:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/16803-linfoma-cutaneo-a-cellule-t-mogamulizumab-rimborsabile-in-italia2020-12-13T21:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/16610-linfoma-cutaneo-a-cellule-t-nuove-conferme-di-efficacia-per-mogamulizumab2020-10-24T11:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/16581-linfoma-cutaneo-a-cellule-t-la-gestione-dei-pazienti-in-emergenza-covid-192020-10-18T22:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/16311-linfomi-cutanei-necessario-un-percorso-diagnostico-e-terapeutico-multidisciplinare2020-07-20T10:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/16206-linfoma-cutaneo-a-cellule-t-mogamulizumab-in-commercio-in-europa2020-06-21T21:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/15471-linfoma-cutaneo-a-cellule-t-le-terapie-cambiano-a-seconda-delle-forme-di-malattia2019-12-02T12:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/15285-linfoma-cutaneo-a-cellule-t-a-brescia-un-ambulatorio-che-unisce-ematologia-e-dermatologia2019-10-08T18:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/15246-linfoma-cutaneo-a-cellule-t-come-distinguerlo-da-una-semplice-dermatite2019-09-30T19:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/14223-linfoma-cutaneo-a-cellule-t-approvazione-europea-per-mogamulizumab2019-06-14T18:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-cutaneo-a-cellule-t/13162-linfoma-cutaneo-a-cellule-t-la-commissione-europea-approva-brentuximab-vedotin2019-06-14T18:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile2026-01-12T16:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18992-emangioma-infantile-i-genitori-devono-poter-disporre-di-informazioni-chiare-e-affidabili2022-08-10T14:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18955-emangioma-infantile-fondamentale-individuare-i-centri-di-riferimento-presenti-sul-territorio2022-07-24T17:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18950-emangioma-infantile-un-modello-di-organizzazione-per-la-corretta-presa-in-carico-del-paziente2022-07-24T15:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18927-emangioma-infantile-se-necessario-il-paziente-va-inviato-al-centro-di-riferimento-gia-nel-primo-mese-di-vita2022-07-16T21:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18907-emangioma-infantile-la-chiave-e-una-diagnosi-accurata2022-07-09T21:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18836-emangioma-infantile-a-volte-e-la-manifestazione-di-una-sindrome-piu-grave2022-06-25T15:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18708-emangiomi-infantili-un-pediatra-adeguatamente-formato-puo-prendere-decisioni-giuste-e-tempestive2022-05-30T11:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18593-emangiomi-infantili-in-circa-il-15-dei-casi-necessitano-di-opportune-terapie2022-05-17T14:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18471-emangioma-infantile-fondamentale-che-il-pediatra-sappia-valutare-questo-tumore-benigno2022-04-01T17:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18297-emangiomi-infantili-una-diagnosi-tempestiva-massimizza-i-benefici-di-un-eventuale-trattamento2022-02-13T16:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18262-emangiomi-infantili-al-via-la-campagna-di-sensibilizzazione-con-influencer-e-mamme-blogger2022-03-14T16:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/18231-emangioma-infantile-una-neoplasia-benigna-da-saper-riconoscere-e-gestire2022-01-31T12:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/10432-emangiomi-infantili-l-importanza-della-sinergia-e-della-diagnosi-precoce2021-10-11T11:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/10296-emangiomi-infantili-online-un-nuovo-sito-di-supporto-ai-genitori2021-10-11T11:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/9895-emangioma-infantile-uso-improprio-della-terminologia-aumenta-rischio-di-diagnosi-errata2021-10-11T11:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/9381-emangioma-infantile-presto-anche-in-italia-il-primo-farmaco-destinato-ai-bambini2021-10-11T11:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/8527-emangiomi-infantili-arrivano-le-prime-raccomandazioni-europee2021-10-11T11:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/8457-emangioma-infantile-necessaria-una-rete-nazionale-di-centri-plurispecialistici2021-10-11T11:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/emangioma-infantile/5614-emangiomi-infantili-ok-del-chmp-per-il-propranololo2021-10-11T11:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche2025-03-04T11:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche/21686-neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche-la-diagnosi-e-frutto-di-un-lavoro-di-squadra2025-02-03T17:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche/21613-neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche-il-trapianto-di-midollo-e-l-obiettivo-per-guarire2025-01-09T14:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche/21600-neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche-un-intervento-tempestivo-puo-fare-la-differenza2024-12-20T11:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche/21553-neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche-la-diagnosi-ha-inizio-dalle-lesioni-della-cute2024-12-02T18:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche/21501-neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche-promuovere-la-conoscenza-della-patologia-serve-a-non-far-sentire-isolato-chi-ne-e-affetto2024-11-18T17:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche/21307-neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche-un-nuovo-farmaco-mirato-aiuta-a-definire-lo-schema-terapeutico2024-09-25T11:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche/21191-neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche-un-tumore-ematologico-raro-e-aggressivo2024-11-19T10:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b2026-06-04T07:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/22679-linfoma-diffuso-a-grandi-cellule-b-il-recettore-bcr-influisce-sullaggressivita-del-tumore2026-01-20T18:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/22452-linfoma-diffuso-a-grandi-cellule-b-la-stadiazione-e-una-tappa-indispensabile-nel-percorso-di-cura2025-10-28T15:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/21813-linfoma-diffuso-a-grandi-cellule-b-prospettive-di-cura-migliorate-grazie-alla-ricerca2025-03-17T09:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/21351-linfoma-diffuso-a-grandi-cellule-b-aifa-approva-la-rimborsabilita-di-epcoritamab2024-10-16T10:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/20799-thebigb-una-performance-artistica-per-sensibilizzare-sul-linfoma-a-grandi-cellule-b-dlcbl2024-10-16T12:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/20622-linfoma-diffuso-a-grandi-cellule-b-polatuzumab-approvato-in-italia-come-trattamento-di-prima-linea2024-10-16T10:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/20010-linfoma-diffuso-a-grandi-cellule-b-approvazione-europea-per-glofitamab2024-10-16T10:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/19332-linfoma-diffuso-a-grandi-cellule-b-via-libera-di-aifa-al-rimborso-di-tafasitamab2024-10-16T10:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/18200-linfoma-diffuso-a-grandi-cellule-b-polatuzumab-vedotin-rimborsabile-in-italia2024-10-16T10:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/17728-linfoma-diffuso-a-grandi-cellule-b-approvazione-europea-per-tafasitamab2024-10-16T11:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/17680-linfomi-a-cellule-b-da-uno-studio-italiano-una-potenziale-nuova-terapia2024-10-16T15:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/17206-linfomi-pubblicato-uno-studio-fil-sul-primo-indice-prognostico-per-pazienti-anziani2024-10-16T15:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/16806-linfoma-diffuso-a-grandi-cellule-b-nuovi-dati-a-supporto-di-polatuzumab-vedotin-piu-bendamustina-e-rituximab2024-10-16T11:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/15553-linfoma-non-hodgkin-da-uno-studio-fil-un-nuovo-approccio-terapeutico-per-pazienti-anziani2024-10-16T16:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/14242-linfoma-diffuso-a-grandi-cellule-b-benefici-duraturi-dalla-terapia-con-polatuzumab-vedotin2024-10-16T11:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/13871-linfoma-a-grandi-cellule-b-approvazione-europea-per-la-terapia-car-t2024-10-16T12:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/13740-leucemia-lla-e-linfoma-dlbcl-parere-positivo-del-chmp-per-tisagenlecleucel2024-10-16T15:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/11063-linfoma-diffuso-a-grandi-cellule-b-dati-di-parziale-efficacia-per-il-farmaco-lenalidomide2024-10-16T11:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/10049-linfoma-a-grandi-cellule-b-efficace-terapia-con-blinatumomab2024-10-16T12:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-tumori-rari/linfoma-diffuso-a-grandi-cellule-b/6578-linforma-diffuso-a-grandi-cellule-b-studio-italiano-indaga-sulla-dose-massima-tollerata2024-10-16T12:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/errore2019-05-15T15:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorispondeweekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/linfedema-e-lipedema2020-05-18T10:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/fibrosi-polmonare-idiopatica2020-11-16T18:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/fibrosi-cistica2020-11-16T18:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/angioedema-ereditario2023-01-30T09:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/sindrome-di-hunter2023-07-12T08:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/citomegalovirus-congenito2020-11-16T18:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/ipercolesterolemia-familiare-e-dislipidemie2020-11-16T18:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/malattie-epatiche-autoimmuni2020-11-16T18:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/deficit-di-lipasi-acida-lisosomiale2020-11-16T18:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/deficit-di-lipasi-acida-lisosomiale-bambini2020-11-16T18:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/lipodistrofia2020-11-16T18:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/distrofia-muscolare-di-duchenne-pediatrici2025-03-19T09:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/distrofia-muscolare-di-duchenne-giovani-e-adulti2022-06-06T16:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/malattia-di-fabry2025-02-05T11:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/malattia-polmonare-da-micobatteri-non-tubercolari-pazienti-del-centro-sud2020-11-16T18:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/malattia-polmonare-da-micobatteri-non-tubercolari-pazienti-del-centro-nord2020-11-16T18:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/porfiria2020-11-16T18:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/ceroidolipofuscinosi-neuronali2020-11-16T18:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/rachitismo-ipofosfatemico2025-04-30T12:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/malattie-rare-e-coronavirus2021-03-17T17:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/emofilia2022-09-05T15:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/malattia-di-gaucher2023-05-26T17:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/amiloidosi2023-05-26T17:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/miastenia-grave2026-01-12T15:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/leucodistrofia-metacromatica2024-03-25T11:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/espertorisponde/deficit-di-piruvato-chinasi2023-06-06T09:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rariweekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/20547-come-incidono-permessi-e-congedi-per-assistenza-sul-calcolo-di-tredicesima2024-01-22T18:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/20491-congedo-straordinario-per-assistenza-e-permessi-104-sono-compatibili2024-01-08T12:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/19631-assegni-e-pensione-legati-all-invalidita-quali-sono-le-differenze2023-03-14T16:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/19453-lavoratori-con-disabilita-come-funziona-il-congedo-per-cure2023-02-20T15:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/19441-malattie-rare-e-periodo-di-comporto-quanti-sono-giorni-di-assenza-giustificata-per-malattia2023-01-11T15:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/19410-online-la-guida-tutti-i-diritti-dei-talassemici-dedicata-a-pazienti-e-caregiver2022-12-22T12:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18632-emergenza-ucraina-le-misure-di-accoglienza-previste-dal-friuli-venezia-giulia2022-05-10T17:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18580-emergenza-ucraina-le-misure-di-accoglienza-previste-dalla-basilicata2022-04-27T10:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18512-emergenza-ucraina-le-misure-sanitarie-dell-accoglienza-il-dossier-di-omar2022-05-10T17:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18486-emergenza-ucraina-le-misure-di-accoglienza-previste-dal-piemonte2022-04-04T07:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18484-emergenza-ucraina-le-misure-di-accoglienza-previste-dalla-valle-d-aosta2022-04-04T07:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18482-emergenza-ucraina-le-misure-di-accoglienza-previste-dal-trentino-alto-adige2022-04-04T07:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18480-emergenza-ucraina-le-misure-di-accoglienza-previste-dalla-liguria2022-04-04T07:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18479-emergenza-ucraina-le-misure-di-accoglienza-previste-dall-emilia-romagna2022-04-04T07:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18478-emergenza-ucraina-le-misure-di-accoglienza-previste-dall-abruzzo2022-04-04T07:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18469-emergenza-ucraina-le-misure-di-accoglienza-previste-dalla-toscana2022-04-04T07:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18467-emergenza-ucraina-le-misure-di-accoglienza-previste-dalla-lombardia2022-04-04T07:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18466-emergenza-ucraina-le-misure-di-accoglienza-previste-dal-veneto2022-04-04T07:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18301-quali-sono-le-misure-legate-al-covid-in-vigore-per-i-lavoratori-fragili2022-03-14T14:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18281-reddito-di-cittadinanza-e-invalidita-civile-sono-compatibili2022-02-10T16:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18023-disabilita-il-progetto-individualizzato-per-la-vita-indipendente2021-11-21T21:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/18022-come-si-realizza-il-progetto-individualizzato-per-la-vita-indipendente-l-esperienza-di-claudia2021-11-21T22:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/17940-inclusione-scolastica-la-denuncia-di-nicolo-voglio-andare-a-scuola-con-i-miei-compagni-sullo-scuolabus2021-10-26T12:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/17440-licenziata-paziente-con-fibrosi-cistica-mentre-era-in-coma-in-seguito-a-trapianto-polmonare2021-05-16T11:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/17258-epilessia-farmacoresistente-la-denuncia-troppi-i-diritti-negati-a-causa-della-scarsa-conoscenza2021-04-06T08:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/17249-disabilita-e-covid-congedi-e-smart-working-alternativi-ledono-il-diritto-dei-piu-fragili-e-delle-loro-famiglie2021-06-16T09:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/17215-assegno-per-il-nucleo-familiare-come-funziona-a-chi-spetta-e-come-fare-domanda2021-12-09T15:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/17073-lavoro-posso-chiedere-la-trasformazione-del-contratto-di-lavoro-full-time-in-contratto-di-lavoro-part-time2021-12-09T16:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/17031-invalidita-e-prepensionamento-cosa-prevede-la-legge2022-03-31T15:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/16974-caregiver-familiari-lavoratori-a-tempo-pieno-invisibili-a-tutti2021-02-08T21:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/16883-pensione-di-invalidita-civile-e-assegno-di-mantenimento-sono-compatibili2021-01-15T09:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/16504-covid-docenti-e-personale-ata-chi-ha-patologie-a-rischio-puo-essere-esonerato2020-09-28T18:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/16121-o-una-malattia-rara-sono-considerato-a-rischio-covid-19-posso-assentarmi-dal-lavoro2022-01-13T10:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/14705-assegno-ordinario-d-invalidita-che-cos-e-e-chi-puo-chiederlo2020-11-16T14:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/14632-sindrome-di-williams-stop-alla-revisione-annuale-per-invalidita-civile-e-legge-1042019-06-25T13:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/14437-malattie-rare-stop-agli-extra-lea-i-pazienti-potrebbero-subire-discriminazioni2022-05-24T16:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/13979-deficit-di-cobalamina-c-per-i-piccoli-pazienti-le-iniezioni-sono-un-incubo-si-lotta-per-ridurle2019-06-25T13:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/13271-pma-e-diagnosi-genetica-preimpianto-per-i-portatori-di-malattie-rare-genetiche-e-davvero-un-diritto2019-06-25T13:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/13274-malattie-rare-e-trasferimento-all-estero-quali-diritti-alle-cure-e-accesso-ai-farmaci2019-06-25T13:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/13262-sportello-legale-omar-una-rubrica-di-consulenza-legale-a-disposizione-dei-malati-rari2020-10-08T12:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/sportello-legale-omar-dalla-parte-dei-rari/13176-ilaria-vacca-e-roberta-venturi2020-10-08T12:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/ipf-guida-ai-centri-italiani-per-la-fibrosi-polmonare-idiopaticaweekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/ipf-guida-ai-centri-italiani-per-la-fibrosi-polmonare-idiopatica/10629-ipf-i-centri-della-puglia-per-la-fibrosi-polmonare-idiopatica2022-05-18T16:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/ipf-guida-ai-centri-italiani-per-la-fibrosi-polmonare-idiopatica/10622-ipf-i-centri-della-toscana-per-la-fibrosi-polmonare-idiopatica2022-01-11T17:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italianiweekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/20342-psoriasi-pustolosa-generalizzata-i-centri-dell-abruzzo2025-06-24T08:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19458-psoriasi-pustolosa-generalizzata-i-centri-della-campania2025-06-24T08:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19459-psoriasi-pustolosa-generalizzata-i-centri-dell-emilia-romagna2025-06-24T08:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/20854-psoriasi-pustolosa-generalizzata-i-centri-del-friuli-venezia-giulia2025-06-24T08:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19460-psoriasi-pustolosa-generalizzata-i-centri-del-lazio2025-06-24T08:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19461-psoriasi-pustolosa-generalizzata-i-centri-della-liguria2025-06-24T08:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19462-psoriasi-pustolosa-generalizzata-i-centri-della-lombardia2025-06-24T08:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/20343-psoriasi-pustolosa-generalizzata-i-centri-delle-marche2025-06-24T08:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19463-psoriasi-pustolosa-generalizzata-i-centri-del-piemonte2025-06-24T08:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19464-psoriasi-pustolosa-generalizzata-i-centri-della-puglia2025-06-24T08:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/20344-psoriasi-pustolosa-generalizzata-i-centri-della-sardegna2025-06-24T08:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/20345-psoriasi-pustolosa-generalizzata-i-centri-della-sicilia2025-06-24T09:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19465-psoriasi-pustolosa-generalizzata-i-centri-della-toscana2025-06-24T09:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/20853-psoriasi-pustolosa-generalizzata-i-centri-del-trentino-alto-adige2025-06-24T09:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/20851-psoriasi-pustolosa-generalizzata-i-centri-dell-umbria2025-09-22T18:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/psoriasi-pustolosa-generalizzata-guida-ai-centri-italiani/19466-psoriasi-pustolosa-generalizzata-i-centri-del-veneto2025-06-24T09:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/i-nostri-servizi/rachitismo-ipofosfatemico-guida-ai-centri-italianiweekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioniweekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/23027-ridefiniamo-linclusione-parole-e-azioni-per-la-health-equity2026-05-09T16:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/22461-ipoparatiroidismo-guida-ai-diritti2026-05-14T17:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/21873-i-bisogni-dei-pazienti-con-malattie-rare-del-complemento-casi-studio-epn-e-c3g2025-04-03T08:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/21802-screening-per-la-sma-la-responsabilita-di-una-scelta2025-03-12T14:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/21544-medicina-di-genere-anziano-l-esempio-dell-amiloidosi-cardiaca-il-libro-bianco2024-12-02T08:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/21072-sclerosi-laterale-amiotrofica-sla-manifesto-sui-bisogni-clinici-insoddisfatti-dei-malati-e-delle-loro-famiglie2024-06-11T17:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/20462-guida-ai-diritti-esigibili-dei-pazienti-con-amiloidosi-cardiaca2023-12-19T14:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/20370-progetto-rare-sibling-storia-di-una-rete-che-continua-a-crescere2023-11-21T14:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/20350-guida-sintetica-ai-diritti-esigibili-dei-pazienti-con-miastenia-gravis2023-11-16T10:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/19533-quaderno-sne-prospettive-di-estensione-del-panel2023-02-15T10:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/19407-tutti-i-diritti-dei-talassemici-la-guida-dedicata-a-pazienti-e-caregiver2022-12-22T12:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/19321-malattie-rare-e-sibling-la-presa-in-carico-della-famiglia-e-un-gioco-di-squadra-basato-sulla-comunicazione2022-11-23T15:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/18938-nico-e-cosi2022-07-21T16:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/18619-la-malattia-da-ustione-patologia-rara-orfana-dei-lea2022-07-21T16:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/18011-miastenia-una-malattia-che-non-si-vede2022-06-01T09:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/17432-huntington-da-affare-di-famiglia-a-questione-pubblica-il-libro-bianco2021-12-29T18:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/17366-gli-equilibristi2021-12-29T18:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/17361-invalidita-civile-e-legge-104-tutti-i-diritti-dei-malati-rari2021-04-30T12:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/17367-amiloidosi-cardiaca-conoscerla-per-diagnosticarla-in-tempo-e-gestirla-al-meglio2021-05-12T13:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/17363-sulle-proprie-gambe-racconti-di-xln-e-rachitismo-ipofosfatemico2021-12-29T18:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/17362-malattia-polmonare-da-micobatteri-non-tubercolari-una-malattia-orfana-e-rara2021-12-29T18:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/le-nostre-pubblicazioni/17368-malattie-rare-guida-alle-nuove-esenzioni-edizione-aggiornata2021-12-29T18:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfaniweekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/21121-early-access-programs-eap-ossfor-strumenti-fondamentali-che-necessitano-di-un-aggiornamento2024-06-26T10:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/20432-farmaci-orfani-italia-seconda-in-europa-con-50-terapie-disponibili-e-tempi-di-immissione-in-commercio-al-di-sopra-della-media-ue2023-12-13T09:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/19493-farmaci-orfani-130-molecole-autorizzate-da-ema-nel-2021-122-disponibili-in-italia2023-01-31T10:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/19382-malattie-rare-e-pnrr-opportunita-e-proposte-per-una-digitalizzazione-della-sanita-efficace-ed-equa2022-12-12T10:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/19117-pnrr-e-malattie-rare-necessario-investire-su-sanita-digitale-e-intelligenza-artificiale2022-09-27T11:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/18695-malattie-rare-il-6-quaderno-di-ossfor-e-sui-servizi-di-assistenza-domiciliare-integrata2022-05-25T17:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/18098-v-rapporto-ossfor-l-impatto-della-pandemia-sui-malati-rari2021-12-13T11:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/18097-malattie-rare-dal-v-rapporto-ossfor-le-proposte-per-l-utilizzo-del-pnrr2021-12-13T14:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/17780-assistenza-domiciliare-partecipa-all-indagine-online-per-il-miglioramento-del-servizio-a-livello-nazionale2021-09-15T10:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/17015-malattie-rare-ossfor-presenta-il-riconoscimento-dell-innovativita-per-i-farmaci-orfani2021-02-12T10:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/16741-malattie-rare-e-farmaci-orfani-presentato-il-4-rapporto-ossfor2020-11-27T11:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/15740-farmaci-orfani-un-indagine-francese-ne-ha-valutato-l-accessibilita2020-03-10T18:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/12816-malattie-rare-che-cos-e-l-hta-dei-piccoli-numeri2017-10-23T16:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/12600-malattie-rare-la-piu-vasta-indagine-europea-sui-costi-e-sulla-qualita-di-vita2017-08-24T16:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/12026-la-figlia-ha-la-sindrome-di-sanfilippo-la-mamma-decide-di-fondare-un-azienda-biotech2017-03-05T19:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/progetti/osservatorio-farmaci-orfani/12025-uso-off-label-di-farmaci-orfani-una-risorsa-valida-ma-servono-regole-piu-precise2017-03-05T18:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rareweekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/23133-rassegnati-tu-la-danza-sfida-i-limiti-dellatassia-di-friedreich2026-06-12T13:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/23082-les-is-more-mappati-per-la-prima-volta-i-centri-di-cura-per-il-lupus-in-italia2026-05-28T11:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/23071-sperimentazioni-cliniche-la-campagna-informativa-di-accademia-eupati-arriva-nelle-regioni2026-05-20T15:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/23044-giornata-delle-mucopolisaccaridosi-sanfilippo-fighters-rilancia-lappello-lunione-fa-la-cura2026-05-13T17:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22910-sindrome-di-rett-le-associazioni-stanno-reinventando-la-presa-in-carico2026-04-04T13:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22884-sindrome-di-xia-gibbs-dalla-storia-di-simone-nasce-lassociazione-italiana-dei-pazienti2026-03-27T18:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22736-piattaforma-nazionale-cude-se-ne-discute-in-parlamento2026-02-09T16:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22676-deficit-di-creatina-da-un-appello-solitario-a-una-rete-di-famiglie2026-02-12T10:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22612-biwy-il-cartone-animato-per-i-piccoli-pazienti-protagonista-al-meeting-europeo-di-ern-ithaca2025-12-18T09:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22427-reumatologia-al-via-progetto-di-ricerca-su-spondiloartriti-lupus-e-nefrite-lupica2025-10-21T12:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22410-malattie-reumatologiche-i-pazienti-vanno-coinvolti-per-garantire-equo-accesso-alle-cure2025-10-16T10:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22318-riforma-della-disabilita-dalle-associazioni-una-lettera-al-ministro-locatelli-perche-riprenda-il-processo-attuativo-della-legge-delega2025-09-18T20:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22292-disabilita-sensoriali-linclusione-si-fa-anche-camminando-insieme2026-04-26T11:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22251-malattie-reumatologiche-e-croniche-i-consigli-degli-esperti-per-un-estate-sicura2025-08-19T17:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22178-porpora-trombotica-trombocitopenica-anptt-gestione-sia-collettiva2025-07-22T17:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22155-l-alleanza-malattie-rare-compie-8-anni-omar-al-fianco-dei-pazienti-con-rispetto-e-solidarieta2025-07-03T17:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22156-sindrome-di-sjoegren-primaria-sistemica-una-malattia-invisibile-rara-e-degenerativa2025-07-03T17:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22120-incontinenza-oltre-5-milioni-di-italiani-colpiti-ma-resta-un-tabu-la-fais-lancia-la-campagna-parliamone2025-06-24T10:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22107-malattie-reumatologiche-apmarr-conquista-il-premio-eccellenze-in-sanita-20252025-06-18T17:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22054-malattie-reumatologiche-la-presidente-di-apmarr-nominata-cavaliere-al-merito-della-repubblica2025-06-05T16:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/22029-malattie-ematologiche-rare-dai-diritti-riconosciuti-sulla-carta-alle-difficolta-reali2025-05-29T17:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21994-malattie-ematologiche-rare-i-pazienti-sollecitano-l-istituzione-della-distribuzione-per-conto-dei-farmaci2025-05-16T16:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21989-progetto-inpags-una-survey-per-conoscere-le-associazioni2025-06-03T13:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21978-giornata-mondiale-delle-mps-un-mignolo-per-sensibilizzare-sulle-mucopolisaccaridosi2025-05-14T06:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21977-infermiere-di-famiglia-e-comunita-si-cerca-un-modello-condiviso2025-05-12T16:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21929-stelle-ai-piedi-una-battaglia-rara-ma-non-solitaria2025-05-05T08:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21908-foxg1-la-storia-di-un-padre-di-un-associazione-e-di-una-sindrome-rara-ancora-poco-conosciuta2025-04-15T11:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21868-sindrome-di-arnold-chiari-aisap-e-punto-di-riferimento-per-le-famiglie2025-04-02T15:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21783-malattie-reumatologiche-quasi-6-pazienti-su-10-riportano-problemi-nella-relazione-con-il-partner2025-03-06T18:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21730-paraparesi-spastica-ereditaria-fahn-spg35-una-giornata-per-la-prevenzione-della-malattia2025-02-18T13:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21670-sindrome-da-fatica-cronica-indetta-la-seconda-edizione-del-concorso-frammenti-di-vita-con-la-cfs-me2025-01-31T11:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21654-un-delfino-una-farfalla-e-un-coniglietto-tre-favole-per-spiegare-la-sclerosi-sistemica-ai-piu-piccoli2025-01-24T15:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21660-malattie-neurologiche-rare-sabato-la-prima-tappa-dell-aisap-clinic-itinerante2025-01-24T10:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21631-sindromi-pans-pandas-la-realta-virtuale-a-supporto-della-terapia-del-dolore-nei-bambini2025-01-15T12:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21557-giornata-delle-persone-con-disabilita-nicoletti-nessuno-e-escluso-odv-una-azione-concreta-tra-tante-parole-vuote2024-12-04T20:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21538-endometriosi-sui-nuovi-lea-si-sta-facendo-troppa-disinformazione2024-11-29T09:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21520-disabilita-e-sessualita-lanciata-la-settima-edizione-del-concorso-sensuability-comics2024-12-09T09:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21497-vaccinazioni-istituzioni-clinici-e-cittadini-riuniti-per-garantire-la-tutela-dei-piu-fragili2024-11-18T17:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21423-psoriasi-il-29-ottobre-ricorre-la-giornata-mondiale2024-10-28T17:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21402-giornata-della-mastocitosi-2024-le-citta-si-illuminano-di-viola2024-10-17T14:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21302-sindrome-di-usher-domani-la-nona-giornata-mondiale2024-09-19T13:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21192-oscar-s-angels-l-associazione-che-supporta-le-famiglie-di-bambini-ricoverati-in-ospedale2024-07-22T14:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21155-sindrome-charge-l-ecografia-fetale-puo-consentire-la-diagnosi-prenatale2024-07-08T09:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21160-all-universita-di-bologna-si-studia-un-triplice-approccio-per-contrastare-il-cancro2024-07-09T11:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21114-cataratta-congenita-una-malattia-fortemente-invalidante-non-riconosciuta-come-rara2024-06-25T13:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21089-malattie-bollose-autoimmuni-il-rischio-piu-grande-e-la-solitudine2024-06-18T16:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21075-sindrome-di-sjoegren-in-italia-colpisce-circa-20mila-persone2024-06-12T15:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/21040-sindrome-da-fatica-cronica-amcfs-compie-venti-anni-di-attivita2024-06-03T09:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20994-sindromi-di-sotos-e-di-malan-nasce-assi-tv2024-05-20T11:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20956-festa-della-mamma-i-nostri-bambini-non-ci-sono-piu-ma-noi-siamo-madri-lo-stesso2024-05-09T12:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20864-sindrome-col4a1-a2-il-12-aprile-e-la-giornata-di-sensibilizzazione2024-04-11T10:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20826-gnao1-dalle-famiglie-100mila-euro-per-la-ricerca-ma-non-solo2024-04-02T14:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20822-insonnia-firmato-un-protocollo-d-intesa-tra-rls-italia-e-aipas2024-04-01T16:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20768-malattia-da-deficit-di-cdkl5-online-il-podcast-raramente-viaggio-intorno-alla-disabilita2024-03-21T11:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20713-sindromi-da-iperaccrescimento-il-cartone-animato-biwy-arriva-ai-piccoli-pazienti-di-forlimpopoli2024-03-05T13:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20667-incontinenza-e-stomia-sempre-piu-ricca-la-campagna-di-sensibilizzazione-fais2024-02-22T18:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20624-sindrome-di-brugada-il-rischio-di-una-morte-improvvisa-la-storia-di-lollo-per-la-giornata-mondiale-delle-cardiopatie-congenite2024-02-12T17:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20570-ricerca-sostegno-alle-famiglie-e-sensibilizzazione-ecco-gli-obiettivi-di-nistagmo-italia2024-01-29T11:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20538-sindrome-di-ondine-da-dieci-anni-l-associazione-aisicc-allevia-l-ansia-dei-genitori2024-01-25T08:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20531-paraplegia-spastica-7-al-via-un-progetto-di-ricerca-sulla-sintomatologia-oftalmologica2024-01-18T19:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20490-regione-lombardia-taglia-i-fondi-per-le-disabilita-gravi-e-gravissime-la-preoccupazione-delle-associazioni2024-01-08T10:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20329-fenilchetonuria-donata-all-ospedale-di-birmingham-la-prestigiosa-medaglia-john-scott2023-11-13T10:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20324-neurofibromatosi-avviato-il-progetto-famiglie-di-rara-bellezza2023-11-15T08:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20304-mutazione-del-gene-slc6a1-in-italia-partira-a-breve-la-prima-ricerca-sulla-patologia2023-11-17T17:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20286-disordini-da-esposizione-fetale-ad-alcol-e-droghe-diaz-racconto-la-mia-storia-di-dolore-per-divulgare-la-prevenzione-di-questi-disturbi2023-11-06T10:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20257-stomycraft-grande-successo-per-il-gioco-dedicato-ai-bambini-stomizzati2023-10-25T08:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20233-mastocitosi-sistemiche-oggi-la-giornata-internazionale2023-10-14T21:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20229-ceroidolipofuscinosi-l-associazione-a-ncl-finanzia-progetto-su-modello-preclinico-di-cln82023-10-14T11:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20205-sindrome-di-phelan-mcdermid-la-soddisfazione-di-uniphelan-per-le-nuove-linee-guida2023-10-08T20:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20196-sindromi-pandas-e-pans-prof-ssa-gagliano-non-solo-streptococco-necessaria-piu-attenzione-alla-diagnosi-clinica2023-10-06T15:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20195-giornata-mondiale-pandas-e-pans-galardini-in-italia-oltre-1-200-casi-certi-ma-e-probabile-una-sottodiagnosi2023-10-06T15:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20159-giornata-delle-malattie-rare-della-retina-ora-necessario-implementare-la-diagnosi-genetica2023-09-28T17:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20118-alleanza-malattie-rare-rinnova-la-collaborazione-con-osservatorio-sanita-digitale-e-osservatorio-life-science-innovation-del-politecnico-di-milano2023-09-18T18:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20070-sclerosi-sistemica-con-ails-non-si-ferma-la-lotta-alla-malattia2023-08-28T13:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20069-maniblu-raccontare-la-sclerosi-sistemica-con-un-fumetto2023-08-22T10:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20065-malattie-rare-siglato-accordo-tra-associazione-as-ma-ra-e-federazione-nazionale-tsrm-e-pstrp2023-08-22T10:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20005-cardiopatie-congenite-tante-malattie-un-unica-associazione2023-07-17T08:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/20006-disabilita-c-e-anche-se-non-la-vedi-la-campagna-di-aicca-sulle-problematiche-di-salute-invisibili-agli-occhi2023-07-17T08:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19956-incontinenza-e-stomia-da-oltre-20-anni-la-fais-rappresenta-le-associazioni-italiane-dei-pazienti2023-06-27T15:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19957-incontinenza-e-stomia-la-campagna-siamo-un-opera-d-arte-abbatte-i-pregiudizi2023-06-28T09:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19905-macrodattilia-e-sindromi-pros-i-pazienti-italiani-possono-contare-sull-aimp2023-06-16T13:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19889-inclusione-scolastica-da-associazione-cimadori-alcune-proposte-per-migliorare-l-accoglienza-dei-ragazzi-con-autismo2023-06-14T10:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19895-sla-dall-associazione-viva-la-vita-uno-spazio-virtuale-dedicato-ai-caregiver2023-06-12T18:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19853-asal-l-associazione-per-la-sindrome-di-alport-che-guarda-soprattutto-ai-giovani2023-05-31T10:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19854-sindrome-di-alport-dall-associazione-asal-un-supporto-psicologico-alle-famiglie2023-05-31T15:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19816-ittiosi-uno-spot-per-far-conoscere-al-grande-pubblico-questa-rara-patologia-della-pelle2023-05-18T16:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19772-fenilchetonuria-per-l-associazione-ape-l-inclusione-si-fa-a-tavola2023-05-02T17:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19773-malattie-metaboliche-ereditarie-l-educazione-alimentare-inizia-a-scuola2023-05-02T17:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19704-sindrome-di-prader-willi-in-italia-undici-associazioni-riunite-sotto-un-unica-bandiera2023-04-13T11:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19705-sindrome-di-prader-willi-necessaria-piu-attenzione-alle-complicanze-psichiatriche2023-04-13T17:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19714-giornata-nazionale-donazione-organi-il-91-dei-riceventi-sono-malati-rari-percentuale-che-sale-se-si-guarda-ai-soli-minori-di-16-anni2024-11-03T10:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19675-disabilita-l-alleanza-malattie-rare-alle-istituzioni-occorre-garantire-maggiore-inclusione2023-03-31T09:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19664-sindrome-col4a1-a2-e-italiana-l-unica-associazione-europea-dei-pazienti2023-03-26T21:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19665-sindrome-col4a1-a2-presto-una-realta-le-prime-linee-guida-sulla-gestione-della-patologia2023-03-26T21:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19586-dalla-ricerca-al-supporto-l-impegno-dell-associazione-conslancio-per-le-persone-affette-da-sla2023-03-06T17:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19587-sla-dall-associazione-conslancio-un-corso-di-formazione-rivolto-a-familiari-e-caregiver2023-03-06T07:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19496-da-caregiver-a-caregiver-la-onlus-gilo-care-si-prende-cura-di-chi-si-prende-cura2023-02-03T20:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19495-caregiver-condividere-le-proprie-esperienze-per-vincere-la-solitudine2023-02-03T20:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19436-sarcoma-epitelioide-a-milano-ora-esiste-l-associazione-mc4-in-corsa-per-la-vita2023-01-09T21:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19437-sarcoma-epitelioide-le-parole-di-mariagrazia-combattero-la-malattia-per-onorare-il-mio-matteo2023-01-09T21:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19421-sperimentazioni-cliniche-ecco-come-avere-sul-proprio-sito-un-motore-di-ricerca-in-italiano-e-gratis2022-12-27T11:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19334-lega-italiana-sclerosi-sistemica-il-nostro-primo-obiettivo-e-promuovere-una-diagnosi-precoce2022-12-01T10:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19335-sclerosi-sistemica-ho-scoperto-di-avere-la-malattia-grazie-al-progetto-ospedale-aperto2022-12-01T10:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19299-sindrome-di-beckwith-wiedemann-un-cartone-animato-per-aiutare-i-bambini-ad-affrontare-visite-e-ospedalizzazioni2022-11-23T22:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19143-sindrome-di-sjoegren-si-chiama-animass-odv-l-associazione-nazionale-dei-pazienti2022-10-11T14:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19142-sindrome-di-sjoegren-indagine-nazionale-conferma-la-rarita-della-patologia2022-10-11T14:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19105-sclerosi-laterale-amiotrofica-nel-lazio-viva-la-vita-onlus-supporta-pazienti-e-familiari2022-09-26T07:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19102-sla-dagli-aperitivi-ai-concerti-viva-la-vita-onlus-si-impegna-ad-esaudire-i-desideri-dei-pazienti2022-09-26T07:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19073-nessuno-e-escluso-l-associazione-al-servizio-delle-famiglie-che-convivono-con-gravi-disabilita2022-09-16T15:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19071-scuola-e-disabilita-quando-la-campanella-non-suona-per-tutti2022-09-16T15:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19037-mutazione-del-gene-iqsec2-le-iniziative-dell-associazione-italiana-per-il-benessere-dei-piccoli-pazienti2022-09-09T11:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19002-federazione-malattie-rare-infantili-14-associazioni-unite-per-far-sentire-la-propria-voce2022-09-01T09:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/19001-intersessualita-in-piemonte-se-ne-occupa-la-federazione-malattie-rare-infantili2022-09-01T09:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18935-charcot-marie-tooth-riunire-supportare-e-informare-i-pazienti-e-la-missione-di-acmt-rete2022-07-28T14:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18940-charcot-marie-tooth-i-pazienti-incontrano-seri-problemi-nel-vedersi-riconosciuta-l-invalidita2022-07-25T13:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18886-mutazione-del-gene-nexmif-in-italia-nasce-la-prima-associazione-dei-pazienti2023-04-27T13:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18885-la-voce-di-diva-la-vita-di-una-bambina-nexmif-nelle-pagine-di-un-libro2022-07-04T15:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18865-l-alleanza-malattie-rare-festeggia-i-5-anni-di-attivita2022-07-04T09:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18776-distrofia-facio-scapolo-omerale-per-i-pazienti-il-rinnovo-della-patente-e-un-calvario-infinito2022-06-17T09:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18780-sla-al-via-un-corso-per-caregiver-sulla-gestione-dell-impatto-emotivo-della-malattia2022-06-16T16:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18758-alopecia-areata-lo-schiaffo-di-will-smith-e-stato-vissuto-dai-pazienti-come-una-rivalsa2022-06-14T09:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18693-sindrome-di-sanifilippo-in-italia-attiva-l-associazione-sanfilippo-fighters2024-04-08T17:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18694-sindrome-di-sanfilippo-la-cura-arrivera-una-canzone-per-sostenere-la-ricerca2024-04-08T17:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18583-malattie-rare-non-diagnosticate-per-i-pazienti-italiani-e-attiva-la-fondazione-hopen2022-04-27T15:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18568-sla-prendersi-cura-dei-pazienti-significa-anche-migliorare-la-loro-qualita-di-vita2022-04-26T16:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18371-decreto-tariffe-omar-e-cittadinanzattiva-alle-regioni-aggiornate-subito-i-lea2022-04-14T10:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18330-decreto-tariffe-il-ritardo-nell-approvazione-e-ormai-inaccettabile2022-04-13T07:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18329-decreto-tariffe-le-associazioni-basta-attese-si-raggiunga-accordo2022-04-13T07:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/17826-testo-unico-malattie-rare-approvare-subito-e-prepararsi-ad-alcuni-correttivi-per-il-futuro2021-11-30T15:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/17370-alleanza-malattie-rare-il-think-net-permanente-al-quale-partecipano-oltre-430-associazioni2025-03-14T16:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/17299-al-via-alleati-per-crescere-il-corso-di-formazione-promosso-dall-alleanza-malattie-rare-e-da-omar2022-03-18T11:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/17111-malattie-rare-bisogni-sanitari-ma-non-solo-oggi-l-incontro-con-ministre-di-famiglia-disabilita-e-politiche-giovanili2021-05-04T09:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/15019-l-alleanza-malattie-rare-alla-maratona-sul-patto-per-la-salute2022-03-18T11:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/14747-riabilitazione-la-richiesta-di-chiarimento-di-40-associazioni-dell-alleanza-malattie-rare-sui-provvedimenti-del-ministro-della-salute2022-03-18T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/18429-i-documenti-dell-alleanza-malattie-rare2022-03-21T11:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/13339-appello-dell-alleanza-malattie-rare-al-futuro-ministero-della-salute-accolto-dalla-senatrice-rizzotti2022-03-18T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/13303-alleanza-malattie-rare-pubblica-una-lettera-aperta-al-prossimo-ministro-della-salute2022-03-18T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/12874-alleanza-italiana-malattie-rare-il-primo-incontro-ufficiale2022-03-18T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/12826-le-malattie-rare-e-la-medicina-personalizzata-alleanza-malattie-rare-per-i-pazienti2022-03-18T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/12490-nata-l-alleanza-malattie-rare-ecco-le-modalita-per-l-adesione2022-03-18T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/12471-sen-bianconi-alleanza-per-malattie-rare-ridurra-distanza-tra-societa-civile-e-politica2022-03-18T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alleanza-malattie-rare/12469-nata-l-alleanza-italiana-per-le-malattie-rare2022-03-18T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionaliweekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/22965-malattie-rare-in-abruzzo-finalmente-un-coordinamento-con-sede-personale-dedicato-e-autonomia2026-04-24T10:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/19473-coordinamento-malattie-rare-della-campania-nuovi-pdta-molta-formazione-attenzione-ai-cittadini2023-06-15T09:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/19425-lazio-per-il-coordinamento-malattie-rare-la-parola-d-ordine-e-abbattere-le-diseguaglianze2023-06-15T09:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18964-friuli-venezia-giulia-parola-chiave-del-coordinamento-malattie-rare-e-fare-rete2023-06-15T09:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18960-friuli-venezia-giulia-il-coordinamento-regionale-e-aperto-alla-rappresentanza-dei-pazienti2022-07-28T09:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18959-lombardia-per-i-pazienti-una-rete-regionale-malattie-rare-con-59-presidi-che-ha-prodotto-oltre-120-pdta2022-07-28T09:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18891-malattie-rare-i-centri-di-coordinamento-regione-per-regione2026-04-24T10:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18882-centro-di-coordinamento-malattie-rare-trento-e-bolzano2024-05-08T11:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18880-centro-di-coordinamento-malattie-rare-toscana2024-05-08T11:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18845-centro-di-coordinamento-malattie-rare-della-campania2024-06-19T07:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18840-centro-di-coordinamento-malattie-rare-della-basilicata2024-05-08T11:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18815-centro-di-coordinamento-malattie-rare-del-veneto2024-05-08T11:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18692-assistenza-domiciliare-integrata-per-malati-rari-un-modello-da-declinare-su-bisogni-complessi2022-07-28T09:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/centri-coordinamento-malattie-rare-regionali/18625-malattie-rare-prioritario-incrementare-la-formazione-in-ambito-medico-ma-non-solo2022-07-28T09:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/videoweekly0.5 https://www.osservatoriomalattierare.it/redazione2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hivweekly0.5 https://www.osservatoriomalattierare.it/hiv/22857-hiv-dati-positivi-dagli-studi-di-fase-iii-sulla-terapia-con-doravirina-islatravir2026-03-19T18:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/22560-hiv-in-italia-e-stabile-in-numero-di-nuovi-casi2025-12-19T14:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/22213-hiv-il-chmp-dice-si-all-uso-di-lenacapavir-in-regime-di-profilassi-per-esposizione2025-07-28T17:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/22211-hiv-l-appello-di-anlaids-crescono-le-infezioni-necessario-fare-il-test2025-07-27T10:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/22078-icar-2025-vivere-con-l-hiv-oggi-significa-gestire-nuove-sfide-ma-anche-nuove-possibilita2025-06-12T07:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/21987-per-la-prima-volta-in-veneto-il-congresso-di-riferimento-su-hiv-epatiti-e-virus-emergenti2025-05-14T07:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/21540-hiv-simit-aumentano-i-casi-ma-con-la-terapia-antiretrovirale-e-cambiata-la-storia-dell-infezione2024-11-29T19:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/19915-hiv-la-rimborsabilita-della-prep-come-chiave-per-una-prevenzione-accessibile-in-italia2023-06-19T10:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/19647-la-cura-inaspettata-un-libro-racconta-i-due-volti-opposti-dell-hiv2023-03-19T12:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/19349-aids-una-nuova-procedura-per-riconoscere-se-il-virus-e-dormiente2022-11-30T19:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/18061-hiv-le-persone-che-vivono-con-il-virus-affrontano-ancora-oggi-pregiudizi-e-discriminazioni2021-12-01T13:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/17963-hiv-e-sars-cov-2-gli-anticorpi-monoclonali-al-centro-delle-terapie-del-futuro2021-11-01T19:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/17029-hiv-fostemsavir-approvato-in-europa2021-02-14T22:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/16823-hiv-dalla-russia-segnali-incoraggianti-sullo-sviluppo-di-un-vaccino2020-12-20T21:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/16757-hiv-in-progressivo-calo-le-nuove-diagnosi-ma-crescono-i-contagi-tra-i-giovani2020-11-30T18:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/16587-hiv-i-pazienti-chiedono-migliore-qualita-di-vita-e-piu-tollerabilita-delle-terapie2020-10-19T14:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/16090-hiv-dal-bambino-gesu-un-test-istantaneo-per-controllare-la-carica-virale-nei-bambini2020-05-20T11:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/15661-hiv-qual-e-il-ruolo-delle-cellule-nk-nella-risposta-all-infezione2020-02-13T22:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/15479-hiv-parte-il-progetto-sperm-positive-la-rivincita-dei-carica-zero2019-12-05T10:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/15425-hiv-i-pazienti-sieropositivi-in-terapia-antiretrovirale-non-trasmettono-il-virus2019-11-18T20:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/15035-hiv-approvazione-europea-per-la-combinazione-dolutegravir-lamivudina2019-07-12T21:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/14530-hiv-il-vaccino-tat-riduce-il-virus-latente2019-02-27T22:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/13267-hiv-al-via-l-ottavo-studio-di-fase-iii-su-combinazione-dolutegravir-e-lamivudina2018-02-22T17:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/10913-lipodistrofia-hiv-associata-l-efficacia-della-leptina2017-04-10T17:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/10583-hiv-si-allunga-l-aspettativa-di-vita-nel-2030-record-degli-over-cinquanta2016-05-12T14:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/6393-lotta-allaids-amedeo-di-savoia-torino-riorganizzato-per-la-centralita-dei-pazienti2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/1525-hiv-anti-retrovirali-promossi-efficaci-nel-trattamento-prolungato-restano-la-terapia-delezione2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/944-hiv-arriva-she-il-primo-programma-per-le-donne-affette-dal-virus2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/915-hiv-stefano-vella-il-trattamento-puo-essere-visto-anche-come-prevenzione2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/911-hiv-oggi-possiamo-parlare-di-malattia-virale-cronica2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/807-aids-alliss-nuovo-trial-clinico-per-il-vaccino-su-usa-la-proteina-tat-associata-a-env2025-10-14T18:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/650-hiv-liss-premiata-con-100mila-dollari-dalla-fondazione-di-bill-gates2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/631-aids-lauranofin-gia-usato-per-lartrite-reumatoride-stana-lhiv-nel-magazzino-dove-si-annida2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv/282-lipodistrofia-da-hiv-gli-adolescenti-americani-che-ne-sono-affetti-potranno-usare-il-tesamoreli2025-10-14T18:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimerweekly0.5 https://www.osservatoriomalattierare.it/alzheimer/23129-alzheimer-firmato-a-roma-il-documento-di-consenso-europeo-mindshift2026-06-11T15:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/23043-alzheimer-una-malattia-neurodegenerativa-dai-numeri-in-crescita2026-05-14T22:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/22530-alzheimer-possibile-opportunita-terapeutica-da-due-farmaci-oncologici-gia-approvati2025-11-18T18:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/22239-alzheimer-dalla-ricerca-nuove-prospettive-per-migliorare-la-conoscenza-della-patologia2025-08-10T11:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/22073-terapia-genica-per-l-alzheimer-i-risultati-preclinici-sembrano-essere-incoraggianti2025-06-11T17:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/21657-alzheimer-gli-anticorpi-monoclonali-arrivano-anche-in-europa2025-01-22T17:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/21516-malattia-di-alzheimer-ema-approva-lecanemab2024-11-22T16:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/21301-alzheimer-identificato-un-nuovo-meccanismo-molecolare-coinvolto-nella-perdita-di-memoria2024-09-18T14:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/20955-alzheimer-passi-avanti-nella-comprensione-della-genetica-della-malattia2024-05-09T14:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/20388-legge-di-bilancio-nessun-finanziamento-per-il-piano-nazionale-demenze2023-12-01T12:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19971-anticorpi-monoclonali-contro-la-malattia-di-alzheimer-una-strada-piu-impervia-del-previsto2023-07-04T17:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19728-demenza-le-linee-guida-per-una-comunicazione-etica-e-inclusiva2023-04-28T10:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19598-malattie-neurologiche-a-monza-un-incontro-per-discutere-di-sostenibilita-delle-cure2023-03-04T12:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19432-alzheimer-delude-la-sperimentazione-di-fase-iii-sull-anticorpo-monoclonale-gantenerumab2023-01-02T16:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19251-alzheimer-dementia-friendly-italia-e-nontiscordaredivolermibene-premiati-in-europa2022-11-05T15:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19113-demenza-al-via-indagine-nazionale-sulle-condizioni-socio-economiche-delle-famiglie-dei-pazienti2022-09-24T20:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19075-malattia-di-alzheimer-il-21-settembre-e-la-giornata-mondiale2022-09-17T20:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19045-alzheimer-una-molecola-sperimentale-potrebbe-aprire-nuovi-scenari-nel-trattamento-della-malattia2022-09-11T14:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/19017-alzheimer-settembre-e-il-mese-dedicato-alla-patologia2022-09-02T12:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/18928-malattie-neurologiche-croniche-redatto-dalla-sin-il-documento-s-m-a-r-t-care2022-07-16T21:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/18710-alzheimer-allo-studio-anticorpi-monoclonali-e-cocktail-di-farmaci2022-05-30T12:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/18658-demenza-pubblicato-il-manuale-vivere-con-l-alzheimer-rivolto-a-familiari-e-caregiver2022-05-16T11:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/18536-piano-nazionale-demenze-definita-la-ripartizione-dei-fondi-stanziati2022-04-10T13:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17878-alzheimer-al-via-in-7-centri-italiani-il-primo-progetto-pilota-di-telemedicina2021-10-09T20:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17811-alzheimer-identificato-il-ruolo-della-proteina-pin1-nella-degenerazione-neuronale2021-09-23T11:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17808-demenza-uno-studio-rivela-che-il-covid-19-puo-accelerarne-i-sintomi2021-09-22T17:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17799-alzheimer-oggi-e-la-giornata-mondiale2021-09-21T14:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17773-alzheimer-al-via-la-campagna-nontiscordaredivolermibene2021-09-14T11:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17704-demenza-nasce-il-sito-dedicato-alle-comunita-amiche2021-08-01T15:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17537-alzheimer-la-sin-accoglie-con-favore-l-approvazione-accelerata-di-aducanumab-da-parte-della-fda2021-06-13T19:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17320-demenza-in-italia-la-gestione-della-malattia-e-migliorata-del-10-in-tre-anni2021-04-18T19:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/17210-demenze-federazione-alzheimer-italia-aderisce-alla-proposta-del-network-non-autosufficienza2021-03-21T23:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/16986-demenza-i-medici-fanno-chiarezza-sul-consenso-informato-per-la-vaccinazione-anti-covid2021-02-07T20:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/16906-alzheimer-l-assistenza-sanitaria-a-rilevanza-sociale-per-i-pazienti-deve-essere-gratuita2021-01-20T00:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/15983-alzheimer-e-covid-19-l-impatto-dell-obbligo-di-non-uscire-su-pazienti-e-caregiver2020-04-20T18:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/15900-coronavirus-e-alzheimer-10-consigli-per-affrontare-la-quarantena2020-04-02T17:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/15550-alzheimer-i-consigli-di-sin-e-federazione-alzheimer-italia-per-le-festivita-natalizie2020-01-01T18:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/15346-alzheimer-aducanumab-pronto-per-la-richiesta-di-approvazione-negli-stati-uniti2019-10-25T09:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/14681-malattia-di-alzheimer-interrotto-lo-sviluppo-clinico-del-farmaco-aducanumab2019-04-04T18:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/13947-alzheimer-arriva-chat-yourself-un-app-che-aiuta-i-pazienti2018-09-20T10:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/12484-guardami-negli-occhi-parlami-sono-una-persona-speciale-ho-l-alzheimer2017-07-12T12:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/12478-alzheimer-e-parkinson-due-malattie-innescate-dallo-stesso-enzima2017-07-08T10:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/11319-alzheimer-l-uso-di-antipsicotici-e-correlato-al-rischio-di-polmonite2017-06-19T16:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/8981-alzheimer-e-demenza-al-gemelli-un-percorso-clinico-assistenziale-dedicato2015-09-24T13:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/8608-malattia-di-alzheimer-il-legame-con-il-diabete-e-la-proteina-neuroprotettiva2015-07-13T09:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/8609-malattia-di-alzheimer-basta-sedativi-meglio-formare-chi-si-prende-cura-dei-pazienti2015-07-13T09:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/5923-alzheimer-nasce-a-napoli-il-primo-ambulatorio-pubblico-della-campania2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/4162-alzheimer-delude-la-sperimentazione-su-animali-del-bexarotene2016-03-14T16:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/3012-alzheimer-al-cemi-del-gemelli-sostegno-psicologico-per-familiari-e-caregivers-dei-malati2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/2843-alzheimer-un-solo-trauma-cerebrale-medio-o-grave-possibile-concausa2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/2546-alzheimer-gia-in-commercio-farmaci-utili-per-rallentarne-levoluzione2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/1592-alzheimer-cnr-brevetta-vaccino-contro-gli-accumuli-di-beta-amiloide-nel-cervello2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/1018-alzheimer-troppo-sale-nel-piatto-fa-male-al-cervello2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/1011-alzheimer-sintetizzato-in-laboratorio-lhuperzine-a-fino-ad-oggi-lo-si-ricavava-da-un-muschio-a-rischio-estinzione2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/alzheimer/939-alzheimer-trovato-possibile-biomarcatore-per-rilevare-malattia-20-anni-prima-dellesordio2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculareweekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/23039-maculopatie-da-problema-clinico-a-emergenza-sociale2026-05-13T15:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/22900-degenerazione-maculare-avanzata-un-microimpianto-retinico-wireless-per-tornare-a-vedere2026-04-01T17:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/21326-atrofia-geografica-la-protesta-dei-pazienti-dopo-il-no-dell-ema-al-farmaco-pegcetacoplan2024-09-26T18:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/20634-degenerazione-maculare-al-gemelli-una-ricerca-innovativa-con-cellule-staminali-cordonali2024-02-15T17:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/20263-oftalmologia-al-via-nuovo-bando-roche-per-i-servizi2023-10-27T09:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/20235-degenerazione-maculare-arriva-in-italia-il-primo-anticorpo-bispecifico-per-uso-oculare2023-10-14T21:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/20188-atrofia-geografica-nessun-legame-tra-il-farmaco-pegcetacoplan-e-i-sette-casi-di-vasculite-retinica2024-09-19T07:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/20074-uscito-il-nuovo-singolo-di-fiamma-celano-cantante-affetta-da-degenerazione-maculare2023-09-05T08:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/19833-maculopatie-un-rischio-per-over-60-e-diabetici2023-05-25T10:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/19469-degenerazione-maculare-legata-all-eta-presentato-il-rapporto-altems-sull-impatto-economico-della-patologia2023-01-23T10:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/19112-degenerazione-maculare-legata-all-eta-approvazione-europea-per-faricimab2022-09-24T20:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/18601-e-online-sottosopra-il-nuovo-singolo-di-una-cantautrice-rara2023-08-24T17:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/17981-degenerazione-maculare-legata-all-eta-fda-approva-un-trattamento-alternativo-alle-iniezioni-oculari-mensili2021-11-08T12:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/17646-degenerazione-maculare-legata-all-eta-fondamentali-una-diagnosi-accurata-e-un-percorso-terapeutico-ad-hoc2021-07-13T16:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/16438-maculopatia-la-campagna-salvarelavistasipuo-si-arricchisce-di-un-nuovo-video2020-09-14T00:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/13432-degenerazione-maculare-benefici-visivi-da-terapia-sperimentale-basata-su-staminali2018-05-05T16:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/13321-degenerazione-maculare-nuovi-dati-su-aflibercept2018-03-08T02:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/12870-degenerazione-maculare-molti-italiani-non-conoscono-la-patologia2017-11-08T17:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/12491-degenerazione-maculare-senile-in-italia-troppe-differenze-nel-percorso-di-cura2017-11-08T17:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/7566-maculopatia-disponibile-una-app-per-semplificare-la-diagnosi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/6877-maculopatie-per-la-terapia-con-ranibizumab-arriva-la-siringa-preriempita-hi-tech2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/6732-maculopatia-lospedale-schiara-di-trento-e-in-crisi-di-personale2019-06-18T17:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/6340-aflibercept-ha-ricevuto-la-chmp-opinion-per-il-trattamento-del-danno-visivo-causato-da-edema-maculare-diabetico2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/5827-degenerazione-maculare-legata-alleta-da-oggi-e-rimborsato-il-farmaco-eylea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/5676-degenerazioni-retiniche-lo-zafferano-abruzzese-sembra-avere-effetti-antiossidanti-e-antiapoptotici2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/4847-maculopatie-a-treviso-visite-gratuite-grazie-al-centro-deccellenza-cafoncello2016-03-07T10:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/4112-degenerazione-maculare-legata-alleta-un-nuovo-farmaco-la-mette-in-trappola2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/4090-degenerazione-maculare-senile-i-farmaci-per-abbassare-il-colesterolo-potrebbero-essere-efficaci2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/3344-edema-maculare-bayer-presenta-vegf-trap-eye-soluzione-di-aflibercept-per-iniezione-per-lautorizzazione-marketing-europea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/degenerazione-maculare/1945-maculopatia-senile-scoperto-meccanismo-alla-base-dei-casi-piu-gravi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosiweekly0.5 https://www.osservatoriomalattierare.it/endometriosi/22881-endometriosi-per-ottenere-la-diagnosi-occorrono-in-media-dai-5-agli-8-anni2026-03-26T16:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/22386-big-data-e-intelligenza-artificiale-aiutano-a-capire-meglio-lendometriosi2025-10-08T10:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/17466-endometriosi-piccole-cose-arrabbiate-dentro-di-te2021-05-26T08:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/17177-endometriosi-diventare-mamme-si-puo2021-03-14T15:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/14481-endometriosi-in-italia-si-stimano-circa-3-milioni-di-casi2025-10-03T15:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/7504-endometriosi-in-vigore-la-legge-approvata-in-sardegna2017-06-19T16:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/7036-endometriosi-al-gemelli-congresso-su-nuove-sfide-diagnostiche-chirurgiche-e-terapeutiche2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/6910-endometriosi-siena-e-milano-coordinano-studio-unico-in-italia-per-una-nuova-terapia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/6247-endometriosi-profonda-laparoscopia-in-3d-nel-trattamento-della-patologia2015-05-28T11:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/5860-endometriosi-e-gestione-del-dolore-ecco-le-piu-recenti-acquisizioni-scientifiche2019-06-18T18:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/5067-endometriosi-severa-fertilita-a-rischio-dopo-la-chirurgia2025-10-03T15:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/4914-endometriosi-una-malattia-sociale-a-forte-impatto2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/endometriosi/4108-endometriosi-adesso-si-puo-dire-basta-ai-dolori-grazie-a-un-nuovo-progestinico-orale2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-cweekly0.5 https://www.osservatoriomalattierare.it/epatite-c/21729-malattie-epatiche-presentato-al-ministero-della-salute-il-libro-bianco-di-aisf2025-02-14T10:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/20911-l-obiettivo-dell-oms-eradicare-l-epatite-c-entro-il-20302024-04-24T13:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/20040-epatiti-oggi-ricorre-la-giornata-mondiale2023-08-10T16:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/18951-epatite-c-lanciato-nuovo-test-diagnostico-che-rileva-antigene-e-anticorpi-del-virus-hcv2022-07-24T15:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/16864-epatite-c-il-bilancio-aifa-2020-sull-eradicazione-del-virus2020-12-30T22:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/16313-epatite-c-aifa-approva-nuova-rimborsabilita-per-glecaprevir-pibrentasvir2020-07-20T11:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/15694-epatite-c-71-milioni-di-euro-stanziati-in-italia-per-screening-gratuiti2020-02-25T19:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/10696-epatite-c-emerge-un-legame-genetico-con-un-raro-disordine-da-accumulo-di-grassi2016-05-31T15:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/8114-epatite-c-tipo-2-5-gilead-annuncia-i-risultati-degli-studi-sui-regimi-terapeutici-a-base-di-sofosbuvir2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/8117-epatite-c-in-fase-avanzata-harvoni-e-sovaldi-mostrano-efficacia-e-sicurezza2015-06-08T11:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/7079-epatite-c-cronica-gilead-annuncia-i-risultati-dello-studio-con-harvonir2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/5332-epatite-c-autorizzata-la-commercializzazione-di-sofosbuvir-in-europa2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/3960-epatite-c-nuovi-dati-positivi-per-il-trattamento-con-sofosbuvir2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/epatite-c/1280-epatite-c-ricercatore-sissa-indaga-lrna-per-capire-come-interrompere-la-replicazione-del-virus2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgiaweekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/22725-dpcm-lea-verso-lapprovazione-cfu-italia-chiede-modifiche-alla-voce-dedicata-alla-fibromialgia2026-02-09T18:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/22253-fibromialgia-cfu-italia-lancia-indagine-nazionale-rivolta-ai-pazienti2025-08-21T08:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/21464-fibromialgia-i-pazienti-italiani-chiedono-il-riconoscimento-della-patologia2024-11-07T11:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/20988-fibromialgia-uno-studio-cerca-i-fattori-in-comune-con-l-emicrania2024-05-20T06:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/19972-fibromialgia-a-barbara-suzzi-cfu-italia-odv-il-riconoscimento-di-ufficiale-della-repubblica2023-07-07T14:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/19353-fibromialgia-in-sardegna-approvata-l-indennita-regionale-di-800-euro-annui2022-12-02T12:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/18355-fibromialgia-un-indagine-rivela-i-bisogni-dei-pazienti-per-vivere-meglio2022-03-02T11:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17907-fibromialgia-tutte-le-opportunita-terapeutiche-disponibili-l-approccio-non-farmacologico2021-10-20T15:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17912-fibromialgia-questa-illustre-sconosciuta2021-10-22T07:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17911-fibromialgia-i-criteri-diagnostici-adottati-dalla-comunita-scientifica-internazionale2021-10-21T07:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17910-fibromialgia-identificati-i-criteri-per-definire-la-severita-di-malattia2021-10-21T07:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17909-fibromialgia-un-disegno-di-legge-per-riconoscerla-come-cronica-e-invalidante2021-10-20T15:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17906-fibromialgia-un-pdta-italiano-esiste-ma-ancora-non-viene-applicato-a-livello-nazionale2021-10-20T15:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17908-fibromialgia-le-opportunita-terapeutiche-disponibili-l-approccio-farmacologico2021-10-20T15:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17890-fibromialgia-uno-studio-italiano-svela-i-legami-con-il-covid-192021-10-16T21:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17429-fibromialgia-cinque-giovani-illustratrici-danno-un-volto-alla-malattia2021-05-12T14:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17383-fibromialgia-un-indagine-fa-luce-su-una-patologia-ancora-poco-compresa2021-05-02T21:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/17318-fibromialgia-il-nostro-dolore-e-un-invisibile2021-04-18T18:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/16673-fibromialgia-dalla-cannabis-una-possibile-opzione-terapeutica2020-11-11T11:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/16357-fibromialgia-studio-genomico-evidenzia-una-componente-autoimmune2020-08-02T16:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/15002-fibromialgia-e-disagio-lavorativo-al-via-uno-studio-sugli-accomodamenti-ragionevoli2020-02-27T15:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/14915-fibromialgia-una-proposta-di-legge-per-riconoscerne-la-natura-cronica-e-invalidante2020-02-27T15:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/14405-fibromialgia-tutte-le-iniziative-del-parlamento-e-delle-regioni2020-02-27T15:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/14233-fibromialgia-il-parlamento-al-lavoro-riconoscerne-la-condizione-invalidante2020-02-27T15:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/14205-fibromialgia-un-interrogazione-per-riconoscerne-la-condizione-invalidante2020-02-27T15:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/11557-fibromialgia-la-puglia-approva-mozione-per-il-riconoscimento-nazionale-di-malattia-rara2020-02-27T15:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/11013-fibromialgia-emilia-romagna-prima-regione-a-fare-luce-sulla-malattia-invisibile2020-02-27T15:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/9410-il-dr-giovanni-lombardi-la-crioterapia-sistemica-e-efficace-ma-dev-essere-sempre-associata-alla-terapia-convenzionale2020-02-27T15:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/6960-fibromialgia-il-farmaco-memantina-riduce-il-dolore2020-02-27T15:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/6306-fibromialgia-da-uno-studio-spagnolo-conferme-sullutilita-dellapproccio-terapeutico-multidisciplinare2020-02-27T15:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/5728-fibromialgia-per-trattare-il-dolore-una-nuova-metodica-multidisciplinare2020-02-27T15:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/5560-fibromialgia-ecco-i-nuovi-criteri-classificativi-per-la-diagnosi2020-02-27T15:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/5376-fibromialgia-la-vitamina-d-puo-migliorare-il-dolore2020-02-27T15:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/5159-fibromialgia-nasce-a-verona-il-primo-centro-di-riferimento-nazionale-anfisc2020-02-27T15:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/4904-fibromialgia-risultati-positivi-per-la-sperimentazione-con-il-farmaco-pregabalin2020-02-27T15:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/4814-fibromialgia-dopo-anni-di-rifiuti-la-als-concede-il-riconoscimento-dellinvalidita2020-02-27T15:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/3914-fibromialgia-confermata-lefficacia-della-creatina2020-02-27T15:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/2565-fibromialgia-molti-pazienti-usano-la-marijuana-per-ottenere-sollievo-e-illegale-ma-non-ci-sono-studi-a-sufficienza-per-escludere-che-funzioni2020-02-27T15:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/2405-fibromialgia-la-terapia-con-gh-allevia-il-dolore-migliorando-la-vita-dei-pazienti2020-02-27T15:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/1735-fibromialgia-naltrexone-a-dosi-ridotte-potrebbe-ridurre-il-dolore2020-02-27T16:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/1630-fibromialgia-lesercizio-fisico-allevia-il-dolore-cronico-e-migliora-la-memoria2020-02-27T16:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibromialgia/10106-fibromialgia-per-ora-niente-esenzione-permanente-come-malattia-cronica2020-02-27T15:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronieweekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronie/22400-malattia-di-la-peyronie-disponibile-una-nuova-terapia-con-acido-ialuronico2025-10-13T16:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronie/13554-malattia-di-la-peyronie-sempre-piu-raro-il-ricorso-alla-chirurgia-tradizionale2018-05-11T18:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronie/13496-malattia-di-la-peyronie-oggi-c-e-una-terapia-efficace-per-il-pene-curvo2018-04-28T12:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronie/12970-malattia-di-la-peyronie-con-collagenasi-miglioramenti-oggettivi-nel-96-dei-pazienti-trattati2019-08-18T17:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronie/12761-malattia-di-la-peyronie-i-dati-real-life-confermano-l-efficacia-del-trattamento-con-collagenasi2017-10-11T09:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronie/12316-malattia-di-la-peyronie-presentati-i-primi-dati-real-life-di-pazienti-trattati-con-collagenasi-in-italia2017-10-11T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronie/12197-malattia-di-la-peyronie-eseguiti-in-italia-i-primi-interventi-terapeutici-con-collagenasi2017-06-19T16:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-la-peyronie/12198-malattia-di-la-peyronie-disponibile-in-italia-il-nuovo-trattamento-farmacologico-con-collagenasi2017-06-19T16:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinsonweekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/22917-parkinson-i-segnali-da-non-ignorare-e-i-comportamenti-utili-per-la-salute-del-cervello2026-04-08T17:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/22922-parkinson-arriva-in-italia-la-nuova-terapia-con-levodopa-carbidopa-ed-entacapone2026-04-10T08:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/22875-parkinson-allasst-gaetano-pini-cto-disponibile-una-nuova-terapia2026-04-09T17:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/22858-parkinson-esperti-italiani-invitano-alla-cautela-sulla-terapia-con-staminali-approvata-in-giappone2026-03-19T18:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/22555-dialoghi-con-mr-parkinson-al-cinema-il-documentario-che-racconta-la-convivenza-con-la-patologia2025-11-27T09:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/21651-parkinson-risultati-positivi-dallo-studio-post-autorizzativo-sulla-citicolina2025-01-22T09:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/21612-terapie-cellulari-per-il-parkinson-una-storia-lunga-50-anni-e-l-europa-e-in-prima-linea2024-12-27T13:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/21541-parkinson-oltre-il-tremore-una-malattia-che-e-cento-malattie2024-11-29T16:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/21535-giornata-nazionale-parkinson-porte-aperte-ai-pazienti-in-piu-di-100-centri-specializzati-in-tutta-italia2024-11-28T16:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/21368-parkinson-creato-un-modello-sperimentale-di-malattia-giovanile-per-studiarne-lo-sviluppo2024-10-09T18:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/21194-parkinson-lo-stretto-di-messina-a-nuoto-per-sensibilizzare-il-pubblico-sulla-malattia2024-07-22T15:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/20820-malattia-di-parkinson-rimborsabile-in-italia-la-terapia-con-foslevodopa-foscarbidopa2024-03-29T09:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/20732-parkinson-al-mondino-di-pavia-prime-somministrazioni-di-una-nuova-terapia2024-03-08T11:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/20192-parkinson-300mila-gli-italiani-colpiti-dalla-patologia2023-10-03T17:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/19741-parkinson-e-alzheimer-nella-laguna-di-venezia-il-segreto-per-sconfiggere-le-due-patologie2023-04-21T19:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/19711-parkinson-l-esposizione-ad-ambienti-naturali-puo-ridurre-il-rischio-di-ospedalizzazioni2023-04-11T14:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/18769-parkinson-il-consumo-moderato-di-caffe-potrebbe-essere-un-fattore-protettivo2022-06-13T15:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/18475-parkinson-al-via-indagine-record-sulle-mutazioni-del-gene-gba2022-03-28T20:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/18040-malattia-di-parkinson-il-27-novembre-si-celebre-la-giornata-nazionale2021-11-27T09:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/17982-malattia-di-parkinson-nuove-speranze-terapeutiche-dall-alfa-sinucleina2021-11-08T12:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/17341-parkinson-scoperto-un-nuovo-meccanismo-alla-base-della-malattia2021-04-25T23:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/17319-parkinson-nasce-a-milano-un-laboratorio-per-la-valutazione-della-disautonomia2021-04-18T19:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/16290-malattia-di-parkinson-dimostrati-gli-effetti-di-lunga-durata-della-terapia-con-levodopa2020-07-13T12:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/16268-parkinson-3-200-interventi-in-teleassistenza-durante-l-emergenza-covid-192020-07-05T20:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/16192-malattia-di-parkinson-la-patologia-non-aumenta-il-rischio-di-covid-192020-06-16T17:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/15898-covid-19-una-help-line-per-i-pazienti-con-parkinson-o-altri-disordini-del-movimento2020-04-02T15:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/14838-parkinson-aifa-rassicura-sulla-disponibilita-del-farmaco-sinemet2019-05-21T14:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/14141-parkinson-il-legame-con-la-gaucher-e-la-speranza-di-una-diagnosi-precoce2018-11-09T15:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/13949-parkinson-in-giappone-il-primo-trial-clinico-con-staminali-pluripotenti-indotte2018-09-22T10:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/12935-parkinson-al-via-studio-italiano-per-scoprire-come-prevenire-la-malattia2017-11-21T19:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/12697-malattia-di-parkinson-un-nuovo-metodo-per-la-riabilitazione-cognitiva-del-movimento2017-09-26T10:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/12576-malattia-di-parkinson-come-conviverci-in-estate2017-08-09T15:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/12038-malattia-di-parkinson-una-storia-lunga-due-secoli2017-06-19T16:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/11645-parkinson-un-legume-puo-migliorare-le-condizioni-dei-pazienti2017-06-19T16:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/8252-malattia-di-parkinson-zambon-lancia-xadago-in-germania2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/7765-parkinson-maggiori-difficolta-per-le-donne2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/7039-malattia-di-parkinson-scoperta-la-causa-della-forma-giovanile2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/6312-malattia-di-parkinson-gli-istituti-clinici-di-perfezionamento-di-milano-icp-hanno-inaugurato-i-nuovi-ambulatori2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/5953-parkinson-i-dieci-segnali-che-possono-precedere-linsorgenza-della-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/5942-parkinson-un-cerotto-per-tenere-sotto-controllo-i-parametri-e-somministrare-i-farmaci2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/3737-parkinson-la-neurostimolazione-subtalamica-precoce-puo-essere-unarma-contro-le-complicanze-motorie2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/2033-malattia-di-parkinson-linfusione-intestinale-di-levodopa-e-carbidopa-promette-risultati-migliori-di-quella-orale2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/2010-malattia-di-parkinson-gli-antidepressivi-sono-potenzialmente-efficaci2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/1713-parkinson-la-sopravvivenza-dipende-da-fattori-demografici-e-clinici-meno-a-rischio-le-donne2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/1683-parkinson-e-hiv-calano-i-costi-degli-integratori-alla-papaya-fermentata2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/1430-parkinson-dormire-fa-bene-ma-il-sonno-puo-essere-un-problema2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/1405-parkinson-durante-la-terapia-con-levadopa-utile-evitare-proteine-di-giorno2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/1400-parkinson-le-cadute-sono-un-problema-grave-ecco-come-prevenirle2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/1399-arkinson-corrette-informazioni-allenamento-motorio-e-supporto-psicologico-sono-il-primo-passo-per-convivere-con-la-ma2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/1267-parkinson-chi-si-ammala-oggi-ha-solo-il-40-per-cento-delle-possibilita-di-avere-le-migliori-cure2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/949-parkinson-completato-larruolamento-di-pazienti-per-lo-studio-di-fase-tre-motion2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson/932-parkinson-studio-sulla-popolazione-sarda-ha-permesso-di-trovare-nuovo-gene-responsabile2018-12-27T19:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multiplaweekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/23141-sclerosi-multipla-quando-la-diagnosi-arriva-da-giovani2026-06-13T08:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/22963-sclerosi-multipla-recidivante-fenebrutinib-riduce-gli-episodi-di-ricaduta-nella-malattia2026-04-24T09:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/22698-sclerosi-multipla-due-nuovi-tasselli-sul-ruolo-del-virus-di-epstein-barr2026-01-27T23:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/22528-sclerosi-multipla-pediatrica-e-mononucleosi-la-correlazione-potrebbe-essere-diretta2025-11-18T18:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/22036-la-sclerosi-multipla-cambia-volto-grazie-ai-big-data2026-02-28T15:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/21434-sclerosi-multipla-al-via-il-progetto-agenda-della-sclerosi-multipla-e-patologie-correlate-20252024-10-28T17:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/21275-sclerosi-multipla-tolebrutinib-raggiunge-l-endpoint-primario-nello-studio-di-fase-iii-hercules2024-09-10T16:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/21023-sclerosi-multipla-oggi-la-giornata-mondiale2024-05-28T10:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/21010-sclerosi-multipla-disponibile-in-italia-il-primo-biosimilare-a-base-di-natalizumab2024-05-24T14:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/20928-sclerosi-multipla-recidivante-nuovi-dati-clinici-confermano-l-efficacia-sostenuta-di-frexalimab2024-05-03T10:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/20693-sclerosi-multipla-recidivante-positivi-i-dati-clinici-di-fase-ii-su-frexalimab2024-02-28T17:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/20443-sclerosi-multipla-e-neuromielite-ottica-da-aism-le-nuove-comunicazioni-tecnico-scientifiche-per-l-accertamento-dell-invalidita2024-02-28T17:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/20187-malattie-neurologiche-disimmuni-grazie-a-marcatori-sierologici-passi-avanti-nella-diagnosi2023-10-02T17:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/19477-sclerosi-multipla-ad-aism-e-fism-il-premio-icpermed-best-practice-in-personalised-medicine-recognition-20222023-01-21T21:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/19443-sclerosi-multipla-pubblicati-i-risultati-del-primo-studio-al-mondo-con-cellule-staminali-neurali2023-01-12T13:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/19232-sclerosi-multipla-nuovi-dati-confermano-efficacia-e-sicurezza-di-ocrelizumab2022-10-30T12:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/19233-sclerosi-multipla-al-via-la-campagna-diamo-uno-strappo-alla-sm2022-10-30T12:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/19185-sclerosi-multipla-ponesimod-rimborsabile-in-italia2022-10-19T14:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/19079-sclerosi-multipla-l-appello-di-aism-alle-forze-politiche2022-09-17T20:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/18994-sclerosi-multipla-dalla-sin-le-prime-linee-guida-italiane-dedicate-alla-patologia2022-08-12T10:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/18799-sclerosi-multipla-nasce-un-app-per-l-autovalutazione-delle-funzioni-cognitive2022-06-18T14:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/18626-sclerosi-multipla-nasce-l-app-esprimiti2022-05-07T21:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/18360-sclerosi-multipla-dall-analisi-delle-proteine-del-sangue-nuove-prospettive-di-ricerca2022-02-27T20:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/18266-sclerosi-multipla-al-via-la-campagna-di-aism-l-apparenza-inganna2022-02-07T15:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/18161-sclerosi-multipla-al-via-la-campagna-aism-il-futuro-sei-tu2022-01-07T12:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/18075-sclerosi-multipla-due-video-per-far-conoscere-la-spasticita-associata2021-12-05T22:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17937-sclerosi-multipla-presentati-nuovi-dati-clinici-a-lungo-termine-su-tolebrutinib2021-10-28T22:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17837-sclerosi-multipla-alla-milano-fashion-week-le-scarpe-di-chi-non-si-ferma2021-09-30T14:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17825-sclerosi-multipla-e-gravidanza-compito-del-ginecologo-e-anche-quello-di-trasmettere-serenita-alla-paziente2021-09-30T14:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17775-sclerosi-multipla-progressiva-identificata-proteina-chiave-nel-processo-neurodegenerativo2021-09-14T11:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17762-sclerosi-multipla-e-gravidanza-l-aspetto-psicologico-non-va-sottovalutato2021-09-10T17:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17732-sclerosi-multipla-alle-pazienti-va-fornito-un-counseling-sulla-maternita-fin-dalla-diagnosi2021-08-29T18:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17626-sclerosi-multipla-scoperto-nuovo-meccanismo-di-demielinizzazione2021-07-06T17:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17564-sclerosi-multipla-realizzato-un-white-paper-su-nuove-tecnologie-per-il-patient-journey2021-06-20T17:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17565-sclerosi-multipla-dalle-lipossine-un-possibile-strumento-per-combattere-la-malattia2021-06-20T18:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17489-giornata-mondiale-della-sclerosi-multipla-2021-uno-studio-sul-covid-192021-05-30T16:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17426-sclerosi-multipla-la-malattia-di-per-se-non-comporta-una-gravidanza-a-rischio2021-05-18T09:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17331-sclerosi-multipla-nelle-donne-in-gravidanza-il-rischio-di-depressione-e-piu-alto2021-04-25T16:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17183-sclerosi-multipla-nasce-la-rete-red-di-aism2021-03-14T19:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/17100-sclerosi-multipla-i-pazienti-trattati-con-cladribina-sviluppano-una-risposta-ai-vaccini-comuni2022-04-21T12:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16905-sclerosi-multipla-al-via-il-programma-virtual-nurse2021-01-20T00:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16831-sclerosi-multipla-con-un-adeguata-pianificazione-la-gravidanza-e-assolutamente-possibile2020-12-21T20:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16818-sclerosi-multipla-le-cellule-che-producono-mielina-sono-sane-e-funzionanti2020-12-16T14:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16617-sclerosi-multipla-al-via-la-campagna-sm-e-gravidanza-semplicemente-mamma2020-10-26T14:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16478-sclerosi-multipla-presentato-uno-studio-sui-livelli-di-fatigue-dei-pazienti2020-09-24T14:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16390-sclerosi-multipla-il-mancato-controllo-del-virus-di-epstein-barr-e-concausa-della-malattia2020-08-27T23:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16333-sclerosi-multipla-fino-al-19-ottobre-si-puo-partecipare-al-premio-innovazione-digitale2020-07-26T18:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16266-sclerosi-multipla-da-fism-un-finanziamento-di-5-milioni-di-euro-per-la-ricerca2020-07-05T20:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16267-sclerosi-multipla-il-futuro-della-gestione-del-paziente-tra-continuita-e-innovazione2020-07-05T20:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16191-sclerosi-multipla-verificata-l-efficacia-del-questionario-per-la-diagnosi-di-disfagia2020-06-16T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16162-sclerosi-multipla-nuovi-dati-a-lungo-termine-su-efficacia-e-sicurezza-di-evobrutinib2020-06-10T10:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16122-sclerosi-multipla-il-30-maggio-un-evento-per-connettere-i-pazienti-di-tutto-il-mondo2020-05-29T09:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16114-sclerosi-multipla-nasce-il-progetto-formativo-sm2020-05-26T22:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/16066-sclerosi-multipla-e-covid-19-pubblicati-i-risultati-del-primo-studio-al-mondo2020-05-13T21:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15949-sclerosi-multipla-e-covid-19-nasce-piattaforma-globale-per-la-raccolta-dati2020-04-14T11:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15899-covid-19-e-sclerosi-multipla-arriva-l-assistente-virtuale-amica-mya2020-04-02T15:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15850-sclerosi-multipla-raccomandazioni-globali-su-covid-192020-03-25T14:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15684-sclerosi-multipla-e-malattie-rare-abbinate-in-nuovo-modello-di-ricerca2020-02-20T22:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15640-sclerosi-multipla-sul-palco-di-sanremo-la-danza-di-ivan-cottini-contro-la-malattia2020-02-07T08:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15558-sclerosi-multipla-piu-bisogni-insoddisfatti-e-meno-qualita-di-vita2020-01-07T18:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15298-sclerosi-multipla-identificata-una-mappa-genetica-dettagliata-della-patologia2019-10-10T21:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15225-sclerosi-multipla-nuovi-dati-su-ocrelizumab-mostrano-una-ridotta-progressione-della-disabilita2019-09-22T00:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/15084-sclerosi-multipla-i-consigli-per-gestire-il-caldo2019-07-30T14:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/14812-sclerosi-multipla-nuovi-dati-confermano-l-efficacia-di-dimetil-fumarato-e-natalizumab2019-05-15T16:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/14813-sclerosi-multipla-identificata-nei-linfociti-b-e-nei-monociti-l-espressione-alterata-di-nuovi-geni-associati-alla-malattia2019-05-15T16:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/14680-sclerosi-multipla-approvato-negli-usa-il-farmaco-orale-siponimod2019-04-04T17:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/14026-sclerosi-multipla-ocrelizumab-approvato-in-italia2018-10-11T09:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/13634-sclerosi-multipla-interferone-beta-sicuro-e-tollerato-anche-in-gravidanza2018-06-07T11:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/13406-sclerosi-multipla-siponimod-ritarderebbe-significativamente-la-progressione-della-disabilita2018-04-04T15:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/12753-sclerosi-multipla-e-squilibrio-del-microbiota-possibile-una-relazione2017-10-08T14:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/12336-sclerosi-multipla-al-san-raffaele-primo-studio-clinico-sul-trapianto-di-staminali-neurali2017-06-04T14:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/10268-sclerosi-multipla-scoperto-il-meccanismo-che-blocca-la-riparazione-del-danno-della-mielina2016-03-29T16:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/10101-sclerosi-multipla-apre-il-bando-fism-2016-per-la-ricerca2016-03-02T16:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9980-sclerosi-multipla-diagnosi-piu-semplice-e-veloce-con-la-rm-3tesla2016-02-17T09:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9834-insufficienza-venosa-cronica-cerebrospinale-ccsvi-la-patologia-esiste-correlata-o-meno-alla-sclerosi-multipla2016-01-28T16:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9534-sclerosi-multipla-diventare-genitori-e-possibile2015-12-04T11:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9364-sclerosi-multipla-la-prof-ssa-marrosu-cagliari-in-sardegna-la-piu-alta-incidenza-al-mondo2015-11-20T07:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9363-sclerosi-multipla-la-prof-ssa-marrosu-cagliari-finalmente-avremo-una-possibilita-terapeutica-per-la-forma-progressiva-primaria2015-11-20T07:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9180-sclerosi-multipla-incoraggianti-i-nuovi-dati-su-teriflunomide-e-alemtuzumab2015-10-20T09:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9165-ocrelizumab-per-la-sclerosi-multipla-i-commenti-dell-azienda-del-mondo-scientifico-e-delle-associazioni2015-10-19T09:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9144-sclerosi-multipla-la-soddisfazione-dell-aism-per-il-nuovo-trattamento-con-ocrelizumab-per-la-forma-prograssiva2016-01-26T16:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9162-sclerosi-multipla-nuova-terapia-con-ocrelizumab-comi-un-giorno-che-restera-nella-storia2015-10-15T08:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/9123-sclerosi-multipla-primariamente-progressiva-la-prima-terapia-efficace-potrebbe-essere-disponibile-fra-un-anno2015-10-15T08:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8820-sclerosi-multipla-fda-aggiunge-il-rischio-di-infezione-cerebrale-all-etichetta-del-farmaco-gilenya-fingolimod2015-08-25T14:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8723-sclerosi-multipla-quali-i-problemi-e-i-punti-di-forza-nel-mantenere-il-posto-di-lavoro2015-07-31T08:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8558-sclerosi-multipla-il-prof-comi-spiega-l-efficacia-del-farmaco-ocrelizumab2015-07-03T09:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8557-sclerosi-multipla-dati-positivi-per-ocrelizumab-da-due-studi-di-fase-iii2018-02-01T12:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8215-settimana-della-consapevolezza-sulla-ccsvi-bilancio-positivo-per-ccsvi-sm-onlus2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8162-sm-recidivante-remittente-il-trattamento-con-inf-beta-non-e-correlato-all-insorgenza-di-sm-secondariamente-progressiva2015-06-08T11:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8139-sclerosi-multipla-studio-italiano-individua-nel-punteggio-mrs-il-miglior-fattore-predittivo2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8103-sclerosi-multipla-disponibile-anche-in-italia-alemtuzumab2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/8073-sclerosi-multipla-nuovi-dati-di-efficacia-per-alemtuzumab2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/7636-sclerosi-multipla-al-via-lo-studio-zamboni-l-associazione-pazienti-chiede-attenzione-al-ministero2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/7256-sclerosi-multipla-possibile-affrontare-la-gravidanza-in-sicurezza2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/7102-sclerosi-multipla-in-lazio-il-piano-diagnostico-terapeutico-assistenziale-lintervista-al-dott-gasperini2019-03-26T17:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/7099-sclerosi-multipla-la-regione-lazio-determina-uno-specifico-pdta2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6869-sclerosi-multipla-alla-dottssa-silvia-rossi-il-premio-per-la-migliore-pubblicazione-scientifica2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6722-sclerosi-multipla-bluetooth-connessione-usa-e-desing-semplificano-la-terapia-con-betaferon2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6673-sclerosi-multipla-il-futuro-e-staminale-buoni-i-primi-risultati-del-progetto-mesems2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6705-sclerosi-multipla-genzyme-al-congresso-ectrims-20142015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6675-sclerosi-multipla-la-terapia-con-alemtuzumab-dimostra-risultati-a-lungo-termine2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6610-sclerosi-multipla-disponibile-dal-1d-settembre-in-italia-teriflunomide-terapia-orale-in-monosomministrazione-giornaliera-per-pazienti-con-decorso-di-malattia-recidivante-remittente2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6584-sclerosi-multipla-i-tagli-allassistenza-domiciliare-mettono-in-difficolta-cento-famiglie2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6571-sclerosi-multipla-ue-approva-peginterferone-beta-1a-di-biogen-idec2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6413-sclerosi-multipla-fingolimod-ottiene-nuova-approvazione-della-commissione-europea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6300-sclerosi-multipla-presenti-al-neuromed-i-migliori-esperti-nazionali-della-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6263-sclerosi-multipla-merck-serono-mettera-a-disposizione-dei-pazienti-un-nuovo-software-e-un-dispositivo-per-iniezioni-aggiornato2019-06-18T18:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6148-sclerosi-multipla-30-maggio-primo-h-open-day-onda-italiano2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6151-sclerosi-multipla-recidivante-remittente-peginterferone-beta-1a-ha-ottenuto-il-parere-positivo-del-chmp-per-il-trattamento-della-patologia-nellunione-europea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6149-sclerosi-multipla-genzyme-celebra-la-sesta-giornata-mondiale-dedicata-alla-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/6007-sclerosi-multipla-biogen-idec-presenta-i-nuovi-dati-sul-peginterferone-beta-1a2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/5997-sclerosi-multiplarallentamento-dellatrofia-cerebrale-e-riduzione-del-numero-di-nuove-lesioni-prolungati-a-tre-anni-nei-pazienti-trattati-con-alemtuzumab2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/5950-sclerosi-multipla-recidivante-remittente-confermata-efficacia-di-fingolimod2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/5805-sclerosi-multipla-il-polo-del-san-giuseppe-di-empoli-diventa-maggiorenne2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/5413-sclerosi-multipla-il-dimetil-fumarato-approvato-nellunione-europea-come-trattamento-orale2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/5379-sclerosi-multipla-tra-le-cause-ci-sarebbe-un-batterio-di-origine-alimentare2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/4875-sclerosi-multipla-avviato-a-torino-il-primo-percorso-diagnostico-terapeutico-assistenziale-pdta2019-03-26T17:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/4636-sclerosi-multipla-la-commissone-europea-approva-alemtuzumab2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/4589-sclerosi-multipla-teriflunomide-approvato-in-ue-prof-comi-dobbiamo-giocare-danticipo-sulla-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/4398-sclerosi-multipla-al-giglio-di-cefalu-ambulatorio-interamente-dedicato-alle-donne2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/4007-sclerosi-multipla-i-diritti-sul-lavoro-e-le-agevolazioni-assistenziali2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/3993-sclerosi-multipla-il-trattamento-con-natalizumab-e-i-rischi-di-leucoencefalopatia-multifocale-progressiva-lmp2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/3986-sclerosi-multipla-teriflunomide-terapia-orale-per-singola-somministrazione-giornaliera-ritarda-linsorgenza-della-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/3825-sclerosi-multipla-parere-positivo-dellue-per-luso-di-tecfidera-dimetil-fumarato2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/3636-slcerosi-multipla-richiesto-luso-di-natalizumab-come-trattamento-di-prima-linea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/3437-sclerosi-multipla-e-cannabis-terapeutica-mancano-ancora-conferme-sui-reali-benefici-di-sativex2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/2804-la-mia-vita-contro-la-sclerosi-multipla-la-prima-facebook-fan-page-curata-da-un-panel-di-specialisti2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/2768-sclerosi-multipla-la-fda-approva-il-teriflunomide-niente-iniezioni-ma-una-sola-compressa-al-giorno2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/2387-sclerosi-multipla-basta-aghi-adesso-ce-la-penna-pre-riempita-con-linterferone-beta-1-a2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/2195-sclerosi-multipla-negli-usa-11-milioni-di-dollari-lanno-spesi-per-diagnosi-errate2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/2190-sclerosi-multipla-sul-new-england-journal-nuova-analisi-di-rischio-pml-per-la-somministrazione-di-tysabri2016-02-16T14:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/2037-sclerosi-multipla-un-farmaco-sperimentale-riduce-le-lesioni-cerebrali2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1988-sclerosi-multipla-il-trattamento-con-betaferon-comporta-un-vantaggio-in-termini-di-sopravvivenza2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1581-sclerosi-multipla-fingolimod-usato-solo-come-farmaco-di-seconda-linea-in-via-precauzionale2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1578-sclerosi-multipla-fino-al-15-febbraio-basta-un-sms-al-45597-per-sostenere-il-trial-brave-dreams-guidato-da-zamboni2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1555-sclerosi-multipla-per-chi-usa-tysabri-ce-un-nuovo-modo-di-calcolare-il-rischio-di-leucoencefalopatia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1549-sclerosi-multipla-serve-monitoraggio-cardiovascolare-dopo-la-prima-dose-di-gilenya2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1414-sclerosi-multipla-approvata-la-somministrazione-di-rebifr-alla-comparsa-dei-primi-sintomi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1376-sclerosi-multipla-ecco-come-la-risonanza-magnetica-fotografa-il-sistema-nervoso-centrale2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1377-sclerosi-multipla-ecco-i-nuovi-criteri-per-la-diagnosi-attraverso-la-risonanza-magnetica2015-06-05T16:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1340-sclerosi-multipla-pozzilli-il-vero-problema-oggi-e-laderenza-alla-terapia2024-10-09T18:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1341-sclerosi-multipla-dalla-diagnosi-alla-terapia-fino-al-dibattito-sulla-ccsvi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1277-sclerosi-multipla-laffaticamento-cronico-come-elemento-nella-diagnosi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1258-sclerosi-multipla-luso-precoce-di-betaferon-previene-necessita-di-terapie-di-seconda-linea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1259-sclerosi-multipla-maggiore-sopravvivenza-se-si-comincia-precocemente-trattamento-con-betaferon2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1260-sclerosi-multipla-per-chi-e-in-terapia-con-interferone-beta-ce-il-programma-betaplus2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1243-sclerosi-multipla-sara-litaliana-maria-trojano-a-guidare-lectrims-dal-20122015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1205-sclerosi-multipla-il-teriflunomide-efficace-contro-le-recidive-della-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1146-sclerosi-multipla-concluso-il-primo-studio-di-magics-per-la-stimolazione-transcranica2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1140-sclerosi-multipla-dalle-staminali-mesenchimiali-una-possibile-speranza2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1035-sclerosi-multipla-studio-padovano-smentisce-associazione-con-ccsvi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1050-sclerosi-multipla-sul-ruolo-della-ccsvi-continua-il-dibattito-a-colpi-di-studi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/1019-sclerosi-multipla-secondo-studio-canadese-troppe-complicazioni-nel-trattamento-con-angioplasica2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/992-sclerosi-multipla-studio-condotto-anche-in-italia-conferma-natura-autoimmmune-della-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/966-sclerosi-multipla-ricercatori-umbri-chiariscono-il-ruolo-dellenzima-ido-nel-controllo-della-reazione-autoimmune2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/943-sclerosi-multipla-il-fampyre-autorizzato-in-ue-potra-essere-usato-nei-pazienti-con-problemi-della-deambulazione2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/895-sclerosi-multipla-e-ccsvi-la-sardegna-finanzia-studio-sul-metodo-zamboni2018-12-27T19:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/891-sclerosi-multipla-merk-serono-chiede-allema-di-poter-usare-il-rebif-per-la-terapia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/618-sclerosi-multipla-la-causa-scatenante-potrebbe-essere-una-batterio2018-01-16T11:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sclerosi-multipla/228-sclerosi-multipla-da-una-farmaco-contro-la-leucemia-linfoide-la-speranza-di-rallentare-la-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-cronicheweekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/23063-diabete-di-tipo-1-solo-un-italiano-su-10-sa-distinguerlo-correttamente-dal-tipo-22026-05-21T14:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/23042-diabete-e-rinnovo-patente-verso-un-cambiamento-reale2026-05-21T14:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/23019-dal-9-al-17-maggio-torna-la-settimana-nazionale-della-celiachia2026-05-07T13:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/23013-diabete-di-tipo-1-la-prima-sfida-resta-lo-screening-specie-degli-adulti2026-05-07T10:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22947-insonnia-cronica-presentato-un-policy-paper-per-riconoscere-la-patologia-come-prioritaria2026-04-20T16:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22905-autismo-limportanza-di-diagnosi-e-interventi-basati-su-evidenze-scientifiche2026-04-02T08:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22786-sindrome-di-tourette-gli-insulti-ai-bafta-accendono-lo-scontro-tra-clinica-e-sensibilita2026-02-23T15:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22760-bronchiectasie-una-malattia-respiratoria-cronica-ancora-troppo-sottovalutata2026-02-17T09:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22608-malattia-di-crohn-lintelligenza-artificiale-svela-un-mistero-genetico-e-apre-a-nuovi-approcci-terapeutici2025-12-15T11:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22540-bronchiectasie-approvazione-europea-per-brensocatib2025-11-21T18:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22500-celiachia-la-dieta-senza-glutine-tra-nuove-ricerche-e-falsi-miti2025-11-08T11:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22406-malattie-infiammatorie-croniche-intestinali-quando-la-cura-dipende-dalla-relazione-medico-paziente2025-10-13T17:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22407-malattie-infiammatorie-croniche-intestinali-una-guida-pratica-per-migliorare-laderenza-terapeutica2025-10-13T17:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22164-idrosadenite-suppurativa-urge-il-riconoscimento-come-malattia-cronica2025-07-07T13:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22129-disturbi-respiratori-ostruttivi-asma-grave-e-bpco-ancora-legati-ad-alti-tassi-di-morbilita-e-mortalita2025-06-25T14:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22088-malattia-renale-associata-a-diabete-di-tipo-2-risultati-positivi-dalla-combinazione-di-finerenone-ed-empagliflozin2025-06-13T11:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22043-ictus-cerebrale-perche-nei-giovani-e-in-aumento2025-06-03T14:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/22021-malattie-infiammatorie-croniche-intestinali-a-cagliari-il-confronto-tra-clinica-e-ricerca2025-05-23T18:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21948-spondiloartrite-assiale-meno-di-un-paziente-su-4-ottiene-un-controllo-completo-dei-sintomi-con-i-fans2025-04-30T15:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21921-gotta-una-malattia-antica-ma-ancora-attuale2025-04-19T11:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21662-ictus-cerebrale-da-alice-italia-un-progetto-per-migliorare-la-gestione-della-disfagia2025-01-24T12:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21595-malattia-renale-cronica-il-menu-di-natale-della-sin2024-12-18T10:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21590-diabete-autoimmune-di-tipo-1-al-via-la-campagna-un-passo-avanti2024-12-18T11:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21514-al-via-la-vitiligine-week-una-settimana-completamente-rivolta-ai-pazienti-e-ai-loro-bisogni2024-11-22T13:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21486-colite-ulcerosa-al-via-la-campagna-voci-di-pancia2024-11-13T12:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21489-malattie-mediate-da-infiammazione-di-tipo-2-dupilumab-rimborsabile-in-italia-in-4-nuove-indicazioni2024-11-13T15:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21483-malattia-renale-cronica-una-corretta-alimentazione-aiuta-a-preservare-la-funzionalita-dei-reni2024-11-12T18:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21457-presentato-a-roma-il-manifesto-futurista-delle-malattie-reumatologiche2024-11-05T18:58:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21398-malattia-renale-cronica-verso-una-cura-ottimale2024-10-16T09:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21389-malattie-cardiache-arriva-il-primo-pacemaker-bicamerale-senza-fili-al-mondo2024-10-15T08:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21390-i-pacemaker-senza-fili-una-rivoluzione-tecnologica-in-cardiologia2024-10-15T08:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21392-malattie-del-cuore-se-si-facesse-prevenzione-il-50-delle-morti-sarebbe-evitabile2024-10-14T16:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21250-artrite-reumatoide-la-biopsia-dei-tessuti-infiammati-per-cure-piu-efficaci-e-personalizzate2024-09-02T08:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21203-salute-verso-un-programma-di-screening-per-diabete-e-celiachia2024-07-29T13:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21177-broncopneumopatia-cronica-ostruttiva-approvazione-europea-per-dupilumab2024-07-17T13:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/21025-bronco-pneumopatia-cronica-ostruttiva-presentati-i-risultati-di-fase-iii-di-dupilumab2024-05-28T08:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20949-diabete-1-e-celiachia-parte-da-napoli-lo-screening-nazionale-per-la-loro-individuazione-precoce2024-05-09T09:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20925-sindrome-di-tourette-alessandro-borghi-racconta-la-sua-esperienza-con-la-malattia2024-05-03T11:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20913-asma-eosinofilico-grave-nuovo-studio-approfondisce-il-meccanismo-d-azione-di-mepolizumab2024-04-24T13:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20891-poliposi-nasale-un-profumo-speciale-creato-per-supportare-i-pazienti2024-04-19T18:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20849-stenosi-aortica-severa-a-padova-interventi-con-valvola-di-nuova-generazione-con-consente-di-ridurre-la-mortalita-all-12024-04-08T09:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20818-disturbi-dello-spettro-autistico-in-italia-ne-e-affetto-1-bambino-su-772024-03-29T09:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20731-fegato-grasso-al-via-un-progetto-europeo-per-la-diagnosi-precoce2024-03-08T11:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20705-giornata-mondiale-dell-obesita-il-4-marzo-consulti-gratuiti-all-irccs-multimedica2024-02-29T18:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20662-vitiligine-un-manifesto-in-cinque-punti-per-rispondere-ai-bisogni-insoddisfatti-dei-pazienti2024-02-20T17:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20636-malattie-infiammatorie-croniche-intestinali-in-italia-sono-250mila-i-pazienti2024-02-15T17:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20601-occlusione-venosa-retinica-nuovi-dati-positivi-a-lungo-termine-su-faricimab2024-02-07T16:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20549-epatite-b-al-san-raffaele-sperimentata-per-la-prima-volta-al-mondo-una-molecola-immunoterapica2024-01-23T12:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20481-ictus-presentato-il-manuale-di-valutazione-della-comunicazione-del-percorso-assistenziale-del-paziente2023-12-22T19:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20303-anemia-da-malattia-renale-cronica-arriva-il-primo-libro-bianco2023-11-09T17:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20266-ictus-ogni-anno-colpisce-nel-mondo-12-milioni-di-persone2023-10-28T19:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20221-malattie-reumatiche-anmar-tutte-le-regioni-attivino-tavoli-e-gruppi-di-lavoro2023-10-12T13:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20066-dolore-cronico-ne-soffrono-13-milioni-di-italiani-e-150-milioni-di-europei2023-08-23T17:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20013-vitiligine-approvata-in-europa-la-prima-terapia-specifica-per-la-patologia2023-08-14T18:00:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/20050-psoriasi-al-via-la-nuova-campagna-awarness-respectpsorias-di-apiafco2023-08-07T08:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19867-vulvodinia-un-nuovo-approccio-terapeutico-a-base-di-cortisonici-analgesici-e-cannabis2023-06-08T07:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19687-ictus-al-via-il-progetto-fast-heroes2023-04-05T18:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19528-malattie-infiammatorie-croniche-intestinali-al-via-master-universitario-della-cattolica2023-02-12T18:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19515-nefrite-lupica-belimumab-indicato-per-il-trattamento-della-patologia2023-02-04T12:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19504-malattie-reumatologiche-fira-nuove-evidenze-scientifiche-raccomandano-il-vaccino-anti-covid2023-02-02T20:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19476-malattie-infiammatorie-croniche-intestinali-al-via-ibd-cooking-channel2023-01-23T10:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19422-malattie-reumatologiche-i-consigli-a-tavola-per-le-feste2022-12-27T11:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19403-vitiligine-dagli-usa-un-nuovo-farmaco-inibitore-della-janus-chinasi2022-12-20T17:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19374-osteoporosi-virginia-visconti-vince-borsa-di-studio-per-giovani-ricercatori2022-12-12T16:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19361-malattie-reumatologiche-cure-sempre-piu-digitali-e-integrate2022-12-04T19:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19305-malattie-infiammatorie-croniche-intestinali-l-importanza-dell-alimentazione2022-11-20T11:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19208-vitiligine-una-malattia-dall-origine-complessa2022-10-25T13:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19167-patologie-gastrointestinali-croniche-online-il-portale-gi-point-it2022-10-13T17:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19044-colite-ulcerosa-la-battaglia-di-martina-santagiuliana-al-festival-di-venezia2022-09-11T14:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/19042-dermatite-atopica-oggi-la-giornata-mondiale2022-09-11T14:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18989-nefrite-lupica-aifa-approva-belimumab2022-08-05T12:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18874-psoriasi-un-cortometraggio-per-superare-le-paure-e-liberare-le-proprie-emozioni2022-07-03T19:51:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18875-steatosi-epatica-non-alcolica-presentate-le-nuove-linee-guida2022-07-08T09:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18896-aneurisma-dell-aorta-addominale-un-killer-silenzioso-che-uccide-6000-italiani-all-anno2022-07-07T14:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18837-malattie-reumatologiche-confermata-la-validita-dei-farmaci-biobetter2022-06-25T16:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18768-depressione-disponibile-in-italia-il-primo-farmaco-spray-nasale2022-06-13T15:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18736-malattia-renale-cronica-lanciata-la-campagna-anemia-non-aspettare-agisci2022-06-05T15:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18613-dermatite-atopica-al-via-la-campagna-rimettiti-in-gioco2022-05-06T09:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18535-malattie-reumatiche-approvata-alla-camera-una-mozione-per-la-tutela-dei-pazienti2022-04-10T13:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18474-osteoporosi-pubblicato-il-rapporto-scope-212022-03-28T20:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18443-colite-ulcerosa-ustekinumab-disponibile-in-italia2022-03-21T17:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18265-asma-grave-il-chmp-raccomanda-l-approvazione-di-dupilumab-nei-bambini2022-02-07T15:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18258-ictus-cerebrale-attenzione-alla-depressione-postuma2022-02-07T00:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18241-prurigo-nodularis-secondo-studio-di-fase-iii-conferma-i-benefici-di-dupilumab2022-01-31T10:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18242-poliposi-nasale-la-storia-di-rossana-un-incubo-durato-dodici-anni2022-01-31T10:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18235-bronco-pneumopatia-cronica-ostruttiva-nasce-un-sistema-per-il-telemonitoraggio-dei-pazienti2022-01-30T21:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18236-malattie-croniche-e-pandemia-le-associazioni-chiedono-al-governo-di-salvaguardare-il-diritto-alla-salute-dei-pazienti2022-01-30T23:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18179-scompenso-cardiaco-cronico-dapagliflozin-rimborsabile-in-italia2022-01-15T17:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18160-malattie-reumatiche-il-dolore-cronico-colpisce-un-paziente-su-quattro2022-01-07T17:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18154-asma-grave-dupilumab-si-dimostra-efficace-nei-bambini-che-non-rispondono-alle-terapie2022-01-02T15:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18120-dermatite-atopica-la-ce-approva-abrocitinib2021-12-20T19:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18094-malattie-reumatologiche-apmarr-chiede-la-cancellazione-dell-art-5-del-decreto-fiscale2021-12-12T18:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18095-insufficienza-intestinale-cronica-benigna-e-sindrome-dell-intestino-corto-al-via-un-progetto-per-migliorare-il-percorso-assistenziale2021-12-12T18:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18074-malattia-di-crohn-e-colite-ulcerosa-aumentano-i-casi-in-italia2021-12-05T22:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18052-artrite-psoriasica-la-commissione-europea-approva-risankizumab2021-11-28T00:13:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18004-autismo-nasce-il-progetto-farm4autism2021-11-13T21:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/18018-poliposi-nasale-una-patologia-da-conoscere-e-riconoscere2021-11-19T17:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17960-osteoporosi-dall-universita-di-trieste-una-nuova-tecnologia-per-lo-studio-dell-osso2021-10-31T23:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17935-artrite-psoriasica-parere-positivo-del-chmp-per-risankizumab2021-10-28T22:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17942-psoriasi-il-29-ottobre-e-la-giornata-mondiale2021-10-26T14:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17901-malattie-autoimmuni-e-infiammatorie-scoperte-quattro-nuove-sindromi2021-10-17T21:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17902-psoriasi-e-dermatite-atopica-stop-a-lesioni-e-prurito-con-le-nuove-terapie2021-10-17T21:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17914-malattie-infiammatorie-autoimmuni-e-covid-19-societa-italiana-di-gastroenterologia-fondamentale-vaccinarsi2021-10-19T18:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17877-malattie-autoimmuni-reumatologiche-e-dermatologiche-il-genere-fa-la-differenza2021-10-09T19:59:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17850-malattia-renale-cronica-approvazione-europea-per-dapagliflozin2021-10-03T18:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17851-asma-e-bpco-urge-una-maggiore-aderenza-terapeutica-da-parte-dei-pazienti2021-10-03T18:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17777-dermatite-atopica-il-14-settembre-e-la-giornata-mondiale2021-09-14T14:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17749-dermatite-atopica-lo-studio-registrativo-su-dupilumab-soddisfa-tutti-gli-endpoint2021-09-05T14:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17750-artrite-reumatoide-la-causa-scatenante-potrebbe-risiedere-in-un-batterio-delle-gengive2021-09-05T14:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17692-malattie-croniche-autoimmuni-l-appello-di-apmarr-green-pass-obbligatorio-anche-negli-hotel-e-sulle-spiagge2021-07-27T06:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17625-dermatite-atopica-parere-positivo-del-chmp-per-upadacitinib2021-07-06T17:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17596-diabete-hack-to-the-future-premia-il-progetto-olimpiadi-della-salute-2-02021-06-28T00:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17518-asma-da-moderata-grave-presentati-i-dati-di-fase-iii-su-dupilumab-nei-bambini-tra-i-6-e-gli-11-anni2021-06-06T21:29:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17500-malattie-reumatiche-presentata-una-web-listening-sulle-problematiche-dei-pazienti2021-05-31T18:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17471-asma-dal-7-all-11-giugno-torna-la-settimana-di-sensibilizzazione2021-05-23T20:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17449-patologie-autoimmuni-gli-esperti-nessuna-controindicazione-per-vaccino-anti-covid2021-05-19T19:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17445-psoriasi-al-via-la-campagna-buongiorno-pelle2021-05-16T16:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17425-asma-al-via-l-iniziativa-nextbreathchallenge2021-05-11T17:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17416-lupus-il-10-maggio-e-la-giornata-mondiale-dedicata-alla-patologia2021-05-10T17:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17382-bpco-approvazione-europea-per-beclometasone-formoterolo-glicopirronio-in-inalatore-a-polvere-secca2021-05-03T08:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17262-asma-grave-eosinofilico-arriva-in-italia-il-primo-trattamento-per-bambini2021-04-03T15:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17237-artrite-reumatoide-aifa-approva-infliximab-in-formulazione-sottocutanea2021-03-28T22:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17238-spondiloartrite-sieronegativa-la-nuova-vita-di-camilla-grazie-ai-farmaci-biologici2021-03-28T22:25:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17138-coronaropatia-e-arteriopatia-periferica-aifa-ammette-rivaroxaban-al-rimborso2021-03-12T12:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17099-malattie-epatiche-croniche-nuovo-trattamento-orale-evita-il-ricorso-a-trasfusioni-piastriniche2021-02-28T18:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17027-ictus-ischemico-il-covid-19-ne-aumenta-il-rischio-e-il-ritardo-diagnostico2021-02-14T21:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/17028-colite-ulcerosa-tofacitinib-disponibile-in-italia2021-02-14T22:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16985-diabete-di-tipo-2-una-webserie-per-aiutare-i-pazienti-a-semplificarne-la-gestione2021-02-07T20:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16928-malattie-reumatologiche-e-rare-al-via-reumart-la-creativita-come-risorsa2021-01-24T21:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16788-artrite-reumatoide-e-diabete-di-tipo-2-anakinra-efficace-in-entrambe-le-patologie2020-12-09T12:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16699-scompenso-cardiaco-dapagliflozin-approvato-in-europa2020-11-16T15:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16676-dermatite-atopica-lo-stress-che-ne-deriva-coinvolge-tutta-la-famiglia2020-11-12T18:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16645-lupus-conoscerlo-e-il-primo-passo-per-non-temerlo2020-11-04T18:32:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16647-autismo-uno-studio-evidenza-i-potenziali-effetti-positivi-dei-probiotici2020-11-06T08:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16644-dermatite-atopica-l-appello-andea-maggiori-supporti-economici-e-sociali-ai-pazienti2020-11-04T18:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16618-malattie-infiammatorie-intestinali-a-volte-colpiscono-piu-di-un-bersaglio2020-10-26T14:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16620-ictus-cerebrale-il-29-ottobre-e-la-giornata-mondiale2020-10-27T12:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16609-malattie-reumatiche-no-alla-sospensione-dei-ricoveri-programmati-in-campania2020-10-24T17:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16585-malattia-di-crohn-nuovi-risultati-di-fase-iii-su-ustekinumab2020-10-19T12:01:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16586-artrite-reumatoide-approvazione-europea-per-filgotinib2020-10-19T12:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16582-autismo-in-basilicata-un-centro-per-il-trattamento-precoce-dei-piccoli-pazienti2020-10-19T09:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16584-dermatite-atopica-e-covid-19-la-normativa-a-tutela-dei-pazienti2020-10-19T10:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16578-dermatite-atopica-l-impatto-psicologico-del-bullismo2020-10-18T21:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16573-malattie-reumatiche-crollo-del-40-di-nuove-diagnosi-durante-la-pandemia2020-10-18T20:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16570-ipertensione-dal-17-al-24-ottobre-screening-gratuito-in-farmacia2020-10-16T09:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16559-covid-19-ancora-trascurata-la-cura-delle-malattie-croniche2020-10-12T11:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16568-il-percorso-di-gravidanza-della-donna-con-lupus-eritematoso-sistemico-e-sindrome-da-anticorpi-antifosfolipidi2020-10-16T09:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16551-dermatite-atopica-come-affrontare-le-difficolta-dovute-alla-pandemia2020-10-13T10:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16522-dermatite-atopica-garantire-la-continuita-terapeutica-nella-fase-ii-della-pandemia2020-10-13T10:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16476-psoriasi-nasce-il-nuovo-canale-virtuale-psopoint2020-09-24T14:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16497-dermatite-atopica-e-covid-19-le-difficolta-dei-pazienti2020-10-13T10:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16439-dermatite-atopica-arriva-l-assistente-personale-ida2020-09-14T09:53:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16442-dermatite-atopica-e-covid-19-i-rischi-per-i-pazienti-e-le-necessita-di-cure2020-09-14T14:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16356-broncopneumopatia-bpco-al-via-il-progetto-narrarsi-ai-tempi-del-covid-192020-08-02T16:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16331-osteoporosi-al-via-la-campagna-multimediale-fai-vincere-le-tue-ossa2020-07-26T18:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16332-ictus-cerebrale-i-consigli-di-alice-italia-per-l-estate2020-07-26T18:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16312-malattie-croniche-intestinali-ibdpoint-di-takeda-vince-il-premio-informazione-scientifica-multicanale2020-07-20T11:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16211-diabete-di-tipo-2-canagliflozin-riduce-del-30-40-il-rischio-di-malattia-renale2020-06-21T23:08:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16212-emicrania-nuovo-studio-rivela-i-meccanismi-dell-allodinia-cutanea-associata2020-06-21T23:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16158-diabete-via-libera-dell-ema-a-nuove-indicazioni-per-canagliflozin2020-06-10T09:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16160-diabete-occorre-migliorare-la-cura-delle-complicanze-renali-e-cardiovascolari2020-06-10T09:54:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16065-malattie-croniche-prosegue-il-progetto-di-telemedicina-vicini-di-salute2020-05-13T20:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/16015-covid-19-non-provato-che-il-contagio-si-manifesti-inizialmente-con-crisi-epilettiche2020-05-03T17:18:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15982-malattie-croniche-terapie-a-domicilio-grazie-a-sanofi4you2020-04-20T18:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15929-lupus-eritematoso-sistemico-con-le-nuove-terapie-migliora-la-qualita-della-vita2020-04-08T19:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15931-coronavirus-i-consigli-di-a-l-i-ce-italia-per-l-attivita-fisica-in-casa2020-04-08T20:22:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15897-lupus-eritematoso-sistemico-preoccupazione-circa-l-eventuale-carenza-d-idrossiclorochina2020-04-02T15:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15843-coronavirus-i-pazienti-con-diabete-chiedono-semplificazione-del-ritiro-dei-farmaci-in-dpc2020-03-25T15:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15746-colite-ulcerosa-e-malattia-di-crohn-parere-positivo-del-chmp-per-vedolizumab2020-03-10T20:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15747-malattia-renale-cronica-confermato-il-ruolo-positivo-del-consumo-di-caffe2020-03-10T20:47:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15700-malattie-reumatologiche-presentata-un-interpellanza-parlamentare2020-02-27T17:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15701-disabilita-e-condizioni-di-lavoro-lanciata-indagine-nazionale2020-02-27T17:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15698-malattie-croniche-ancora-troppa-la-distanza-tra-medico-e-paziente2020-02-27T10:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15685-malattie-reumatiche-autoimmuni-i-vaccini-appaiono-sicuri-ma-servono-piu-studi2020-02-20T22:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15657-diabete-e-dipendenza-da-nicotina-uno-studio-ne-dimostra-la-relazione2020-02-13T22:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15639-dermatite-atopica-fda-valuta-dupilumab-anche-per-pazienti-pediatrici2020-02-07T08:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15597-psoriasi-studio-di-fase-iii-dimostra-la-superiorita-di-bimekizumab-su-adalimumab2020-01-21T17:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15577-psoriasi-bimekizumab-ottiene-risultati-positivi-nello-studio-di-fase-iii-be-ready2020-01-14T18:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15557-artrite-reumatoide-la-commissione-europea-approva-upadacitinib2020-01-07T17:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15299-epatite-b-cronica-una-molecola-riattiva-il-sistema-immunitario-contro-il-virus2019-10-10T21:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15252-epatite-b-cronica-disponibile-in-italia-un-nuovo-trattamento-dopo-oltre-un-decennio-di-latenza-terapeutica2019-10-02T09:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15256-rinosinusite-cronica-con-poliposi-nasale-il-chmp-raccomanda-l-approvazione-di-dupilumab2019-10-02T09:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15257-lupus-eritematoso-sistemico-3-persone-su-4-non-ne-hanno-mai-sentito-parlare2019-10-01T16:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15206-disturbi-dello-spettro-autistico-analisi-statistica-conferma-l-efficacia-di-amo-022019-09-19T12:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15141-vulvodinia-una-lettera-dai-pazienti-per-accendere-i-riflettori-sulla-patologia2023-05-23T10:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15142-vulvodinia-la-denuncia-di-cecilia-manca-una-figura-medica-di-riferimento2023-05-23T10:14:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/15061-spondiloartrite-assiale-tre-quarti-dei-pazienti-faticano-a-trovare-un-lavoro2019-07-21T18:07:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14912-ictus-cerebrale-si-allunga-fino-a-9-ore-la-finestra-temporale-per-la-terapia-trombolitica2019-06-12T15:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14887-spondilite-anchilosante-i-dati-preoccupanti-del-sondaggio-emas2020-02-27T13:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14811-poliartriti-croniche-nuovi-approcci-di-cura-e-counselling-mirato-aiutano-le-donne-a-realizzare-il-desiderio-di-maternita2020-02-27T13:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14612-rene-policistico-il-ruolo-centrale-della-terapia-nutrizionale2019-03-21T19:23:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14603-ictus-cerebrale-in-aumento-tra-i-giovani-l-allarme-di-a-l-i-ce-italia-onlus2019-03-20T14:09:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14222-disturbi-dello-spettro-autistico-miglioramenti-con-il-farmaco-sperimentale-amo-022018-11-29T22:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14157-dermatite-atopica-oggi-i-pazienti-italiani-possono-contare-su-dupilumab2018-11-15T16:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14104-caroline-wozniacki-la-tennista-che-vince-contro-l-artrite-reumatoide2020-02-27T14:20:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14083-rinosinusite-cronica-con-poliposi-nasale-positivi-i-dati-clinici-di-fase-iii-su-dupilumab2018-10-25T16:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14084-malattie-reumatiche-apmar-lancia-la-campagna-reumache2020-02-27T12:36:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14025-artrite-reumatoide-tofacitinib-disponibile-anche-in-italia2018-10-11T09:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/14028-colite-ulcerosa-simone-sabbioni-io-ce-l-ho-fatta-e-partecipero-ai-mondiali-di-nuoto2018-10-11T11:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13896-lupus-eritematoso-sistemico-possibile-il-coinvolgimento-di-batteri-intestinali2018-09-06T17:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13844-autismo-individuati-due-geni-responsabili-della-patologia2018-08-16T13:42:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13770-artrite-reumatoide-sarilumab-disponibile-anche-in-italia2018-07-19T11:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13702-spondilite-anchilosante-parte-la-campagna-sai-se-hai-la-sa-scegli-il-tuo-futuro2020-02-27T14:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13662-malattie-reumatiche-l-appello-della-presidente-apmar-al-ministro-grillo2020-02-27T12:37:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13577-tumori-le-malattie-reumatiche-autoimmuni-e-infiammatorie-ne-aumenterebbero-il-rischio2018-05-21T09:06:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13124-malattie-reumatiche-la-sir-scende-in-piazza-con-la-campagna-reumadays2020-02-27T14:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13100-malattia-di-crohn-si-studia-una-terapia-orale-che-non-preveda-immunosoppressione2018-01-16T11:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/13019-obesita-grave-la-chirurgia-bariatrica-ha-effetti-positivi-anche-sul-fegato2017-12-11T17:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12965-malattie-reumatiche-un-paziente-su-tre-deve-lasciare-il-lavoro2020-02-27T14:30:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12968-malattia-di-crohn-una-diagnosi-su-5-riguarda-gli-under-182019-10-16T14:45:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12973-artrite-reumatoide-a-breve-in-italia-nuovo-farmaco-orale-per-le-forme-resistenti2019-08-18T17:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12843-rene-policistico-inserito-nei-nuovi-lea-come-malattia-cronica-e-invalidante2017-10-31T11:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12770-artrite-reumatoide-nasce-il-progetto-di-teatroterapia-ripartiamo2020-02-27T14:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12737-artrite-reumatoide-nel-40-dei-pazienti-e-in-forma-precoce-e-aggressiva2020-02-27T14:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12583-gvhd-cronica-il-farmaco-ibrutinib-approvato-negli-usa2019-01-17T17:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12555-ictus-cerebrale-la-disfagia-si-verifica-in-circa-il-50-dei-pazienti2017-08-01T15:05:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12474-spondilite-anchilosante-il-video-della-campagna-sai-che-la-sa2020-02-27T14:38:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12451-osteoporosi-in-italia-circa-4-milioni-e-mezzo-di-pazienti2017-06-29T13:27:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12290-spondilite-anchilosante-non-confondiamola-con-il-mal-di-schiena2020-02-27T14:41:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12237-malattie-reumatiche-una-vita-senza-dolore-cronico-e-possibile2020-02-27T14:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12241-malattie-reumatiche-nasce-fimr-la-federazione-italiana-che-unisce-medici-e-pazienti2020-02-27T14:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12224-lupus-eritematoso-sistemico-in-arrivo-una-terapia-promettente-capace-di-fermarne-la-progressione2017-04-27T14:39:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12158-dermatite-atopica-nasce-l-associazione-nazionale-dedicata-ai-pazienti2017-04-06T07:24:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12105-artrite-psoriasica-celgene-lancia-il-social-contest-light-on-psoriatic-arthritis2020-02-27T14:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/12075-malattia-di-crohn-e-colite-ulcerosa-due-patologie-in-aumento-soprattutto-tra-bambini-e-adolescenti2017-03-16T10:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/11927-artrite-reumatoide-e-artrite-psoriasica-quando-il-paziente-puo-sospendere-i-farmaci2017-02-13T16:40:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/11892-malattie-autoimmuni-uno-studio-conferma-la-tendenza-a-colpire-lo-stesso-soggetto-con-patologie-diverse2022-10-23T13:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/11663-malattia-di-crohn-approvato-dalla-commissione-europea-ustekinumab2016-11-27T21:35:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/11359-insufficienza-cardiaca-partita-sperimentazione-di-fase-iii-su-vericiguat2016-10-01T11:03:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/10998-gravidanza-l-uso-di-lamotrigina-non-e-associato-a-un-rischio-di-schisi-oro-facciale-e-piede-torto2016-07-19T14:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/10960-sindrome-da-intestino-corto-europa-approva-il-farmaco-revestive-teduglutide-per-pazienti-pediatrici2024-02-08T15:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/10642-bpco-l-associazione-ics-laba-per-inalazione-extrafine-riduce-le-esacerbazioni2016-05-18T15:26:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/10638-l-endometriosi-deve-essere-considerata-una-malattia-invalidante2016-05-18T08:12:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/10252-congiuntiviti-allergiche-nei-bambini-attenzione-alla-vernal2016-03-24T16:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/9628-malattia-renale-cronica-in-italia-al-primo-posto-per-rilevanza-epidemiologica-gravita-invalidita-peso-assistenziale-ed-economico2015-12-16T10:10:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/9409-malattie-articolari-il-dr-bonomi-con-crioterapia-sistemica-possibile-remissione-dei-dolori-fino-a-un-anno2022-03-28T14:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/9422-crioterapia-sistemica-con-la-terapia-del-freddo-i-farmaci-non-sono-piu-necessari2015-11-23T15:49:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/9081-broncopneumopatia-cronica-ostruttiva-bpco-nel-2030-sara-la-terza-causa-di-morte2015-10-09T10:21:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/8747-pemfigo-il-rischio-di-mortalita-aumenta-solo-dopo-i-65-anni2015-07-31T13:43:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/8592-neuroimmunologia-due-studi-dimostrerebbero-relazione-tra-sistema-nervoso-centrale-e-quello-immunitario2015-07-09T09:04:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/7444-psoriasi-secukinumab-primo-farmaco-biologico-approvato-da-ema-come-trattamento-di-prima-linea2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/6972-diabete-abbott-presenta-freestyler-libre-il-rivoluzionario-sistema-di-monitoraggio-flash-del-glucosio-da-ora-disponibile-anche-in-italia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/6883-artrite-psoriasica-divulgato-documento-di-approfondimento2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/6822-artrite-psoriasica-ustekinumab-ottiene-lapprovazione-per-lartrite-psoriasica-attiva2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/6357-neovascolarizzazione-coroideale-secondaria-a-miopia-patologica-mcnv-ranibizumab-e-ora-rimborsato-dal-sistema-sanitario-nazionale-per-il-trattamento-della-patologia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/6303-malattie-gastrointestinali-e-reumatologiche-confermate-cause-comuni2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/6064-lupus-erimatoso-sistemico-le-rare-manifestazioni-neonatali-e-la-correlazione-con-la-sindrome-di-sjogren2019-06-18T18:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/5396-morbo-di-crohn-dagli-stati-uniti-nuove-linee-guida2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/5334-asma-broncopneumopatia-enfisema-polmonare-piu-vicini-a-terapie-personalizzate-ed-efficaci2017-06-19T17:15:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/4968-malattia-di-crohn-adalimumab-mantiene-la-malattia-in-remissione-fino-a-4-anni2016-10-23T17:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/4754-malattie-reumatiche-da-apmar-associazione-persone-con-malattie-reumatiche-una-campagna-di-sensibilizzazione-per-i-pazienti-piu-piccoli2020-02-27T12:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/4710-obesita-infantile-la-misurazione-della-circonferenza-addominale-e-un-indicatore-utile-anche-nei-bambini2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/4341-neovascolarizzazione-coroidealie-miopica-ranibizumab-approvato-in-ue2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/4075-celiachia-uno-studio-italiano-permette-la-diagnosi-precoce-con-un-nuovo-test2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/3701-celiachia-dalla-svezia-unipotesi-si-puo-prevenire-aggiungendo-glutine-nella-prima-nutrizione2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/3213-sindrome-del-colon-irritabile-il-male-non-e-tutto-nella-testa2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/2983-emicrania-cronica-arriva-il-neurostimolatore-piu-piccolo-del-mondo2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/2238-malattie-renali-croniche-ne-sono-affetti-42-mila-italiani2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/2171-diabete-e-insufficienza-renale-disponibile-la-terapia-no-limits2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/2140-nevralgia-del-trigemino-lacosamide-puo-ridurre-il-dolore2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/2125-malattie-croniche-complesse-colpiscono-1-bambino-su-2002015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/2042-artrite-reumatoride-le-raccomandazioni-per-la-gestione-del-dolore2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1980-sindrome-di-tourette-i-tic-oculari-sono-un-sintomo-della-malattia2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1934-il-cancro-si-potra-trattare-come-una-malattia-cronica2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1803-mal-di-schiena-scoperta-molecola-responsabile-dellinvecchiamento-della-colonna-vertebrale2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1790-celiachia-denunciato-il-businnes-del-senza-glutine-che-svuota-il-portafogli-dei-presunti-pazienti2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1657-morbo-di-crohn-e-coliti-le-cure-alternative-possono-vanificare-i-trattamenti-farmacologici2016-10-23T18:34:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1529-enhancer-hs-12-interruttore-genetico-che-rende-il-lupus-qferoceq2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1478-trombosi-xarelto-ottiene-due-nuove-indicazioni-terapeutiche-in-ue2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1059-celiachia-nuova-normativa-ue-sulle-etichette-potrebbe-essere-un-rischio2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/1002-celiachia-nelle-donne-potrebbe-provocare-infertilita-che-passa-con-una-dieta-senza-glutine2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/900-malattie-croniche-italia-a-macchia-di-leopardo-sulla-medicina-di-genere2018-10-31T18:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/739-tumore-del-rene-anche-in-italia-il-pazopanib-rallenta-la-progressione-di-quasi-un-anno2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/529-lupus-approvato-negli-usa-un-nuovo-farmaco-prodotto-da-hgs-e-glaxo2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/altre-malattie-croniche/417-lupus-individuato-il-difetto-di-regolazione-degli-anticorpi2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibrosi-polmonare-idiopatica-che-cose2023-04-11T18:02:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-alzheimer-che-cose2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-creutzfeldt-jakob-che-cose2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/hiv-e-aids-cosa-sono2018-01-16T11:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/ipertensione-polmonare-tromboembolica-cronica-cteph-che-cose2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/discinesia-tardiva-che-cose2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sensibilita-chimica-multipla-che-cose2016-03-10T15:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sla-che-cose2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/ipertensione-arteriosa-polmonare-cose2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/distress-respiratorio-neonatale-che-cose2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sindrome-di-hunter-mucopolisaccaridosi-tipo-ii-che-cose2018-11-15T11:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/farmaci-orfani-cosa-sono2017-11-27T21:55:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/tumori-della-testa-e-del-collo-cosa-sono2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sindromi-del-cromosoma-14-che-cosa-sono2015-05-23T09:28:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sindrome-da-stanchezza-cronica-che-cose2016-05-06T15:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sla-che-cose-190672016-05-06T15:19:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/talassemia-che-cose2018-12-19T18:57:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sindrome-di-rett-che-cose2016-03-10T13:52:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-pompe-che-cose2018-03-09T10:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-parkinson-che-cose2018-10-01T08:46:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/sindorme-dellx-fragile-che-cose2016-03-09T16:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/algodistrofia-che-cose2015-06-05T16:31:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/fibrosi-cistica-che-cose2016-03-10T14:11:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-fabry-che-cose2016-03-10T14:17:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-gaucher-che-cose2018-03-09T10:48:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/malattia-di-huntington-che-cose2017-04-23T18:16:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/cosa-sono-le-malattie-rare2017-05-15T10:56:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/cosa-sono-i-tumori-rari2017-08-10T10:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/il-progettoweekly0.5 https://www.osservatoriomalattierare.it/il-progetto/17-chi-siamo2025-12-16T08:50:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/comitato-scientifico2026-03-30T15:33:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/contattiweekly0.5 https://www.osservatoriomalattierare.it/contatti/136-contatti2025-02-05T08:44:00+00:00weekly0.5 https://www.osservatoriomalattierare.it/documentiweekly0.5 https://www.osservatoriomalattierare.it/translate-in-your-language2023-06-28T10:57:00+00:00weekly0.5